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ABSTRACT
The objective of this project was to produ~e bispecific
monoclonal antibodies (SsMaba) which recognise both the tumour
associated carcinoembryonic antigen (eEA) and the
chemotherapeutic agent doxorubicin, as a complel"entary
approach to the use of irnmunoconjugates for site specific drug
delivery. A monoclonal anti-CEll. hybridoma (11-285-14) was
made sensitive to hypoxanthine, aminoptedn and thymidine
(HAT), by back selecting it in increasing concentrations of 8-
azaguanine. Eight s-azaguanine resistant fusion partners were
selected based on growth characteristics and continued anti-
CEA produr::tion. As doxorubicin (Dox) is a hapten, it was
conjugated to carrier proteins keyhole limpet hemocyanin (KLIl)
or bovine serum albumin (BSA) using l-ethyl-)- (dimethYl-
aminopropyl) carbodiimide. DoX-KLH alid Dox-BSA conjugates
were employed to immunize mice and spleen cells were used for
fusions with the HAT sensitive anti-CEA 11-285-14 using
standard hybridoma procedures. Enzyme linked immunosorbent
assays (ELISAs) were developed to test the hybrids obtained
for anti-CEA, anti-Oox, anti-BSA and dual bispecific activity.
Sixteen fusions from Dox-KLH immunized mice yielded 621
hybrids of which 47 showed low level bispecificity. Eight
fusions with Oox-BSA immunized mice yielded 297 hybrids.
,Jybrids showing dual activities were cloned and 7 out of 286
of the positive clones have been s,~lected for expension.
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CHAPTER I
lliTRODUCTION
I. 1.0 I!lTRODUC'l':ION
The initial paqes of this chapter deal with the cellular
aspects of cancer as related to therapy. This is followp.d by
a discussion of antibody mediated targeting (AMT) as a
background to bispecific monoclonal antibodies.
I. 1.1 cancer Cell B10109Y
The growth rate of a popUlation of normal or abnormal
(cancer) cells depends on three properties: the cell cycle
time, the growth fraction and the rate of cell loss (Baserg<lo,
1981). The shorter t~e cell cycle time (interval between
mitoses), the faster cells are produced. The growth fraction
refers to the fraction ot cyclinq cells. The rate of cell loss
refers to the fraction of cells that die or lIigrate to other
tissues. The number of cells produced is deterndned by thc
cell cycle time and gro....th fraction whereas the number of cells
lost is determined by rate of cell loss (Baserg"'.1981).
Normally in an adult where growth has cEased, the number of
cells produced per unit time equals the number that die. In
cancer, this balance has qone awry, resulting in an increase
in cell number. This is not necessarily due to a shorter cell
cycle time, as it has been observed that certain normill
tissues, such as jejunal mucosa of mice, proliferate faster
t:han the fastest growing mouse tumour (Baserga, 1981; Tannock,
1978 (;, 1989). Therefore, chemotherapy aimed at killing rap'~dly
proliferating cells also destroys such normal cells. This is
one of the major limitations of chemotherapy.
1. J.. 2 Cancer Cell !tinetics
Tumour invasion and metastases are additional limitations
in the treatment of cancer. Approximately )0\ of newly
diagnosed solid tumours (excluding carcinoma in situ and skin
cancers, except melanoma) already have clinically detectable
metastases at. the time of diagnosis. Of the remaining 70% of
cancer patients who are clinically free of metastases, only
approximately half can be cured by currently available forms
of therapy. Therefore, over 60\ of patients have either
microscopic or clinically evident metastases at the time of
diagnosis {Liotta (;, stevenson, 1989).
The reason for this may be better understood by the cell
kinetics of cancer. The smallest tumour size clinically
detectabh"! by physical or radiologic examination has a diameter
of about 1 em, containing approximately 10· to 109 cells and
weighing 1 g (DeVita, 1989). Considering this to be clonally
derived, it involves )0 doublings in cell number. From this
minimal detectc:.ble limit to a potentially lethal mass of 1 kg
(1011 cells) involves only 10 additional doublings in cell
number and hence the high probability of metastases at the time
of presentation by the patient (DeVita, 1989).
:t. 1.3 Liaitations of Cancer Cbelllc:herapy
The preceding paragraphs illustrate the challenge of
treating cancer from the cellular aspect and is reflected by
the data from NCI's Surveillance, Epidemiology and End Results
[SEER] program, 1984-1986 (Devita, 1989; Boring, squires"
Tong, 1991). In the U.S.A., cancer is second only to
cardiovascular disease as a cause of death and accounts for 22\
of all deaths. Out of a total of 930,000 cases with serious
cancer (exclUding cases of skin and in situ cancers), 332,000
already have clinically evident metastasis or are considered
inoperable at the time of presentation. 225,000 will recur
after local treatment. Thus around 557,000 patients are
potential candidates for chemotherapy, conf irming the 60\
metastases rate mentioned above. The chemotherapy of cancer
may thus be considered as the treatment of ldetastasis, (DeVita,
1989). The itllpact of chemotherapy since its advent in the late
1950'S, has been significant, reSUlting in over JO\ improvement
in survival rates in the past t'Wo dflcades, 'With the use of
chemotherapy alone or in combination with surgery and
radiotherapy (DeVita, 1989). However, most of the success has
been in the curative treatment of lymphomas, ovarian cancer,
leukemias and several other childhood cancers, Which, although
impressive, comprise only about 12\ !)f advanced human tumours
(DeVita, 1989).
The most common cancers are, the solid tumours of lung
(IS\) , colorectal (14\), breast ami prostate (27\) , and account
for 56\ of the total cancer cases and 55\ of cancer deaths
(Boring et aI, 1991). We have reached a plateau in the
treatment of these tumours with the currently available
modalities of treatment and new approaches are being evaluated
to decrease this mortality rate.
While the advantage of chemotherapy is its use in both
loca lised and disseminated cancer, the toxicity limits the
therapeutic index obtained, particularly for the refractory
solid tumours. The avenues explored include optimization of
drlJg scheduling, development of new cancer chemopreventive
agents with enhanced activity and/or reduced toxicity (Boone,
Kellaff & Malone, 1990) and better evaluation of regional
therapy (Cl1o!!1bner Fine, Allegra, 'leh & Curt, 1984). with the
advances in molecular biology, recombinant haematopoietic
growth factors are playing an increasing role in reducing the
bone marrow tbxicity associated with chemotherapy (Graopman,
Molina & Scadden, 1989).
Another reason for decreased efficacy of drugs is the
appearance of multidrug resistance (MDR) mediated by the
presence of a 170,000 dalton plasma membrane-associated p-
glycoprotein (Kartner & Ling, 1989). The expression of p-
glycoprotein correlates with decreased intracellular
accumUlation of drugs (Gerlach, Kartnor, Bell & Ling, 1986).
Calcium channel blockers such as verapamil have been shown to
be able to reverse mUltidtug resistance by competing with the
drugs for the p-glycoprotein pump and are being further
evaluated (Yin, Bankusli , Rustum, 1989).
considering this limited success of chemotherapy. a fourth
mOdality of treatment called Biologic therapy has rapidly
emerged in the last 15 years. Riologic therapy (imrnunother.1py)
refers to the use of natural host defence mechanisms or natural
mammalian substances in the treatment of cancer (Rosenberg.
Longo & Lotze 1989). The important milestones in biologic
therapy are the advent of monoclonal antibody (Mab) technology
in 1975 (Kohler. 'Milstein, 1975) and of the recombinant DNA
technology that could lead to an unlimited supply of Mabs and
biological modifiers.
I. 1.4 Cancer IllUlUaunotherapy
Immunotherapy can be classified into active and passive
approaches. Examples of each are given in table 1.
Table 1: Classification of" Cancer Immunotherapies
Classification Examples
I. Active Immune adjuvants such as BeG, C-
I--'I"'mm:::u"'n"'o"'th"'e"-r"'ap"'y__---1 ~:~;~~~e L:~~~~i~~:' su~~o~~gical
If-_
'
_'_"_on_s_
p
'_C_if_i_C_+-I_nt_,_r_le_U--:kin_2 (IL-2), Interferon
2. specific Immunisation with tumor cell
vaccines or: mabs (eg, anti-
idiotypic in lymphomas)
II. Passive Mabs or polyclonal antibodies
II-----'t"mm"'u"'n"'ot"'h"'e"r""p"-y__-j ~i~~s~o=t~~e~ra;~~~O~~b~~~jUqated
Antibodies
2. Cells
III. Indirect
cytotoxic T cells. Lymphokine
Activated I<iller cells (LAX
cells), Tumor infiltrating
lymphocytes (TJ:Ls)
Removal of blocking factors or
suppressor factors
Inhibi tion of growth factors or
angiogenic factors
(Adapted from RosenDerg, et aI, 1989)
Active immunotherapy is analogous to immunization for
infections diseases, referring to immunization of a tumour
bearing host with substances that elicit an immune response
capable of retarding or eliminating the tumour. Attempts using
nonspecific adjuvants such as BacUle Call'lette Guerin (BeG),
Corynebacterim Parvum (c. Parvum) and Levamisole have been
disappointing, as were specific iTUlunization attempts using
tumour cells or tumour-cell extracts either alone or as
vaccines (Rosenberg et aI, 1989) . Further, activo
!alllunotherapy may be impeded by a pre-existing imlDunosuppressed
status of the cancer patient. Despite the early promise of
interferons in many cancers, after extensive analysis in
clinical ':.rials, interferon-alpha is currently the treatllent
of choice only for the uncommon Hairy cell leUkaemia, with a
possible effect 011 cutaneous T-cell lymphoma (Krown, 1988;
Galvani, Griffiths & Co....ley, 1988). In addition, its
therapeutic potential has been restricted due to its extensive
list of toxic side effects, which has also been a limiting
factor of high doses of interleukin-2 (IL-2) therapy.
currently, Rosenberg'S group has shown lIeaningt:"ul response
rates in phase 1/11 trial!>, with a combination of low do~e
interleukin~2, LAK (lymphokine activated killer) cells or TILs
(tumour infiltrating lymphocytes) and cyclophospha.ide
(chemotherapy) in selected malignancies such as colonic
adenocarcino1lla and malignant melanolla (Rosenberg, Spiess &
Lafreniere,1986; Cameron,Spiess & Rosenberg, 1990) .
I. 2.0 ANTIBODY MEDIATED TARGETED THERAPY
I. 2.1 Objective
In antibCldy mediated targeted (AMT) therapy, antibodies
are evaluated as carriers of toxic agents such as drugs, toxins
and radioisotopes directly to the cancer site. The objectives
are two-fold: (1) selective delivery to cancer cell!; and (2)
reduced toxicity to normal cells. (Ford & Casson, 1986;
Dillman, 1989; Ford, Richardson, and Reddy, 1990).
II. 2.2 History
The concept of using antibodies as carriers of toxic
agents dates back almost a century, first postUlated by the
Nobel Prize laureate Paul Ehrlich (1854-1915). The term
antibodies, coined by Ehrlich, originated from his famous side-
chain theory (Dale 1957). As proposed by Ehrlich, in 1897,
each cell in the body carried on its surface specific side-
chains (receptors) (Ehrlich 1897). When encountered by toxins
(represented by toxic foodstuffs) for which the side chains
have specific affinity, the receptors (also called anti-toxins)
are produced in excess and liberated from the cells. Appearing
in the body fluids, they unite with the toxins and thus protect
the cells from damage. Such anti-toxins, later called
antibodies can be induced fOllowing a single immunization with
suitable bacteria (eg. cholera) or toxin (eg. diphtheria). He
referred to antibodies as exclusively \parasitotrophic' and so
.. 000 it is not surprising that they seek out their targets like
magic bullets" explaining the miraculous cures sorneti.es
obtained (Ehrlich, 1891).
Ehrlich c01ned the word 'cheDloth~rapy' and is considered
the father of modern chemotherapy (Ehrlich, 1908). Realizing
the nonspecific toxicity of pharmaceutical agents with
treatment at disease on normal tissues of the host, in
Ehrlich's own words, "We have no other choice than to learn to
shoot better" (Ehrlich, 1908). This concept is the basis or
antibody mediated targeted therapy.
Io 2.3 Co.ponent_ in tarqeted tberapy
Targeted therapy comprises broadly the following
components: (1) Target, (ii) Carrier, (iii) Toxic agents.
The!!:~ are further elaborated in subsequent pages with eXBlllples.
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I. 3.0 TAAGET
I. 3.1 00•• t\1Jlour specificity exist?
An ideal target is a cell surface antigen that is specific
to cancer cells and not present on normal cells. The search
for tumour specific antigens (TSA) was begun by Ehrlich. and
almost a century later, despite innumerable efforts by cancer
immunologists, their existence remains to be proven (Old 1981;
Schreiber, Ward, Rowley , strauss, 1988). preliminary
experiments involved imttll..:nization of outbred mice or rats ....ith
tumour tissue, Which, on sUbsequent challenge rejected the
tumours (Woqlom, 1929). Although initial interpretations
suggested tumour immunity, later experiments revealed that
these mice rejected normal tissues from donors as well and led
to the discovery of the major histocompatibility compleX"
dampening the enthusiasm for the existence of TSA (Schreiber
et al 1988).
I. 3.2 'l'WIour specific antiqens
The only evidence suggesting the existence of TSA cOllies
from transplantation studies using hi9'hly inbred mice carrying
tumours induced by chemical or physical carcinogens, ego
methylcholanthrene-induced carcinoma meth A, and the
ultraviolet light-induced skin tumour 1591 (Schreiber et al
1988). However, such studies may not necessarily correlate
with tumours occurring in humans who are extremely outbred,
despite a high incidence of tumours induced by physical
chemical carcinogens.
Therefore, after extensive searching for TSA for nearly
a century and despite recent technological advances, unique TSA
are yet to be discovered in humans. perh&ps the only
exceptions are the presence of the idiotype marker on certain
Band T cell lymphomas and leukemias (Stevenson George &
Glennie. 1990) and, more recently, the product of a p53 mutated
gene, under investigation (Harris, 1990).
1. 3.3 Tumour associated antigens ('I'M)
The best targets available for the commonly occurring
solid tumours are the TAAs which sho.... greater expression on
cancer cells relative to their expression on normal cells. In
addition, their lo....er expression on key normal tissues such as
bone marrow and intestinal mucosa further emphasizes their role
in reducing chemotherapy associated toxicity in antibody
mediated targeting.
Several TAAs have been identified to date (Bates & Longo,
1987) and eVall:t3ted for their use as tumour markers in cancer
diagnosis and management (Table 2). An ideal tumour marker
should possess the following characteristics (Bates & Longo,
1987): i) be produced by tumour cells and easily detectablo
in body fluids; ii) should be present only in malignancy and
not in health or benign diseases; iii) should be useful for
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screening and detecting early cancer levels; iv) should be
detectable in the absence of clinical evidence of tumours and
v) its decrease should correlate with efficacy of anti-cancer
therapy. None of the tumour markers discovered to date Illeet
all of the above criteria.
Table 2: Cla••ification of tuaour markers
TAA
Oncofetal antigens
Carcinoembryonlc
antigen (CEA)
Alphafetoprotein
(AFP)
Ca-19-9
Ca-125
Cancers
colorectal (Sot), lung, pancreas,
breast, gynaecologic (all 30-70\)
Hepatocellular carcin"llIa (72\) or
embryonal cell cancer
Colorectal, pancreatic
ovarian
Placental proteins Trophoblastic tumours (100\)
HUlian chorionic Testicular germ cell tumours
gonadotropin (HCG)
HUllan placental Trophoblastic
lactogen
Regan isoenz~e (of
alkaline phosphatase)
Enzymes Prostatic cancer
Acid Phospha tase
Aaaptea rom Bates" Longo, 1987
Three well characterised TAAs for solid tumours are
carcinoembryonic antigen (CEA), alphafetoprotein (AJo'P) and
human chorionic gonadotrophin (HeG). AFP, although a valuable
marker for hepatomas and testicular cancers is not as
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widespread as CEA. Furthermore, the cure rate for testicular
cancer has risen froll lot in 1973 to 70' in 1983 (Chabner et
aI, 1984) due to a cOllbination of surgery and chemotherapy.
HCG is lilllited to choriocarcinomas which have a cure rate of
over 90t. Since the discovery of etA. by Gold and Freedman
(Gold and Freedman, 1965) progress has been rapid particularly
in the last five years in the dissection of the antigen both
at the cellular and molecular level. Structural and functional
properties of eEA are presented in soction 1.12.0.
:t.3.4 Charactoristics ot tarqet
The choice of a target, apart from tumour specHicity,
depends on several characteristics which are discussed beloW.
t. 3.4 Ca) Antiqenic beteroqeneity
Tumour cell heterogeneity Is a trequent p["oble_
experienced in both diagnosis (phenotypic var iation) and
management of cancer (Fidler' Poste, 1985; Schnipper 1986).
This heterogeneity is illustrated by the differences between
patients bearing the same histological class of tumour leading
to survival times ranging from seven months to seventeen years
(Oldham, 19B7). In addition, heterogeneity exists between
individual cella of each tumour in each patient and has proved
to be a feature of most TAAs (Greiner, 1986). Approaches to
overcome this problem include the use of "COCktails" of Mabs
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recognizing differel1t antigens and/or different epitopes on the
same antigen. In a recent report, Durrant and his colleagues
have demonstrated that a combination of Habs recognizing
different TAAs such as CEA and 791T/36 recognized 100\ of all
the 50 lndividual human primary calorectal cancers studied
(Durrant, Robins, Ballantyne, Marksman, Hardcaastle , Baldwin,
1989). The Mabs were selected because of their preferential
binding to tumour cells compared to a panel of normal tissues
when assayed by immunocytochemical staining of cryopreserved
tissues.
other approaches include the use of interferon (IFH) to
enhance TAA expression resulting in increased localization of
mI-labelled Hab in human colonic xenografts (Greiner,
Guadagni, Noguchi, Pestka, colcher, Fisher' Schloll, 1987) and
of alliIn-labelled Hab 96.5 in patients with melanoma
(Rosenblum, Lalllki, Hurray, Carlo' Gutterman, 1988). However,
in a phase II trial using recollbinant IFlf potentiated antibody
dependent cellular cytotoxicity (ADeC) in patients with
advanced colorectal cancers, the delivery of Habs to the tumour
site remained a major obstacle (loi'einer, Moldofsky, Gatenby,
O'Dwyer, O'Brien, Litwin & comis, 1988).
Another approach is to use radionuclides as the toxic
Illoip.ty in order to eradicate 'bystander' non-antigen expressing
tumour cells (Order, Sleeper, stillwagon, Klein & Leichner,
l'
1990). However, this may lead to nonspecific toxicity to
normal cells.
I. 3.4 (1:1) Antigen expression I .ecretion
The antigen .ay be me.brane bound, intracellUlar or
secreted into the extracellular fluids. Although,
theoretically intracellular location of antigens may impede
recognition by antibodies, their accessibility has been
demonstrated in breast cancer, with Habs to keratin
polypeptides as the target antigen (Oairkee , Hackett, 1988).
In addition, LVI-labelled Mabs to an intracellular melanoma
glycoprotein could be localized in xenogratts up to 10 weeks
post injection (Welt, Mattes, Granda, Thomson, Leonard,
zanzonico et al, 1987). However, although Habs to
intracellular oncogene products have not been found to be
suitable targets (E:mbleton, Habib, Garnett , Wood, 1986)
inhibition of tumour growth in vivo has been delllonstrated by
a Nab reactive with transmembrane glycoprotein encoded by the
neu oncogene (Drebin, Link, weinberg, Greene, 1986).
Most TAAs evaluated in targeting studies are both membrane
associated and secreted into the extracellular fluid (ECF).
The secretion of antigen does not usually prevent antibody
localization, as demonstrated by a number of studies, unless
the plasma antigen concentration is very high (Begent, searle,
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Stan....ay. Jewkes, Jones, Vernon' Bagshawe, 1980; Searle, Baden,
Lewis & Bagshawe, 1981) perhaps leading to formation of
circulating antigen/antibody complexes and rapid removal by the
reticuloendothelial system.
I. 3.4 te) Antigen Density
It has been clearly demonstrated that the degree of tumour
reduction with Mab therapy is proportional to the cell surface
antigen density in solid tumours and hence the expression of
antigen on the surface may be a crucial factor in immunotherapy
(Capone, Papsidero & Chu, 1984). Several agents are being
evaluated for their capability of enhancing expression of TAAs
such as r,<,lcombinant IFN (Rosenblum et aI, 1988), butyrate,
glucacorticoids and cytotoxic drugs (Bagshawe, 1989).
Importantly, transforming growth factor f3 (TGF-,B) has been
shown to augment CEA secretion/expression and modulation in
human colon carcinoma cells (Chakrabarty, Tobon, Varani &
Brattain, 1988).
A low level of antigen expression may lead to
subtherapeutic delivery of Mabs, but is overcome in tumour
cells that show regeneration and re-expression of the antigen
on the cell surface within a short period of time, thus
trapping the Mabs and reSUlting in greater cytotoxicity (wang,
Lumanglas, Silva, Ruszala-Mallan & Durr, 1987).
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I. 3.40 (4) Antigenie modulation
The phenomenon of ant igenic modulation lnvelves the
redistribution of cell surface antigens in the presence of
bivalent antibody (Cobbold & Waldmann, 1984). Modulation
occurs within minutes and is reversible in the absence of
antibody (Schroff, Farrell, Klein, Oldham & Foon, 1984).
However, it may still be feasible to obtain cytotoxicity with
Mabs if conjugated to drugs/toxins and are rapidly
internalized, i., contrast to unconjugated Mabs, as demonstrated
using anti-human T-cell Mab T101 in vitro and In vivo in
patients with chronic lymphocytic leukaemia and cutaneous T
cell lymphoma (ShaWler, Miceli, Wormsley, Royston C. Dillman,
1984; Schroff et a1. 1984). Thus, antigenic modulation can be
a limiting factor in Mab therapy and attempts to o'/ercome it
include the use of univalent antibodies, like bispecific Mabs.
Antigens may also be nonmodulating such as campath-l antigen,
found on T and B cells, but not on stem cells, which •.~an
facilitate the targeting Mab to mediate ADCC or complement
mediated lysis (Riechman, Clark, Waldmann Iil Winter, 1988).
,.
I. 4.0 CARAIERS
I. 4.1 Introduction:
An ideal carrier is one that has the following properties.
Ease of chemical linkage of the toxic agent to the carrier with
both the carrier and agent retaining their function. The
carrier should deliver the toxin to the cancer site, releasing
the agent to act at the specific site. The carrier should have
a reasonable half-life to reach the tumour, but evade the
host's immune defence mechanisms (Ford & Casson, 1986).
SeveraJ carriers have been evaluated for the above
properties and the two outstanding candidates are antibodies
and liposomes (Figure 1). The specificity, monoclonality and
unlimited supply of Mabs makes them more suitable vehicles for
carrying toxic agents to tumour cells and will be discussed in
detail in the follo....ing sections. Liposomes are small spheres
consisting of concentric phospholipid bilayers separated by an
aqueous phase. A variety of substances can be incorporated
into liposomes including drugs, hormones and enzymes
(Weinstein, 1984). The problems .... ith the use of liposome~
include: nonspecific uptake by the reticuloendothelial system,
poor permeability out of the blood stream, degradation,
toxicity and antigenecitiy (weinstein, 1984; Gregoriadis,
1990) .
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I. 4.2 Antibodies as carriers
The concept of using antibodies as carriers of toxic
agents, although simple and attractive (frequently referred to
as magic bullets) did not gain momentum until the early 19705,
since investigators were faced by the following obstacles: (1)
apprehension regarding administration of large quantities of
foreign protein to patients; (2) immune response to
administration of these proteins; (3) lack of relevant pre-
clinical models for in vivo testing; (4) heterogeneity of the
antibodies with respect to their class, antigen specificity and
affinity; and (5) poorly defined targets (Ford and Cassan,
1986). Many of these obstacles have been partially or
completely overcome. For example, it has been demonstrated in
several studies that xenogenic antibodies can be safely
adminintered to patients (Newman, Ford, Davies & O'Neill, 1977;
Hamblin, Abdull-Ahad, Gordon, Stevenson & Stevenson, 1980) and
can localise the tumours in patients (Goldenberg, Leland, Kim,
Bennett, Primus, Van Nagell, Estes, DeSimone & Rayburn, 1978).
Th'2 development of the human tumour xenograft model has been
a major step towards elucidating the targeting potential of
antibodies (Rygaard & Poulsen, 1969).
A milestone in Immunology has been the development of the
hybridoma technique in 1975 by George Kohler and Cesar Milstein
(Kohler & Milstein, 1975) leading to the continuous supply of
antibodies of predefined specificity termed monoclonal
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antibodies for antibody mediated targeting {AHTI. Prior to
this innovation, all attempts at AHT involved polyclonal
l'.ntibodies (Pabs). Pabs are not entirely without advantages,
as Q:w:ploited by Stanley Order's group at John's Hopkins centre
(Lenhard, Order, spunberg, Asbell' Leibel, 1985). Pabs raay
be produced in a wide range of species avoiding repeated
presentation from one species to the patient's immune system.
Additionally, polyclonllolity can result in the recognition of
different epitopes on a given target, thereby increasing the
capacity for drug/toxin delivery. This can also be achieved
by 'cocktails' ot Mabs as mentioned in the above section on
targets. Polyclonal antibodies suffer frolll the disadvantages
of being heterogeneous mix.tures and the lack of reproducibility
from one polyclonal serum to another. A homogeneous unlimited
supply of monoclonal antibodies of predefined specificities,
therefore has advantages over Pabs or other carrier systeJllS.
and the rest of this chapter will be restricted to monoclonal
antibodies. the present status and the future with reference
to targeting.
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I. 5.0 MONOCLONAL ANTIBODIES IN THE DI:AGNOSI:S OF CANCER
The main uses of Mabs in the diagnosis of cancer are in
(1) Immunohistopathologlcal diagnosis of cancer, (2) Serum
tests for assaying various tumour markers, and (3) in
rudioimmcnodetection (RAID) (Ghee Teh, Stacker, Thompson &
McKenzie, 1985; Larson, 1986). principles of RAID are similar
to radio labelled Mab therapy and are presente":J ~n sectlon 1.
7.1).
6. 0 MONOCLONJl.L ANTIBODIES IN THB TREATMENT OF CANCER
,'5 the main focus of this thesis is on the production of
bispecific monoclonal antibodies for targeted drug delivery,
the current status of Mabs in therapy shall be first reviewed
briefly, summarised f:t'om the enormous literature and several
recent reviews and books on this subject (Ford & Casson 1986;
Levy 1987; Embleton 1987; Houghton & scheinberg 1986; Vitetta,
Fulton, May, Till & Uhr, 1987; Byers & Baldwin 1988; Dillman
1989; Hertler & Frankel 1989; Goldenberg 1989; Bagshawe 1989;
Rosenberg at aI, 1989; Ranada 1989; Kosmas, Kolofonos &
Epenetos, 1989; Ford et aI, 1990)
The basic mechanisms by which Mabs could be used in cancer
therapy are outlined in Table 3. Broadly, Mabs may be used in
vivo, either alone or as carriers of cytotoxic agents; in vitro
to purge tumour cells before autologous bone marrow
transplantation after high dose systemic cytotoxic therapy or
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to purge marrow ot T cells to prevent graft-verSus-host. disease
for allogenic bone marrow transplantation (Kernan, Byers,
Scannon, Mischak., Brechstein, Flomenberg, Dupont, O'Reilly,
19881·
Table 3: HOll.oclo4onal Antibodi.a tor Cancer Tberapy
bntibody Alone
Indirect Cytotoxicity
complement - mediated lysis
Antibody - dependent cellular cytotoxicity (ADCC)
polymorphonuclear leUkocytes
Direct cytotoxicity
catalytic antibodies
Regulatory antibodies
ItllJIIunization
Anti-idotyp!c antibodies
Antibody ImmunocoDiuqates
Radiolabelled antibodies
Immunotoxins
Chellotherapy illlDunoconjugates
Immunobiologicala
BODe Harrow Transplantation
In vitro
Anti-T cell purging to prevent gratt-versus-host
disease (GVHD) in allogeneic transplants
Anti-tumour purging before autologous
transplantation
In vivo
Anti-T cell antibodies to abrogate GVHD or rejection
in allogeneic transplants
Aoap ea tram D1.L. man, 1989; Rasennerg, 1990
I. 6.1 Monoclonal antibody alone: Indirect cytotoxicity
Antibodies constitute the main humoral immune defense
mechanism in man, their primary role being to eliminate
microorganisms by causing activation of complement or by
interacting with phagocytic cells. Due to practical and
economical reasons, most of the monoclonal antibodies evaluated
have been of murine origin. As in humans, murine antibodies
exist in different classes and SUbClasses, but a problem in
therapy is that mouse or rat Mabs may not interact wlth human
effector mechanisms. While this may not hinder targeting
cytotoxic agents, it could be a limiting factor in re-directing
human effector cells against cancer, a promising approach
pioneered by Rosenberg's group at the NIH.
Based on data collected from in vitro stUdies, in vivo
animal model systems and on a systematic approach by
constructing panels of chimeric antibodies using recombinant
DNA technology, different isotypes of murine and human origin
have been evaluated (Bruggemann, Williaml:>, Bindon, Clark,
Walker, Jefferis, Waldman & Neuberger, 1987; Riechmann, Clarke,
Waldmann & Winter, 1988; Dillman, 1989; Morrison & Vernon,
1989; Clark 1989). The most useful isotypes for interaction
with human complement are mouse IgM, followed by IgGJ ; rat IgM
and IgGn.. For ADCC, the results are complicated by the three
difft::t"ent Fe receptors on different effector cells. In
general, the best isotypes for ADCC are mouse IgG,• and 19G.I and
rat IgG1b • For human antibodies and mouse-human chimeric
antibodies, the best results of interaction .... ith human
complement are obtained with 19M > IgG , > IgGJ > IgG j ;> 19G~ and
for ADCC with human effectors they are human 19G I and IgG.1
(Dillman 1989). IgM antibodies, however, have technical
disadvantages due to their large size, which may impede
penetration into the tumour and additionally, could produce a
hyperviscosity syndrome.
I. 6.2 Monoclonal antibody alone: Direct effects
A novel approach involves raising Mabs against the
transition state of substances. On binding, antibodies act as
catalysts to induce changes on cell membranes, cellular
proteins or nucleic acids (IversoTJ & Lerner, 1989). The use
of such catalytic antibodies, specific for antigens on cancer
CEllls, may prove to be an alternative avenue for treating
Mabs may prove to be directly cytotoxic when directed
against receptors for growth factors that promote proliferation
of cancer cells. Mabs directed against interleukin-2 and
epidermal growth factor receptors are being evaluated in bone
marrow transplantation and cancer, respectively {Queen,
"
Schneider, soliek, Payne, Landolfi. Duncan, Avdaloric, Levitt,
Junghans, 'Waldmann, 1989).
Clinically, the .ost successful therapeutic use of
unconjuqated antibody has been in the use of OI<TJ • a murine Mab
directed against CD) (T Cell Receptor, TCRI on mature human T
cells, in renal allograft rejection. This is now an approved
therapy in patients experiencing acute rejection, with a
reversal of 94\: of the rejections and significant improvement
of one year graft survival up to 62\: (Ortho Multicenter
transplant stUdy group, 1985; Byers & Baldwin 1988).
I. 6.3 Nab. alone; X_unizatioD
In 1984, Neils Jeroe received the Nobel prize in Medicine
for his idiotype "network hypothesis" (Jerne NK 1974).
According to this hypothesis, murine antibody (AB.) directed
against a tumour associated antigen or a B cell lympholla
idiotype, would induce in addition to an anti-Fe antibody
response, an anti-idiotype antibody response (A~). A~ would
be a mirror image of AB l and thus resemble the original
antigen. AB1 may be more immunogenic and could be used to
immunize human", to induce AB) production that would react with
the tumour antigen, similar to ABu except that ABJ would be a
human antibody produced endogfmously (TraUb, Dejager, Primus,
Losman I ~oldenborg, 1988). Although such active immunization
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with idiotype 19 led to the emergence of surface Ig-negative
variants, the tumours showed a slower growth than the original
tumour, which may prove beneficial (George, Spellerberg &
Stevenson, 1988).
In addition, anti-!diotypic therapy of leukemias and
lymphomas with or without cytotoxic agents linked to the Mabs,
is an attractive approach due to the tumour specificity of the
B cell idiotype (stevenson, George & Glennie, 1990).
I. 7. 0 CONJUGATED ANTIBODY TARGETING
Due to the aforementioned reasons, antibodies
generally not efficient by themselves in eradicating cancer.
In addition, certain privileged sites such as the central
nervous system lac}l" access to the effector mechanisms. To
circumvent this problem, antibodies have been conjugated to
radioisotopes, cytotoxic toxins and drugs. The antibody then
does not contribute directly to the cytotoxic effect, but acts
as a carrier of the cytotoxic agent providing appropriate
target specificity. For a detailed list of cytotoxic agents
used for conjugation to Kabs, the reader is referred to
Houghton & Scheinberg (1986).
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t. 7.1 Radiolabelled antibodies
In addition to their value in diagnosis and therapy,
radialabelled antibodies have contributed much in quantitating
and studying the pharmacokinetics of Mabs in vivo.
t. 7.1 (a) Ra4io!lUluhodetection (RAID) :for Diaqnoais of Cancer
Tumour localization by radialabelled antibodies may be
considered as two eras; the first was pioneered by Pressman in
the 19505 in animal models and the second by Goldenberg and
others in the 19705 onward (Presmann , Korngold, 1953;
Goldenberg et al. 1978). A decade of clinical RAID trials from
1978 to 1988 involving 1831 patients, using 61 antibody
preparations (52 being nonoclonal) against twenty different
tumour types has been summarised by steven M. Larson of the
Memorial Sloan Kettering Cancer Centre (Larson, 1990). Cespite
this diversity, several parameters have been evaluated and the
future includes a standardised, systematic approach. The
problems included the limited fraction (in many cases, less
than 1\) of injected radioactivity localized in the tumour.
The problem of HAMA (human antimouse antibody response)
limi ting repeated administo:-ation may be overcome by the
superiority of Fab fragments over intact Igs in tumour
localization and the use of chimeric Mabs. HAMA is an
impediment to repeated administration of murine mabs and will
be addressed in a separate section (I 8.S).
llII has been .ost frequently used due to its ease of
conjugAtion, wide availability and a half-life ot eight days,
but is not an ideal radiolabel due to its tJ-emission. Newer
isotopes evaluated include lIlIn with good iJla,ging qualities,
but with a half-lite of 68 hrs, it is expensive, emits gamma
energy and accumulates in the reticuloendothelial system (RES).
Technetium-99, has superior iaaging capabilities, and is
relatively inexpensive and widely available. Additional
promise for RAID has been demonstrated with improved imaging
techniques such as S Ingle Photon Emission computerised
TOJllography (SPECT) over conventional gamma camera scanning and
with more recent technology such as hand held probes during
surgery, enhancing tumour localisation (Larson, 19901. In
conclusion, since an early diagnosis of clinically silent
micrometastasis may be the key to successful therapy,
investigators have reasons to be optimistic about a significant
role of RAID in the future. The probleas involved in RAID and
methOds of overcoming them (Sands, 19901 are common to tarqeted
therapy and are considered in the following sections.
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t. 7.1 (b) Ra4ioilDlllunotherapy (RAIT)
The role ot radiolabelled antibodies as therapeutic agents
has been recently reviewed in comparison with conventional
approaches in radiation therapy. RAIT was compared with
geometric isotopic implants, external irradiation, tumour dose
response and summarised with the energy of various isotopes
used (Order, sleeper, stillwagon, Klein & Leichner, 1990). The
goal of RAIT in comparison with RAID is to increase the uptake
by the tumour, preferably by all the cells, and for the
radiotherapeutic effect to be long lived. 131 1 has been used
widely due to its ~ emission and long half-life (8 days) and
has shown partial anti-tumour effects with anti-ferritin Pabs
in hepatomas (Order et aI, 1985) and Hodgkins disease (Lenhard
et aI, 1985). IllI Mabs have shown partial responses in a phase
III! trial of cutaneous T cell lymphomas (Rosen, Zimmer,
Goldman-Leiken, Gordon, Kzikiewicz, J<aplan, variakojis, Harder,
Dykewicz, Piergies, Silverstein, Roenigk lie Spies, 1S"Cl7) and
in B cell lymphomas (DeNardo, DeNardo, O'Grady, Levy, Adams &
Mills, 1990). The route of administration is important
depending on the tumour site, as demonstrated by partial to
complete responses ranging from 7 to 24 months with no toxicity
in 4/5 patients with leptomeningeal tumours injected
intrathccally with l.li r labelled Mabs (Lashford, Davies,
Richardson, Bourne, Bullimore, Eckert, J<emshead & Coakham,
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1.988) . The intraperitoneal (lop.) approach for advanced
ovarian cancer has been evaluated (Kalofonas, stewart "
Epenetos, 1988). Int·erestingly, in a double antibody study,
with radiolabelled antibodies administered both intravenously
(Lv.) and lop. in patients with advanced ovarian cancer, Lv.
'Was better than i.p. when the tumour was subserosal whereas
Lp. was more effective in ovarian cancer with ascites (Britton
1990) •
The properties of the isotope are important to avoid total
body irradiation, a limiting toxicity of RAtT. Alpha particles
have a ver}' high linear energy (5 to 8 Mev) and a short path
length (40 to 80 /-lm) limiting cytotoxicity to several cell
diameters, thus reducing non-specific ir::adiation of distant
tissues. mei, an a emitting radionuclude, despite a short
half-life (approximately 1 hr), has been demonstrated to be
valuable in localised Lp. malignancy in an animal model, ....here
tumour cells are easily accessible (Macklis, Kinsey, Kassis,
Ferrara, Atcher, Hines, Coleman, Aldelstein , eurllkoff, 1988).
Trials in progress include imaging with technetium or indium
labelled Mabs to calculate dosimetry, followed by RAID with 0-
emitters rhenium-18S or yttrium-gO labelled Mabs, respectively.
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I. 7.2 ImJD.unotoxinlll (ITs)
Toxins are attractive cytotoxic candidates for targeting
on a molar basis, as they are more potent than chemotherapeutic
drugs. A single molecule of ricin or diptheria A chain in the
cytosol may be sufficient to kill a cell (YamaizullIi , Mekada,
1978; Vitetta, Fulton, May, Till' Uhr, 1987). As a result,
several toxins have been conjugated to antibodies, and
evaluated as immunotoxins including ricin, abril'l, gelon!n,
pseudomonas exotoxin A, diptheria toxin. Most toxins are
proteins which share in common their mode of action by
inhibiting the elongation step of protein synthesis, elicited
by the toxic moiety of the molecule. The cell binding moiety
of the toxin (a-chain) is removed before the toxic part is
linked covalently to the antibodies, thus reducing nonspecific
binding. Progress has been rapid in the construction of ITs
leading to the production of second and third generation ITs
using recombindnt DNA technology. Their efficacy and
pharmacokinetics, have been reviewed, in vitro and in vivo in
pre-clinical and clinical studies (Vitetta et aI, 1987; Byers
& Baldwin, 1988; Hertler & Frankel, 1989). Numerous clinical
studies have been performed using ITs in the treatment of
diseases such as chronic lymphocytic leukemia (eLL), B cell
leukemia (BeL) and selected solid tumours, including a
systematic-phase III! trial in malignant melanoma (Hertler &
Frankel, 1989; Spitler, Rio, Khentigan, Wedel, Brophy, Miller,
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Harkonen, Rosendorf, Lee, Hischak, Kawahata, Stoudeaire,
Fradkin, Bautista .. Scannon, 1987). A. successful application
has been in the prevention and treatment of steroid resistant
graft-versus-host disease (CWO) by depleting the T cells,
using an anti-CD, IT, from allogenic bone marrow transplants.
Following the dralllatic response in an 8 year old girl with
severe grade III-IV, steroid resistant GVHD (Kernan et ilIl.
1988), phase III! trials are underway on a larger group of
patients, \,lith promising early results (Byers V: H.D. Anderson
Cancer Centre, Personal communication). Equally promising is
the potential in the treatment of AIDS with ITs that can
neutralise HIV virions and kill T CE'.lls infected with diverse
strains of HIV-1 (Kill, Fund, Sun, Sun, Chang, Chang, 1990)
I. 7.3 Antibody-drug i ..unoconjugata_ (IC_'
(I_Uhocbuotberapy)
Chemotherapeutic drugs as toxic agents have the advantages
of fa.iliarity due to their wide use clinically, with their
pharmacokinetics, mode of action, tUliour susceptibility and
toxicity well elucidated. The report by Math6 (1958) with
prolongation of survival of mice with L1210 leukemia treated
with antibody targeted methotrexate, first demonstrated the
feasibility of targeted chemotherapy. It was also shown that
antibody and drug mixed noncovalently were synergistic in their
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action but it was necessary for drugs to be covalently linked
to the antibodies for maximum targeted effect (Davies ,
O'Neill, 1973; Newan et aI, 1977).
Typically, after chellical coupling of drugs and
antibodies, the ICs go through a systematic process of in vitro
testing using cultured human cancer cell lines, in vivo pre-
clinical studies with iSnimal models (the most useful model
being the nude athyllic mouse "'ith human tumour xenografts) and
finally clinical trials. Due to this elaborate production and
testing precess, most clinical trials to date have been
preliminary phase 1/11 trials. The~e trials have demonstrated
the efficacy and t'easibility of this approach, as well as the
problems involved and suggestions for overeo.lng these problems
(Ranada 1989). Preclinical and clinical studies have been
reported with les of different chemotherapeutic agents. Human
studies using ICs were pioneered by Ghose's group from Halifax
in the early 19705, using chlorambucil and the folic acid
antagonist .ethotrexate (Chose, Norvell, Guclu " Macdonald,
1972 " 1975). A few recent examples are with the
anthracyclines, doxorubicin (Dox) (Pietersz, Smyth &: Mckenzie,
.1988; Pietersz, Smyth, Kanellos, cunningham & Hckenzie,1989;
Yang&. Rehfeld 1988) and daunomycin (Dillman et aI, 1988;
Diener, Diner, Sinha, Xie "Vergidis, 1986; Pieters2 et aI,
1988; Diener, Xle, Yu, Longenecker & sinha, 1988). In
addition, recent stUdies have also inclUded methotrexate
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(Ghose, Blair, Kralovec, Halllllen, Vadia, 1988; Baldwin" Byers,
1989) I alkylating agents (Smyth, Pietersz " McKenzie, 198Bll;
Pietersz et aI, 1989) and the work froa this laboratory with
vinca alkaloids (Ford, Bar.tlett, Casson, Marsden' Gallant,
1987a). Preclinical studies of Habs specific for CEA (Habs 11-
285-14 & 14-95-55) linked to vindesine have clearly
demonstrated efficacy, both in vitro and in vivo, which
correlated with the degree of expression of target antigen CEA.
(RoWland, Simmonds, Core, Marsden" smith, 1986; Ford et aI,
1987; Casson, Ford, Marsden, Gallant" Bartlett, 1987a). The
sensitivity of the cell line to the ther4peutic agent plays
an important role as demonstrated by the efficacy of anti-eEA.
Paba or Habs linked to vindesine or doxorubicin (Ford et al.
1987a; Richardson, Ford, Tsaltas , Gallant, 1989).
Although immunoconjugates may often be less effective in
vitro tha.n the free drug, their in vivo efficacy and
therapeutic index :IIay be increased as demonstrated by
vindesine-anti CEA ICs (ROWland et aI, 1986; Casson at a1.
1987) and Do)(orubicin-T1Dl Hab Ics (Dillman et aI, 1986). In
addition, anti-LY-2.1 chlorambucil Ics have shown an increased
efficacy compared to the free drug, both In vitro and in vivo
against a murine thymoma cell line (Smyth, Pietersz, Classon
& HcKenzie, 1986).
"
I. 8.0 PROBLEMS INVOLVED WITH IMKUNOCONJUGATES
The problems of les in therapy may be related to their
production, delivery or the target antigen itself.
Het.erogeneity of antigen expression and antigen modulation were
presented :il section 1.3.0. The following sections deal with
ICs production and delivery.
t. 8.1 Production of imJDunoconjuglltes:
The number of active drug molecules that may be directly
linked depends on the number of mQdifiable sites on the Mab
molecule with a potential for loss of immunoreactivity
(Durrant, Robins, Armitage, Brown, Baldwin & Hardcastle, 1986).
This is a ma~jor problem because most drugs are hydrophobic
compounds and have to be attached to hydrophilic am.lbodies,
with the retention of both Mab and drug activity. Most
l,oupling procedures, like the commonly used glutaraldehyde or
carbodiimlde reagents, result in a loss of drug activity and/or
antibody activity (Pietersz et aI, 1989). Efforts have been
directed at improving thu methods of conjugation.
In addition, secondary carrier molecules may be used, to
which a larger number of drug molecules can be attached,
followed by conjugation to Mabs. Ies produced by Doxorubicin
linked via a cis-aconityl spacer molecule to a Mab (9.2.27)
recognising a melanoma antigen have been demonstrat£!d to be
more effective than the free drug in vivo (Yang & Reisfeld,
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1988). Si1ll.iarly, greater efficacy has been demonstrated for
anti-alpha protein Pabs or l1abs linked to daunolllycin via a
dextran bridge (Tsukada, Ohkawa i Hibi. 1987). Another study
demonstrated that up to 38 moles of methotrexate could be
attached per mole of human serum albumin (HSA) with subsequent
linkage to Hab 79IT/36 directed against an osteogenic sarcoma
cell line. However, despite an increase in cytotoxicity
compared with the free drug, the antigen binding activity of
the Ics was reduced by nearly 70\ (Garnett & Baldwin 1986).
More promising is the report of conjugation of up to 30-50
molecules of MTX by an intermediate amino-dextran carrier
system to antl-CEA Hab with retention of antigen binding
activity (Shih, Sharkey, Primus " Goldenberg, 1988).
disadvantage with this approach is the larger molecular weight
of these secondary carrier les, Which, although effective in
vitro, eli_lnated quiCkly in vivo by the
reticuloendothelial system.
A complementary approach to better methods of conju9ation
is to use new or more potent derivatives. An example is bromo-
idarubicin, an anal09ue of idarubicin. Two to five residues
of bromo-idarubicin have been coupled to antil::lody via an ester
link, with minimal 10s5 of antibody activity. Furthermore, the
conjugation resulted in only a fourfold loss of drug activity
compared to a 40-fold loss with iodacetyl adriamycin and tho
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les were more toxic both in vitro and in vivo in a murine
thymoma model (Pietersz at aI, 1989).
A new two stage approach called antibody directed enzyme
prodrug therapy (ADEPT) involves first targeting an enzyme
which has no human analogue. This is followed by
administration of the prodrug that is activated to those sites
at which the enzyme is distributed by the Mab (Bagshawe, 1989).
Preliminary results from Bagshawe's group in London, have
demonstrated the localisation of an anti-human chorionic
gonadotropin (heG) - carboxypeptidase G2 in choriocarcinoma
xenografts. This was followed by administration of an inert
alkylating agent bis-chloromustard that was activated at the
tumour site eradicating small tumours (Bagshawe, 1989).
I. 8.2 Pharlllacokin.ticB
Few clinical studies have been performed with lCs and the
little that is known of the pharmacokinetics of lCs has come
from studies in in vivo xenograft mOdels. For example, VDS-
anti-CEA (11.285.14) lCs showed a prolonged serum survival and
increased tumour localisation of VDS compared with the free
drug (Rowland et al, 1986). Similarly, a specific increased
uptake of MTX was obtained fro:a HTX-Mab (79lT/36) lCs compared
with unconjugated MTX (Pimm, Clegg, Garnett & Baldwin, 1988).
Most biadistribution and pharmacokinetic studies have been
performed with radiolabelled Mabs. Few studies with Mab-drug
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Ies have been reported due to the difficulty in produc:ing
radtolabelled or suitably tagged drug, and, therefore, the
difficulty in the measurellent of in vitro and 1n vivo
dissociation of drug froll the Ie. However, studies perfor-Ied
recently with tritiulIl or carbon-14 labelled HTX (Plu et aI,
1988), daxarubicin (Yang , Reisfeld, 1988) and vindesine
(Rowland et aI, 1986) clearly demonstrate that antibodies can
target drugs to tumours and lead to a higher accumulation of
drug in the tumour than elsewhere.
In addition, a systel1atic approach has recently been
reported comparing the phllrlldcokinetics and tissue distribution
of tritium labelled ()Hl N-acetyl melphalan, tree anti IY-Z.l
Hab and the Hab-drug ICs in vivo in lIice bearing murine
thyaOilldS (Pieters~, Krauer, Toohey, SlIyth , McKenzie, 1990).
The results clearly demonstratf!d that while the free drug [if)-
N-AcHe! was rapidly eliDinated from the circulation (T".i Q of
0.5 hrs and T".i fJ of 60 hrs), an accuaulation of 2-5 tilles 1I0.e
drug was found in the tu.our with the ICs than with the free
drug. Indeed, the illllunoconjug'ates were superior in their
antitumour activity and a greater therapeutic effect was
obtained than with either N-acetyl melphalan or melphalan
itself. Interestingly, increasing' the dose ot IC tro1l'l JJO J.l9
up to 1650 J.lg did not increase the percentage of injected
1
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dose/gram tumour, indicating saturation in the tumour (Pietersz
et ai, 1990).
The distribution of the unconjugated anti ly-2.1 Mab was
similar to the Ie, while a control anti-CEA antibody conjugate
had no selective accumulation in the tumour. pietersz and
colleagues further extended their study to the effect of route
of administration of the Ie on the localization to tumour and
showed greater efficacy of the Ie given Lp. compared to the
Lv. route. The slower absorption from the i.p. route probably
led to the greater accumulation in the tumour of 15% and 20%
of injected dose/gram tumour compared to 11% and 9% when given
Lv., after 24 hrs and 48 hrs respectively. However, in
patients a prolonged Lv. infusion may be given to achieve a
steady state level and higher concentr;\tion of lCs in the
tumour.
These studies indicate that Hab-drug lCs are finally being
systematically evaluated in a similar fashion to conventional
chemotherapeutic drugs. However, although in most studies up
to 20% of the Mab may reach the tumour in experimental animals,
in humans this amount falls to as low as 0.01% of the
administered dose (Epenetos, Snook, Durbin, Johnson &
Papadimitriou, 1986; Pietersz et a1, 1989). Therefore, once
appropriate conjugates have been produced, the next obstacle
is their optimal delivery to the cancer site and penetration,
as will be discussed in the following section.
I. 8.3 Physiological barriers to delivery anI! penetration
Many investigators consider that the major problem with
AMT is the delivery of Mabs to the tumour site and further
penetration into the tumour. However, it should be reinforced
that this is not restricted to delivery of Mabs but is
universal to all therapeutic molecules used in cancer (Sands,
1990). While delivery of Habs may not be a problem for
radioimmunodetection or treatment of leukemias, lymphomas and
small tumours (micrometastases), heterogeneity of antigen
expression alone has failed to explain the poor localisation
of Mahs in solid tumours and three physiological barriers have
been identified (Jain, 1990):
(a) heterogenous blood supply (poor vascularity), which
limits the delivery of blood borne molecules to well-
perfused areas of a tumour,
(b) elevated interstitial pressure, which opposes the inward
diffusion, and
(c) large transport distances in the interstitium which
increases the time required for diffusion of Habs to
reach distal regions of a tumour.
Approi'l.ches to overcome these barriers include the use of
physical (radiation, heat) and/or chemical (vasoactive) agents
to increase tumour blood flow (Jain, 1990). For example, a
threefold increase in tumour localisation of Mabs was
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demonstrated with combined therapy with ,B-adrenergic blocking
agents like propranolol (Pietersz et aI, 1989). Furthermore,
tumour necrosis factor (TNF), by virtue of its properties of
eliciting a local tumour inflammatory response leading to
vasodilatation, increased permeability, leakiness and blood
flow, acts synergistically with immunoconjugates and has
resulted in the eradication of a number of tumours (Smyth,
Pietersz, McKenzie, 198Bb).
Another approach is to use smaller molecular weight
fragments like F(ab)2 to improve penetration into tumours, but
their advantage may be outweighted by their shorter half-life
and rapid clearance as demonstra'!",ed by several studies (Piertsz
et aI, 1989; Jain, 1990). However-, monovalent antibodies such
as bispecific Mabs, due to their reduced avidity, may be able
to percolate deeper into tumours and this is one of the
potentia! advantages of such antibodies. Bispecific antibodies
are pr-esented in section I. 9.2.
I. 8.4 Internalization
Few studies have addressed the mechanism of
internalization of antibodies, which plays an important role
in the mode of action of Habs (Matzku, Brocker, Bruggen,
Dippold & Ti1gen, 1986; Mariani, Kassis & Adelsstein, 1990).
Several factors are associated with internalization of Mabs
including the Mab itself (conjugated VB unconjugated) and the
dynamics of the antigen (integral membrane protein vs secretory
product). In addition, the fate and action of the antiqen-
antibody complex depends on internalization. This may be
ineffective with modUlating antigens and Ilay result in shedding
of th~ complex (Matzku, Bruggen, Brocker & Sorg, 1987).
The transferrin receptor is a frequently used model for
internalization of Haba in tumour cells due to its abdundancc
and well characterised endocytic pathway (Sutherland, Delia,
schneider, Newman, Cornohoad & Creaves, 1981; Taetle &
Honeysett, 1989). Other studies are focusing on the uptake of
unconjugated antibodies against tumour associated antigens
(Tsaltas, Ford and Gallant, 1992) and on the uptake of les in
hematological and solid lIalignancies (Press, Farr, Borroz,
Anderson & Hartin, 1989; Wargalla , Reisfeld, 1989). These
studies will be beneUcia1 in the selection of appropriate t'lab
and target antigen for complete cytotoxicity with AMT.
I. 8.5 'l'oxicities and. huaan anti.ouse antibod.y respon.e
The most frequently questioned and criticised aspect,
especially from the clinical point of view, remains the human
antimouse antibody (HAMA) response, which limits the repeated
administration of Mabs. Ideally, while human Mabs are most
desirable, nany technical problems remain in their production
(Larrick' Bourla, 1986; Borr2back, 1988). The administration
of nonhuman antibodies could theoretically lead to IgE mediated
hypersensitivity reactions or IgG/lgM mediated blocking
antibodies and even delayed hypersensitivity reactions. A
summary of clinical trials and associated HAMA has been
reviewed by Dillman (1990). Acute hypersensitivity reactions
have been rare with a frequency of less than 1%. Other adverse
effects were minor and included febrile reactions, chills and
pruritic skin rashes, seen in 10-15% of patients. These
effects correlated with HAMh responses. Although most clinical
trials have been preliminary and more than 50% of patients
developed HAMA, there have been fe.... reports of renal disease
or similar complications associated ....ith immune complex
deposition.
Several strategies have been attempted to abrogate HAHA
and these include: (1) the use of immunosuppressants,
cyclophosphamide, cyclosporine A or azathioprine, of which
cyclosporine A seems the most promising (Dillman, 1990). (2)
Certain substances such as pOlyethylene glycol (PEG) (Maiti,
Lang & Sehon, 1988) and low weight dextran (Fagnani, Hagan,
Bartholomew, 1990) When linked to Mabs induce tolerance and
immunosuppression specific to the Mabs. While human studies
are yet to be reported, this approach may be the future answer
to HAMA and even benefit other disorders including allergies.
(J) Wi th recent advances ir. recombinant DNA technology I
chimeric antibOdies have been produced (Morrison, 1985;
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Horrison .. Vernon, 1989). Since the Fe portion is considered
the most immunogenic, such recombinant antibodies contain hUllan
Fe portions and mouse variable regions. The production of
anti-idiotypic antibodies can still be a problem, and chimeric
humanized antibodies which are entirely hUman except for the
antigen binding hypervariable regions should further reduce
anti-idiotypic response (Verhoeyen .. Riechmll.nn, 1988). Such
reshaped antibodies have entered the clinic and the prelininary
results reveal diminished HAMA and longer circulation times
(Lobuglio, Wheeler, Trang, Haynes, Rogers, Harrey. Sun, Ghrayeb
.. Khazaeli, 1989). Finally, the proof that Habs are beinq
seriously considered as an alternative therapeutic measure in
cancer can be realised from the FDA's (Food and Drug
Administration) approval in the document "Points to consider
in the .manufacture and testing of JIlOnoclonal antibody products
for human use- (Hoff.an, 1990).
Some of the problems associated with antibody targeted
therapy and potential solutions to overcome these problems are
summarised in table <I.
..
Table 11: proble•• and pOllsible 801\l~ioD. Assooi_ted with
lUI'
Problem
Antigenic modulation
Antigenic
heterogeneity
Lack of~
expression of antigen
circulating free
antigen blocks
antibody localization
after forming immune
complexes
Incomplete penetration
into tumors
HAMA
Non-specific uptake of
Maba by liver and
other normal tissues
Bone marrow toxicity
from toxin-labelled
Maba
Adapted and modified from:
Lotze, 1989.
Potential Solutions
Use bispecific Mabs (univalent
antibodies) •
Choose nonmodulating antigen.
Treat with cocktail of Maba that
react with different antigens.
Treat with cytokines that induce
antigen expression (IF«, TNF).
Increase dose of Mab to saturate
the blood antigen, so that
remaining dose can localize to
larger antigen pool in the
tumor; plasmapheresis.
Use vasoactive agents (e.g.
Propranolol). Produce capillary
leak with IL-2, TNF; Fab
fragments; SaMaba.
Immunosuppressive drugs; induce
tolerance (with PEG, Dextran,
etc.); human chimeric Mabs; Fab
or Fv -'raqments.
Choose Mabs that do not cross
react with liver; alternatively
block hepatic uptake with 'cold'
antibody before injecting
immunoconjugate.
Use in association with
autologous bone marrow
transplantation.
Larson, 1986; Rosenberg, Longo &
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I. ,. Q BIlJPBClfIC MONOCLONAL UTIBODIEB
1.9.1 History
The idea of using' bivalency of antibodies to cross-link
two antigenic 6ubstanc::es is not new and chemical recorablnatlon
of univalent Fab fragments of different specificities was
attempted in 1961 by Hisono!! and Rivers (1961). The first use
of bispeciflc antibOdies prepared froll polyclonal rabbit
antimouse IgG against anti-ferritin or anti-southern bean
mosaic virus (SSMV) antibodies, was as markers for locating
cell surface llontigens by electron microscopy (HllImmerling. >.old,
DeHarven. Boyse 'Old, 1968; HaDUlerling, Aokl,Wood, Old, Boyse
& DeHarven, 1969). With the realisation that such antibodies
avoided the various problems involved in chemically linking
different markers to the antibodies, early attempts were made
at coupling two different intact iDllllunoglobulin molecules or
half molecules (Nisonoff & Mandy, 1962; Nisonoff & Pal.er,
1964; Ghetie & Mota, 1980). However, these early bispecific
antibodies were polyclonal, heterogeneous mixtures. With the
advent of Mllbs it is now feasible to produce bispecific
monoclonal antibodies (Milstein' Cuello, 1983).
••
I. 9.2 Advantages ot bispecitic monoclonal antibodies (DsMabs)
As was discussed under the immunoconjugate section, a
major problem in the production of res is the chemical
conjugation of highly hydrophobic drugs to hydrophilic
antibodies. These procedures can lead to a loss of up to 70!l;
of antibody activity and up to 90\ of the drug activity.
particularly relevant to the anthracyclines is that the
commonly used conjugation procedures involve chemical linkage
of the amino group of doxorubicin and daunorubicin to the
antibody which may result in inactivity of the drug (Hurwitz,
Ronald, Maron, Wilchke, Arnon, Sela, 1975). In addition, the
activity of the res varies from batch to batch.
Apart from the advantage that no chemical manipUlations
are necessary to link the drugs to the BsMabs, these antibodies
although structurally bivalent, are functionally monovalent.
Monovalency has been shown to prevent antigenic: modUlation, a
mechanism by which tumour cells escape antibody mediated
destruction by redistributing the surface antigens, thus
shedding the antigen antibody complexes (Cobbold' Waldmann,
1984). An added potential advantage is that the amount of
monovalent antibody (BsMabs) bound to the cell is increased,
compared to conventional Mabs. This may be critically
important if there is a paucity of antigen expression on the
tumour cell, leading to delivery of more antibody molecules to
the cell. Binding may also be more efficient with BsMabs in
••
cases of low antigen density, as bivalent Mabs require antigens
sUfficiently close to each other for the two antibody sites to
attach (Milstein Ii Cuello, 1984; Surash, Cuello & Milstein,
1986a) •
Although the reduced avidity of SsMabs due to possession
of only a single antigen binding site may be a disadvantage,
conversely, SsMabs could penetrate deeper into the tumour in
a similar way to the percolation of Fab fragments. This would
be an advantage in vivo leading to delivery of more of thE'!
cytotoxic agent into the normally inaccessable portions in the
centre of the tumour (Vitetta at aI, 1987; Jain 1990).
,.
I. 10. PRODUCTION OF BISPECIPIC ANTIBODIES
Different approaches to producing bispecit'ic antibodies
are presented below.
I. 10.1 Heteraconjugate1 antibodies
Two different intac.~t Mabs may be heteroconjugated by
chemical means using protrJin A or the cross linking reagent N-
succinimydyl 3-(2-pytid.\,' Idithiol) proprionate (SPDP) (Ghetie
& Mota, 1980; Paulus, 1985; Lansdorp, Aalberse, Bas, Schutter,
Van Bruggen, l0!:c). Heteroconjugates of Mabs directed against
the T cell receptor and tumour cell antigen have been
demonstrated to focus cytotoxicity on to tl,e. target cells
(Staerz, Kanag'lwa, Bevan 1985; staerz " Bevan, 1986).
A further rsfinelllent of the above is to recombine
monovalent fragments from Mabs after reduction of F(ab), in the
presence of a specific dithiol comploxing agent such as
arsenite (which prevents the formation of internal disulphides)
and effecting disulphide formation with a thiol activating
agent such as 5,5'-dithiobis(2-nitrobenzioc acid) (Brennen,
Davison, Paulus, 1985; Paulus, 1985). An example is the
production of two bispecific antibodies, both recognising
avidin with one arm and either horseradish peroxidase or (3-
galactosidase with the other. These antibodies act as linkers
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for lmmobilisation of the enzymes on a biotin-substituted
matrix in the presence of avidin (Paulus, 1985).
However. a Ii.itaticn of the above methods is that
chemical manipulations are required tor chain separation and
recombination leading to some protein denaturation, loss of
antibody activity and further, considerable waste of Mabs. In
addition, molecular and functional homogeneity may not be
always assured (Milstein" Cuello, 1983).
X. 10.2 Kybrido•• technoloqy: theoretical considerationa
Normally, individual antibody producing cells express
only one heavy and one light chain allele by a phenomenon
called allelic exclusion. This is facilitated by correct
rearrangement of the variable and constant DNA segments in only
one of the two alleles (Reth, Ammirati, Jackson, Alt, 1985;
Alt, Blackwell, Yancopoulos, 1987). However, when two such
cOmllitted B cells are fused, the derived hybrid codo.inantly
expresses both parental heavy and light chain genes. The four
chains are then free to recombine in the cysternal spar-e,
reSUlting in the formation of both parental and hybrid
immunoglobulins (Milstein & Cuello, 1984; Suresh et aI, 1986b).
Since, theoretically, any light chain can associate with
any of the heavy chains, the main molecular species reSUlting
from such combinations are as follows. Type 1: Total random
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association of the twr~ heavy (HI & HI) and two light chains (Ll
10 ~l results in ten different species. However, only cis
dssociations (HL pairs derived frOIll the genes of a single
parent) can forlll functional Fab arms. Type 2: Randoll heavy
chain association with fully restricted chain association,
results in preferential parental Mll.bs or BsMab formation. Type
J: Random heavy chain association with partly restricted light
chain assembly, resulting in one functional arm (suresh et aI,
IlJB6bj Milstein & cuello, 1984; Songsivilll.i & Lachman, 1990).
In reality, the intracellular assembly of chains shows a
preferential association of homologous vs heterologous pairs.
In addition, depending on the differential rate of chain
synthesis, up to 30\ to 50\ of the secreted illmunoglobulins may
be the desired BsMabs (Milstein' Cuello, 1984; Suresh at a1,
1986a bl· This has been demonstrated with a
antisomatostatin-antiperoxidase hybrido1la. The crude antibody
lIIixture separated into three peaks following ion exchange
chromatography. Peaks 1 and 3 on 5DS-polyacrylamide g81
electrophoresis analysis indicated restricted homologous light
and heavy chain association reslJlting in parental antibodies.
Peak 2 consisted mainly of BsMabs. The activities were
confirmed by immunoassays. Peak 1 had antisomatostatin
activity and composition similar to the parental
antisomatostatin IgG .... ith a single light chain band. While
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peak 3 demonstrated antiperoxidase activity, conta 1n1ng
parental heavy chains, the composition also revealed both light
chains, suggesting a type 3 chain association mentioned
earlier. As the authors suggest, this problem may be overcome
by screening for a more suitable clone yielding a Type 2
pattern of chain association.
Theoretically, if there is a random association of heavy
chains, then upto 50\ of yield could be of BsMabs formation,
with the ratio of the three immunoglobulin peaks being 1:2:1
(Milstein" Cuello, 1984; Suresh at aI, 1986a). As evidence,
a cellulose acetate electrophoretic pattern of ascites of one
of the hybridomas demonstrated a higher intensity of the middle
band (Suresh at aI, 1986b).
I. 10.3 Production of hybrid-bYl'lridOJllBS
Two general methods are described below.
1.10.3 (a) Hybridoma x spleen cell fusions
The principle involves fusion of a hypoxanthinel
andnopterin/thymidine (HAT) sensitive hybridoma (secreting
monoclonal antibodies) with spleen cells from animals immunized
with the second antigen (jf choice. The hybridoma is made HAT
sensitive by growing in increasing concentrations of the purine
analogue, 8-azaguanine. The enzyme hypoxanthine-guanosyl-
phosphoribosyl-transferase (HGPRT) catalyses the incorporation
of 8-azaguanine into DNA, Which interferes with normal protein
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synthesis and the cells die (Hudson & Hay, 1980). Resistant
cells are obtained by mutation or loss of the HGPRT gene. Such
HGPRT deficient cells when placed in hypoxanthine, aminopterin
and thymidine (HAT) medium are unable to utilise hypoxanthine
to synthesise purines. The alternative pathway of DNA
synthesis is de novo synthesis. However, aminopterin is an
analogue of fol i.e acid and binds folic acid reductase, thus
inhibiting the de novo synthesis of DNA (Littlefield, 1964).
a-azaguanine resistant (HGPRT deficient) hybridomas thus die
in the HAT selection medium. These cells, are fused with
normal lymphoid cells and the resulting hybrid-hybrids survive
HAT, as the lymphoid cells provide the HGPRT and the parental
hybrid provides the immortality.
t. 10.3 (bl Bybridom. x Bybrido•• fusions
The principle involves fusion of two est'iblished and well
characterised hybridomas by (a) a chemical inactivation method
or (b) a combination of the chemical inactivation method and
HAT selection.
The method of chemical inactivation involves the use of
two distinct site specific irreversible inhibitors of
macromolecular biosynthesis (suresh et aI, 1986b), thereby
inhibiting independent metabolic pathways of the two cell
lines. Fused cells survive by complementing each other. An
example is the fusion between an antiperoxidase YP4 hybridoma
with antisubstance P NCI/34 hybridorJJi. The NCI/34 was made
sensitive to emetine (an inhibitor of protein synthesis
blocking the translocation step) and the YP4 was made sensitive
to actinomycin D (an inhibitor of RNA synthesis). When grown
in medium supplemented by critical concentrations of these two
drugs, the fused cells survive by complemel:~.ing each other
(Suresh et aI, 1986b).
I. 1.0.4 Recombinant DN" tecbnology.
Chimeric BsMabs have been produced by transfecting
immunoglobulin genes into myeloma cells (Songsivilai, Clissold
& Lachmann, 1989; Songsivilai & Lachmann, 1990). The
limitation of this approach, at present, is the availability
of cloned immunoglobulin genes of the desired specificities.
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11 • 0 OBJECTIVE.
The objective of this project. WAS to produce novel
8s14abs that siaultaneously recoqnizs the target
carcinoembryonic antigen (eEA) and the chemotherapeutic drug
doxarubicin {adriamycin}.
1.12.0 WhyCEA?
In order to evaluate the role of BsMabs in cancer
treatment, the appropriate choice of target ....as crucial and we
required: (a) II target present on major solid tumours for which
improvement in therapy was urgently needed; (b) one whose
structure was familiar, (e) one that could be assayed in the
laboratory, Cd) one to which Mats were available, and (e) II
proven track record in targeting.
Amongst the TMs available, CEA stands out as the .ost
pro.ising and its properties are detailed below.
:I. 12.1 Hi.tory .nd olillie.l rdevance
CEA is an oncofetal antigen normally found in embyronic
and fetal gut and was first discovered to be expressed on
colorectal cancers by Gold and Freedman in 1965. CEA is the
most well studied and widely known tumour associated marker.
and is found to be elevated in >65' of colorectal (up to lOa\:
in metastatic disease), >50' of lung, >60\: ot pancreas, >30\:
of ovary and breast cancers. Le. most of the cOllllllon solid
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tumours with the highest mortality rates (Bates & Longo, 1981).
Monitor!,,'] CEA levels is an important parameter in assessing
the response to therapy and in the post-operative surveillance
of cancer patients (Bates " Longo, 1987).
I. 12.2 Molecular aDel. genetic organization
CEA is a glycoprotein of molecular weight 180,000. The
antigenic structure of CEA has been dissected into its various
epitopes using over 52 well characterized Mabs (Price 198B;
Hammarstrom et aI, 1989).
The CEA gene family, its molecular structure. evolution
and functional significance have been elucidated and
extensively reviewed (Rogers, 1983; Shively & Beatty, 1985;
Thompson & Zimmermann, 1988).
I. 12.3 Evolution and !unct!o.bal dgniticanc.
Despite CEA being the oldest tumour marker studied, its
function remained a mystery to investigators until recenlty,
when its role as an intracellular adhesion molecule was
suggested (Benchimol, FUks, Jothy, Beauchemin, Shirota &
stanners, 1989). CEA has therefore joined the immunoglobulin
(Ig) superfamily, a group of molecules with a common Ig domain
like structure which are involved in hasie cell surface
recognition events (Williams, 1987). Not surprisingly,
increased homotypic intercellular adhesion has been
s.
demonstrated to favour the metastatic process, as cell
aggregates that break away trom the primary tumour may have a
qreater chance than sinqle cells in surviving the circulation
and lodging in secondary sites. A similar metastatic role has
been postUlated for CEA, based on the clinical data that up to
100\ of metastatic colarectal cancers have elevated CEA levels
and, in addition, colonic liver secondaries produce high levels
of CEA mRNA and protein (Benchimol et aI, 1989). Additional
ev idenee is the apical localisation of CEA in the normal
colonIc epithe' lum versus the basolateral localisation in
embryonic and cancerous tissue, leadin9 to disruption of normal
architecture and invasion. This hypothesis is currently under
investigation.
I. 12.4 en as a lD.odel tor AlIT
CEA has proven to be a promising target for both antibody
mediated diagnosis and treatment. Initially, the efficacy of
a Pab sheep anti-CEA-vindesine Ie was del10nstrated in vitro,
with retention of drug and Ab activity and carrier specificity
(Johnson, Ford, Neo,nnan, Woodhouse, Rowland & Simmonds, 1981;
Rowland, Simmonds, Corvalan, Marsden, Johnson, Woodhouse, Ford
, Newman, 1982). Subseguently, an IlII labelled Ie could be
radioimmunolocalised eRIL) in patients with i!ldvanced metastatic
adenocarcinomas (Ford, Newman, Johnson, Woodhouse, Reeder,
s.
Rovland , s1_onds, 1983). In addition, i ..provelllents in RIL
have proven the technique to be safe and to detect CEA
expressing priaary and lIetastatic lesions in patients with
coloreetal or brf!ast cancer using lUI, """C or 1I'ln labelled
Habs or Fabs (Beatty, Duda, Williams, shetbani. Paxton, Beatty,
Philben, Werner, shively, Vlahos, Kokal, Riihimaki, Ten'
Wagman, 1986; Goldenberg, Goldenberg, sharkey, Higginbotham,
Ford, Lee, Swayne, Burger, Tsai, Horowitz, Hall, Pinsky &
Hansen, 1990).
For the better evaluation of res both 1n vitro, for
selection of binding and cytotoxicity properties, and in vivo
for therapeutic potential a model has been established in our
laboratory as follows. Human cell lines of coloreetal, lung.
cervical and breast cancer origin have been characterised by
iamunocytochellical, 'adiolabelled Ab binding and cOJlpetitive
inhibition studies with four Mabs recognising different CEA
epitopes (Ford et al, 1985, 1986, 1987a). One of the Habs (11-
285-14) specific for CU. was confirmed to be non-reactive with
nonspecific cross reacting antigens (NCA) by further studies
comparing fifteen anti-cEA Mabs (Price. 1988). NCA is a
cytoplasmic component of granulocytes which infiltrate into
inflamed parts of the colon. Although CEA and HCA have similar
polypeptide Chains, they differ in their degree ot
glycosylation and are also antigenically distinct (Shively"
6.
Beatty. 1985). Apart from specificity for CU, 11-285-14 has
also been extensively characterised immunocytochemically
(Gatter et aI, 1982; Hockey, Stokes, Thompson, Woodhouse,
Macdonald, Fielding & Ford, 1984; Ford, Gallant & Ali, 1985b).
11-285-14 has been shown to localise in xenografts (MacDonald,
Crowson, Allum, Life & Fielding, 1986) and in patients with
gastroi:,testinal cancer (Allum, Macdonald, Anderson & Fielding,
1986). and was therefore selected for targeting cytotoxic
drugs. 11-28S-14-Vindesine (VDS) conjugates demonstrated (a)
efficacy in vitro, (b) correlation with CEA density and (e)
efficacy in vivo over the free drug with xenografts using a
variety of dosage schedules (Casson et aI, 1987). carrying
this success a step further, 11·285-14·Dox conjugates have
demonstrated considerable efficacy (Richardson et aI, 1989) and
are currently being investigated.
In summary, the rationale for selecting CEA is:
(a) There is an increased expression of CEA on the cell
membrane and in the cytoplasm of cancer cells. These
cancers represent the common solid tumour group including
COlonic, lung and breast cancers, that are presently
refractory to therapy.
(b) CEll. is the most well studied and extensively
characterised of the TAAs. In addition, its expression
from the gene to the cellular level has been well
elucidated.
"(e) Our group and others have a range ot' anti-CEA Nabs which
have proven the value of CEA in histopathology (Corvalan,
Axton, Brandon, smith' Woodhouse, 1984; Hockey et aI,
1984; Ford et aI, 1985b; MacDonald et aI, 1986; Price et
aI, 1988). Furthermore, CEA has been demonstrated to be
bound and internalized by antigen expressing cells in
culture (Rosenthal, Tompkins & Rawls, 1980: Tsaltas et
aI, 1992).
(d) Our Habs have been shown to localise in vivo 1n
calorectal xenografts (MacDonald ct aI, 1986). in
patients with GI Ilalignancies (Allum et: aI, 1986), and to
be non-reactive with cross reacting antigel"s (Corvalan et
aI, 1984).
Cel A CEA model has been developed and the efficacy of anti-
CEA 11-28S-14-VDS (Ford et aI, 1987al and Dox (Richardson
et al, 1989) have been demonstrated both in vitro and in
vivo in a nude mouse xenoqraft system (Casson, Ford,
Marsden, Gallant' Bartlett, 1987).
(f) Furthermore, producing BsMabs recognising both CEA and
Cox would be complementary to the ongoing work in this
laboratory using 11-28S-14-Dox ICs and would contribute
to the evaluation of the potential of BsHabs in
comparison with conventional ICs.
No other tumour associated antigen meets these criteria.
.2
1. 13.0 why Doxorubicin?
Doxorubicin (Cox) 1s an anthracycline antineoplastic agent
originally isolated from the fungus streptomyces peucitius ~nd
is perhaps the most widely used chemotherapeutic drug worldwide
(Weiss. Sarosy, Clagett-Carr, Russo & Leyland-Jones, 1986).
Dox (Adriamycln) has an extraordinarily bNad spectrum of
anti tumour activity against many human cancers, in particular
the solid tumours such as breast, lung, ovary, thyroid and soft
tissue sarcomas.
I. 13.1 structure and aechanislll ot action
The Dox molecule contains an amino sugar, daunosomine,
linked through a glycosidic bond to a naphthacene-quinone
nucleus (Figure 2). Although Dox differs from the other
commonly used anthracycline, daunorubicin (DNR) , by only a
single hydroxyl group on carbon 14, it is much more potent than
ONR. The three mechanisms of antiturnour effect of OOK (Young,
Ozols & Myers, 1981) are: (a) by DNA intercalation, thereby
inhibiting DNA and RNA synthesis, (b) :ree radical formation
(responsible more for cardiotoxicity than antitumour effect;
Myers, 1988), and (c) Cox has been reported to have a cytotoxic
effect by acting directly on the cell membrane (Tokes, Rogers
& Rembaum, 1982; Tritton & Yee, 1982) without having to enter
the cells.
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I. 13.2 Potential in targeting'
Despite its efficacy, OOK has been hampered by both
convnntional (bone marrow sup~ression, nausea and vomiting, and
alopecia) and unique (cardiomyopathy) toxicities (young et aI,
19B1). Furthermore, although many CEA expressing cell lines
are sensitive to Oox, a limitation of OOK in calarectal
cancers, may be its poor penetration beyond the outer 4-6
layers, which could be overcome by Mab-medlated targeting.
supporting this, preclinical evaluation of Ies of Oox linked
via a cis-aconityl spacer to a Mab (9.2.27) recognising a
melanoma antigen, have been shown in vivo to be more effective
than the .Free drug (Yang &r Rclsfeld, 1988).
In summary, the rationale for producing BsMabs against Cox
includes:
(1) Widespread application
(2) The potential of delivering more drug to the cancer site
and less to the cardiac tissue, thus limiting
cardiotoxicity.
(3) BsMabs may also be used to target more potent analogues
of Cox under evaluation, such as cyanomorphilino-
doxorUbicin, which is up to 1000 times more potent than
Oox (Beckman, McFall, sikik & smith, 1988), thereby
increasing BsMab efficacy.
(4) In addition, although the feasibility of using Dox-Ics
has been shown in a phase I trial involving forty-two
"
patients with refractory solid tumours, the Illajor
technical obstacle continues to be the effective chemical
linkage of drug to Mabs (Pietersz et al, 19891. SSMabs
would, therefore, be a novel way to overcollle this
problem.
I. 14.0. OUTLINE OF EXPERIMENTAL PROTOCOL
The steps involved in the production of SsMabs using the
spleen cell x hybrid fusion method (Suresh et. al , 19116b) are
outlined in Figure 3.
(1) Backselection of 11-285-14 in 8-azaguanine to
produce suitable clones based on (a) 1IA'l'
sensitivity; (b) growth characteristics; and, (e)
continued anti-CEA production.
(2) Production of Dox-protein carrier conjugates.
(3) Immunization of mice with (2) and use of spleens for
fusions with mutant 11-285-14.
(4) Fusions using hybridomll technology.
,~} Development of assays to detect (a) anti-eM; (b)
anti-DO>'; and, (c) BsMabs.
{6, 7, 8) Selection of dual positive hybrids and subcloninq.
(9) Expansion in culture.
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KATERIALS AND METHODS
II. 1.0 11-285-14 Mi'l'I-CEA KYBRI~
The caintenance cell culture techniques for 11-285-14 ilrc
given in the following subsections. The techniques arc silli lar
for all cell lines used in this project. Differences exist in
the media used and are dealt with under the appropriiltc
sections.
II. 1.1 History ot 11-2115-101
11-285-14, a hybridolla secretinq l'llclTloc!onal ilnti-C~:A
llntibody, was provided by the Oncology Research l..Jboriltory ,lnd
was produced by Ford and Woodhouse (Woodhouse, 1987.aJ in
collaboration with Corvalan et aI, of EI i J.i Ily , Co .•
(Corvalan et Ill, 1984). 11-285-14 resulted frolll the (us ion 01
the NS-l ayelollll cell line and spleen cells (COlli iI IIlOU:;C
iuunized with eEA. The 11-285-14 fusion protocol, described
in the Ph.D. thesis of C. Woodhouse, has been the guidel inc for
the fusions in this thesis. 11-285-14 is an Ig(;1 Hilb i!nd ha!;
been extensively characterised and evaluated for in vHro ilntJ
in vivo targeting as described in the introductory chilptcr
(Section 1. 12.0).
.s
II. 1.2 Tissue culture aaint.lIance
11-285-14 was qrewn as oil suspension culture in 75 em?
polypropylene tissue culture flasks (Falcon, Becton-Dickinson)
ilond llI<1intainad at 31- C with a 5\ carbon dioxide atmosphere in
i) humidified incubator.
II. 1.3 HecUua for 11-285-14 IRPKI-GLN-FCS)
{I) RPMl-1640 500 ml (/15-040·LV, cellgro, Mediatech,
1Il1 e#2S-00S-LI, Cellqro,
Washington)
(2) ret,)} calt' serum (FCS) 50 ml (129-1Gl-S4, Silver,
Cellect Flow Labs Inc, Mclean Virqinia, 22102)
(J) L-Clutamine (GLN)
Mediatcchl
(4) Penicillin (10,0:)0 units/Illl) Streptomycin (10,000 P9/1lI1)
in 12 ml (IlO-OOI-Lt, Cellgro, Mediatech)
II. 1." Cell growth
Cells were grown as suspension culture and fresh medium
was topped up daily to maintain optimal growth and "i~bility
11. 1. 5 Cell count
A Neubauer Hemocytometer was used for calCUlating the
concentration of cells in suspension. The viability of cells
was assessed by using the dyes acridine orange CAO) and
6'
ethidium bromide (EB). Acridine orange stains viable ccllu
brilliant green and ethidium bromide stains dCild cells brown,
when viewed under a fluorescence microscope.
II.l.5 (ll) Materials
(1) Hemocytometer (Neubauer) with cover slip.
(2) Acridine orange, AO (11\-6014, Sigma Chemical
Co, St. Louis, Missouri).
(3) Ethidium Bromide, EB (lE-8751, Sigma chemic;)l Co).
AO and EB used as a O.OOlt solution and mixed
toC}ether, stored in 1 mt aliquots at -20"C.
(4) Fluorescent microscope (Ortholux 11, LictO':), with.1
50 watt mercury vapour lamp.
II.I.s (b) Method
Cells from the culture flask were transferred to 1!.i ml or
50 ml sterile conical tubes and centrifuged at 1000 I~I'M
(175 x g). The supernatant was discarded and the pellet 01
cells in the bottom resuspended in the appropriate di lution 01
medium (usually 5 to 10 ml). One drop of the cell suspension
was added to one drop of AO/EB lind the mixture placed under th~
coverslip of a hemocytometer. Viable and non-viable cells were
counted under the fluorescent microscope and the percentilgc of
villoble cells calCUlated.
" Viability'" (Total AO cells/Total cell count) x 100\
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1.6 cryopreservation of cells
1.6 (al Materials
Media for freezing cells:
10\ (1:10) DMSu Dimethyl Sulphoxide (/IOn3, BDI-!
Chemicals, Toronto) with Fetal calf serum (FeS),
filtered through a 0.22 j.lm millipore filter (Millipore
Products Division, Bedford MA 01730) and stored in a
B9JL£Q freezer (-70"e) in 5 to 10 ml aliquots.
II. 1. 6 (b) Method
(1) The number of cells to be frozen was counted.
(2) Tt,.::! cell suspension was centrifuged at 1000 rpm (175 x "1)
for five minutes and the super:-:3tant discarded. The
pellet was shaken to mix well,
(3) Depending on the number of cells, the appropriate quantity
of cold medium for freezing (kept in a bucket of ice) was
added to the pellet of cells. 1 ml of the medium ',-·as used
to fre~ze 4 to 6 x lO~ celJ.s.
(<I) 1 ml of the cell s~spension was aliquoted intC' each vial
appropriately marked.
(5) The vials were transported in a bucket of ice to the
Revca, and transferred to the -70°C.
(6) A day later, usually, the vials were submerged in a liquid
nitrogen tank.
II.!.7 Thawing cells
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(1) using a sterile syringe, 9 mt of RPM!-GLN-FCS medium wa~
p laced in a 15 ml centr Huge tUbe.
(2) The vial of cells was removed from liquid nitrogen '1nd
thawed quickly in a J7~C waterbath.
(J) With a few frozen cells remaining in the vial, the viill
was transported in ice to the sterile hood.
(4) The cells were removed with a syringe and added to tlle
tube containing medium.
(5) This was immediately centrifuged at 1000 rpm (L"/5 l( 9)
for 5 min.
(6) The supernatant was discarded.
(7) Using a syringe, 5 ml fresh medium was added and the
suspension poured into a st.erile 50 ml nilsk rcsQrvinq
a little for the cell count.
(8) Aft.er performinq the cell count, the percentage yield wa~:
calculated.
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II. 2.0 SELECTION OP HYBRIDOKA FUSION PARTNER
2.1 Production of HAT sensitive 11-285-14
Azaguimine-resistant Hybrioma lines wero propagated
rallows to obtain HAT sensitive 11-285-14 cell lines. The
procedure followed j:; adapted from !iuresh et aI, (1986b).
2.1 (al Materials
(1) 8-azaguanine (/A-8526, Sigma Chemical Co.), 300 mg.
(2) Distilled water
(J) 1 N Sodium hydroxide
(4) 10 N So'_~ium hydroxide
(5) RPMI-GLN-FCS (Section II. 1.3)
II. 2.1 (bl Method
(1) 20 mM stock of s-azaguanine was prepared by dissolving
300 mg 8-azaguanine in 99 ml of distilled water. Since
1 rnl of 1 N NaOH did not TG"ult in the a-azaguanine
dissolving, (as per Suresh et al 1986b method) 8-10 drops
of 10 Ii NaOH was used instead of 1 N NaOH.
(2) The stock was filter sterilized and stored in aliquots at
-20~C.
(J) Serial dilutions of 8-azaguanine in doubling dilutions of
30, 15, 7.5, 3.75, 1.88, 0.~4 Ilg/ml were prepared in 10'
RPM1-GLN-FCS and equilibrated in a 5% CO2 incubator.
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(4) 24 sUbconfluent wells (6 columns x 4 rows) of vigorously
growing hybidoma cells were prepared.
(5) The various azaquanine concentrations were added in
triplicate to the subconfluent hybridoma plate, with the
last row being kept as a control.
(6) The medium was drained and cells removed every two d<lys
if excess growth was seen.
(7) Cultures growing at the highest drug concentration were
selected and the above procedure repeated with thcuc
cells.
(8) Cells that appea):ed to have adapted to the 30 ug/mL dl'uq
level, were then cloned by limiting dilution (section II
9.7) in RPMI-GLN-FCS containing 30 mgjml azaguanino.
II. 2.2 Growth characteristics ot 11-285-14
II. 2.2 (a, Materials
50 ml sterile tissue culture flasks
RPMI-<.LN-FCS with 30 ug/rnl 8-azaguanlne.
II. 2.2 (b) Method
5 to 10 cells/ml of rapidly growing clones werQ pickQd as
below:
(1) 11-285-14 mutant clones obtained by limiting dilution
aliquoted into tive flasks with fiXCLl
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concentration of cells Le. 0.05 x 106 cells in 10 ml
medium and the number of viable cells counted on each
day.
(2) The supernatants were assayed for anti-CEA production by
enzyme linked immunosarbent assay (ELISA) (section II
8. J).
II. 2.3 Haintenanco of NS-l fusion partner
The NS-l plasmacytoma cell line is a common fusion partner
used in hybridoma production (Hudson and Hay, 1980), since it
is a non-secretor of immunoglobulins.
II. 2.3 la) Materials
(1) NS-l (Surgical Immunology Unit, Birmingham, England).
(2) Medium: RPMI-GLN-FCS (section II 1.3)
1250 ttl of 1 x 10.1 of 6 thioguanine (6-TG) (sigma
Chemical Co)
0.167 gm of 6-thioguanine was dissolved with few
drops of 10 M NaOH. The solution was adjuGted to 100
ml with distilled water and filter sterilised through
a O.22/-1m filter. The final 6-TG concentration was
2 :Ie 10·' M.
10 ml of 4.5 g/litre glucose (I G-5000 Sigma Chemical
Co) •
(3) Sterile 75 cm
'
polypropylene flasks (Falcon, Bccton-
Dickinson) .
(4) Incubator at 378C, humidified and gassed with 5\ CO,.
II. 2.3 (b) Ketbo4
(1) The maintenance or the NS-l cell line was similar to the
maintenance or 11-285-14 (Section II .1. OJ.
(2) Cells for rusion were uSl~d during the exponential phnso
of growth.
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II. 3.0 PRODUCT:ION OP DOX-Jl:LH CONJUGATES
II. 3.1 Introduction
Doxorubicin was initially conjugated to keyhole limpet
hCr.;ocYiJnin (KLH) using Ecor [1-ethyl-3- (dimethylaminopropyl)
ca["bodiimideJ as the heterobifunctional crosslinker. ECOI
links the amino group of doxorubicin to the carboxyl group of
hemocyanin forming an amide bond (Vunakis, Langone, Riceberg
& Levine, 1974; Hurwitz, Levy, Maron, Wilchek, Arnon & Sela,
1975). 'l'he other heterobifunctional linkers that are routinely
used to link hap tens and proteins are glutaraldehyde and
pcriodate.
11. 3.1 (11.1 Haterials
(1) Doxorubicin Hydrochloride (Adriamycin Hel; Adria
Laboratories Inc, Columbus, Ohio)
(2) ECDI (sigma Chemical co.)
(J) Keyhole Limpet Hemocyanin (H-2133, Sigma chemical
Co. )
(4) Phosphate Buffered Saline (PBS) - 7. 2g Nacl (/ACS783,
BOA Chemicals, Toronto),
(5) 14.39 Na1Hpo4 anhydrous (/5274B-500, Fisher
scientific, Ontario),
(6) 4.3 9 of KHIPO. (Fisher Scientific, #P-382) dissolved
in 10 Ii tres of distilled water, pH 7.2.
(7) Phosphate buffered saline tablets (OXoid, Unip.lth
Ltd., England).
(8) Sephadex 0-25 (#CD00470, Phtlrmacia Fine Chcmicfl}s,
Upsala, Sweden).
(9) Gel filtration column (B1oRad Econo column Length 30
cms). The preparation of the gel filtration collumn
is described in the next section (11. J.7.).
II. (b) Method:
Modification of method from Vunakis et a1. (1974).
(1) 5 to 10 mg of Dox was dissolved in 2 rol PBS (mado [rom
tablets). As 4/5 of the weight is due to lilctosc, the
dry weight of the drug ranged from 25 to 50 mg. 1'his WiHJ
found to be the optimal weight of the drug that resulted
in a conjugate.
(2) 15 mg of KLH was dissolved in 2 rnl PBS (made [rom
tablets, Oxoid).
(3) The above two solutions were kept separately .:at
temperature (RT) for half an hour to dissolve.
(4) After being ce.,trifuged separately (175 x g), the
supernatants were rell\oved and the undJ 3s01 vcd pellets
were discarded.
(5) (a) The two supernatants were mixed together.
(b) The absorbance of the supernatants wan assc~scd
spectrophotometrically at 280 nm (for J<LH and Dox) Clnd 495
7B
nm (Oox alone). Since only 1 to 2 ml of each supernatant
was present, a 1/100 dilution was made and the absorbance
read. This resulted in a more precise estimate. of the
amount of the drug and KLH dissolved prior to each
conjugation.
(6) 10 to 15 rng of ECOI was dissolved in \ ml PBS and addod
to the supernatant mixture.
(7) During initial conjugation experiments, a variety of pH
ranges were evalui!lted, but pH 7.2 yielded the best
rF,lsults (Tables 9a, b & c under Results).
(8) The solution containing Dox, KLH and ECOI was kept at
room temperatnre (RT) for 4 hours with occasional
stirring (every half hour) .
(9) The solution was passed down a Sephadex G-25 gal
filtration column (see section below) and collected at
the rate of 5 minutes for each fraction, eluted with PBS.
This was set up in the cold room at a temperature of 4"C.
(10) Approx.imately 50 fractions were collected per conjugation
and the fractions were read by spectrI'Jphotornetry at 280
mI". and 495 n'l'l.
(11) 'Ihe molar ratios were calcUlated based on the following
information. Doxorubicin (Adria Laboratories): Molecular
weight 580, Molar extinction coefficient =
79
.!i1.!:!. (Sigma. Chemicals): Molecular weight (mol. wt.)range 9-to
15 X 106. For calculating the molar ratio, mol. wt. of 10 x
:.o~ WilS used. Molar extinction coefficient of KLH 1.\ solution
(1 g/100 ml) .. ] 6 at 00110 .....
II. 3.2 ael Filtration
II. 3.2 (a) Materials
(1) G-25 Sephadex gel superfine medium (I 75104 Pharmacia
Fine Chemicals, Uppsala, Sweden).
(2) Gel filtration column (sioRad Econocolumn, 30 em),
(3) Fraction collector with glass test tubes. (Pharmacia
programmable fraction collector FAPC-JOU).
(4) Phosphate bUffered saline (PBS)
II.3.2.lb) Hethod
e1) 1'he volume of the column to be used was measured.
(2) The amount of sephadex G-25 to be used was
calculated as 1 g of sephadex for 5 ml volume. The
total column volume 80 ml, therefore
approximately 16 to 18 g of Sephadex G-25 was used.
(J) The gel was boiled in an excess of PBS for 1
hour in a water bath. This gel ....as then poured
into the colUmn and the column placed in cold
room at a temperature of 4°C.
II. 4.0 PROD!JCTION OF DOX-BSA CONJUG7r.TES
Dox was linked to bovine serum albumin (BSA) in an
identical procedure as for Dox-KLH conjugates, except that <l.
higherer concentration of carrier (50 to 80 mg of eSA)
used. Dox-BSA ....as separated form the free drug by gel
filtration, as described above for Dox-KLH conjugation,
II. 5.0 PRODUCTION OF DOX-ENZYME CONJUGATES
In order to develop a dual assay that detects BsMabs
directly, several attempts were made to link Dox to the enzymes
horseradish peroxidase (HRP) or 6-galactosidasc.
II. 5.1 DoX-UP conjugations
II. 5.1 (a) Katerials
(1) Horseradish peroxidase (HRP: IP8375 typo VI and
IP8125 type I Sigma Chemical Co, Missouri),
has a Molecular ....eight of 40,000 and is available in six
types (1 to VI) with a RZ of 1.1 to 3 (RZ: Reinzcthnl
ratio is the optical density ratio at 280 nm: 495nm). The
RZ does not correlate .... ith the activity of the enzyme and
represents the carbohydrate moiety (Sigma Chemical Co).
(2) Glycerol (Sigma Chelnical Co).
(3) Sodium peridoate, NaIO. (/1867070, Analar, 13011
Chemicals Ltd., Poole, England).
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(4) Sodium carbonate, NaZCO) (IACB290, Anachemia Ltd.
LTEE, Montreal).
(5) Sodium bicarbonate, NaHCO, (#5233, Fisher scientific
Co, New Jersey) .
(6) Sodium borohydrate, NaBH4 (/3-V023, 3T Baker Chemical
Co., Phillipsburg, NJ).
(7) Ethylenediamine Tetraaoetic acid Disodium salt, EDTA
(5-311, Fisher Scientific Co.).
(8) Glutaraldehyde (G-S8a2, sigma Chemical Co.)
(9) 2,4,Dichloromethane CH1Cl1 (Aldrich Chemicals).
(10) Dimethyl Sulphoxide (DMSO) (BOH Chemicals).
(11) l-ethyl-3- (dimethylaminopropyl) carbodiimide (ECOI)
(Sigma Chemical Co.)
II. 5.1 (b) Method
Several methods were evaluated to conjugate Do... to
IIRP as given in the following subsections:
II. 5.1 (e) Perlodllte conjugation
Periodate oxidation of the drug cleaves the bond
between C-3 and C-4 of the amino sugar, producing carbonyl
groups capable of reacting with free amino groups on the
protein. The resulting Schiff base linkages were reduced with
U2
sodium borohydrlde (NaBH~) (Nakane " Kawaoi, 1974; Hurwitz at
aI, 1975; Boersma, 1983; Varga, 1985).
(1) 10 rng of Oox was dissolved in 1 ml PBS, and mixed with
a.1M NaIO~ (42.8 mg in 1101 PBS). followed by incuhation
for 1 hour at room temperature in the dark.
(2) 536.8 /-11 of glycerol (1 M) was then added to consume thc
excess periodate.
(3) The reSUlting solution of oxidised drug was mixed with 1
101 of sodium carbonate bicarbonate buffer (0.2 M, pI! 9.5)
containing 4 109 of HRP, followed by incub<ltion at R1' for
one hour.
(4) 3 mg of NaBH~ was added to give a final concentration of
0.3 mg/ml, and the mixture was kept at 4"C for 2 hourE:.
since the above method was unsuccessful, the procedure waz
slightly modified using 0.5 M NaIO., 268 ~l of 1 M glycerol,
2 mg HRP in 1 ml carbonate and the resulting 5 ml of solution
was separated by gel filtration (Sephadex G-25).
II. 5.1 (lSI Carbodiimide conjugation
ECDI was used to link the drug via its amino group to the
cilrboxyl group of the HRP similar to Dox-KLH production
(Hurwitz et aI, 1975; Vunakis et aI, 1974; Goodfriend, Levine
& Filsman, 1964).
(1) 5 rng of Dox in 1 ml PBS was mixed with 3 rng of HRP (RZ
0.6) or 17 mg HRP (RZ 1.1 type I) in 1 ml PBS.
(2) 8 rng of ECDI dissolved in 1 ml PBS was added to the above
mixture and Ieept at RT for 4 hrs in the dark.
(3) Since Dox can produce superoxide radicals in solution
which could periodate the enzyme resulting in self
coupling (Brian Hasinoff, Dept. of Chemistry, Memorial
University of Newfoundland, personal communication),
sodium cyanide (1 IJmol) or flouride (1 romol) was added in
an attempt to prevent such an unwanted reaction.
(4) As the presence of metallic ions also may hinder the
conjugation, 1 mmol of EDTA was used to prevent their
interaction in the reaction.
(5) The enzyme fractions were dialysed against PBS to remove
the free fluoride.
II. 5.1 (8) Glutaraldehyde conjugation I
Glutaraldehyde. cross links the amino groups of Dox and the
enzymes (Vunakis et aI, 1974; Hurwitz et aI, 1975). 200 1J1 of
glutaraldehyde (0.1\) was added to 1 ml of PBS containing 6 rng
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of HRP and 2 mg Cox in 1 ml solution. The reaction WilS allowed
to proceed at RT for 4 hours.
II. 5.1 (tl Glutaraldehyde conjuqation II
Since the prccedure used by Page & Thibeault (1987) was
reportedly successful in linking Oox to protoins without
significant loss of drug or antibody activity, attempts ware
made to link Cox with HRP using this method as tollows.
(1) 150 J11 of 25% aqueous glutaraldehyde was added to 0.5
mg/rol of Dox in 4 ml PBS and the mixture stirred at R'I'
for 20 min.
(2) 2 ml of distilled water was then added and the cxccs~
glutaraldehyde was extracted with dichloromcthanc usin(j
a separating funnel.
(.Jl The activated Dox was washed with 5' NaHCO.H dried with
NalSO~ and evaporated to dryness under nitrogen.
(4) The mixture was dissolved in 1 ml of DMSO and the amount
of drug measured spectrophotometrically at 495 nm.
(5) HRP dissolved in PBS was then added to yield a 13:1 ratio
of Dox:HRP (type I and type VI HRP were utilised).
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II. 5.2 DOX-P qalactosidase conjugations
II. 5.2 (a) Materials
(1) ,a-galactosidase (#G-600S, EC 3.2.1. 23, sigma Chemical
Co), molecular weight 540,000.
(2) M-maleimldobenzoyl-N-hydroxysucclnimide ester (MBS;
Sigma Chemical Co).
(3) Tetrahydrofuran (/ET01316HP, Aldrich Chemical Co.,
Milwaukee, Wisconsin).
(4) 0.05 M Tris bufrer: 7.9 9 of Trizma base (IT-ISO),
sigma Chemical Co) in 800 ml distilled water.
Concentrated Hel was used to adjust the pH to 7.6,
and then the volume was made up to 1 litre.
(5) Phosphate buffer (0.1 M, pH 6.0) sodium dihydrogen
orthophosphate (monobasic) NaH l po4 - 15.6 9 (#ACS795,
BOH ChemicalS, Toronto) I sodium phosphate anhydrous
Na1HP04 - 14.29 (/53748-500, Fisher Scientific Co,
Ontario) dissolved in 1 litre of distilled water.
(6) 0.02M Phosphate buffer (pH 7.0): NaCl 11.688 9 (0.1
M, IACS78J, BOH Chemicals, Toronto), MgCl] 0.406 g
(1 mM, IM-0250, sigma Chemical Co), Albumin, bovine
serum 2.0 9 (0.1\; IA-788B, Sigma Chemical Co),
sodium azide (NaN j ) 2.0 g (O.lt, 18J0111, 80H
Chemicals), NaH1Po~ 6.24 g, made up to 2 litres.
8.
(7) Substrate for ~-galactosidase:
a) 0.1 M Sodium ph~sphate buffer pH 7. J, Na.. IlPO.1
1.141 9 (Fisher scientiric), NaH1PH. 1.37 9 (8011
Chemicals) dissolved in 10(1 ml of distilled water
COW) ;
b) Mercaptoethanol (/M6250, sigma Chemical Co) 1 ml
added to 4.25 ml OW;
c) MgCl1 (/"'-0250, Sigma Chemical co) 122 mg in ?o
ml C.W;
d) ,a-galactosidase (G-60GB, sigma Chemical Co);
e) Q-nitrophenyl-,B-D-galactopyranoside (ONPG, IN-
1127, S1gma) 20.5 mg in 1 ml of a. The abol/e Wil8
mixed in the following proportions, 10.4 ml or a,
0.4 ml or b , 0.4 ml of c and 0.4 rol of e. 100!ll
of the mixture was used as substrate for Dox-{t-ga I
conjugate.
II. 5.2 (bl Method (Fuj iwara, Yasuno & 1<1 tagawa, 1981).
(1) 300 Fl9 of MBS in lOml 0.1 M Phosphate buffer (pH 6)
was added to a solution containing J mg of Dox in 10
ml buffer.
(2) To 2 mls of the above mixture, 300 1-11 of TIlF was
next added followed by incubation at RT for 30 min
with vigorous stirring. 460 /-ll of this solution was
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mixed with 0.5 mg {J-gal in 1 ml buffer and stirred
at RT for 30 min.
(3) The mixture ....as separated on a Sephadex G-25 column
equilibrated with 0.02 H phosphate buffer (pH 7.0).
(4) The conjugates WAre tested with ONPG substrate and
read by spectrophotometer (40S nm).
(5) conjugation was also attempted using ECDI as the
linker in an identical procedure to Dox-KLH
conjugation.
II. 5.3 DoX-AvicHn/Biotin conjugations.
An indirect method of labelling Oax was attempted by first
conjugating Oox to avidin or biotin, using biotin or avidin-HRP
as the label. Avidin-biotin complex is a well studied system
in molecular biology and immunology (Bayer & Wilchek, 1980;
Wood & Warnke, 1981; Wilchek & Bayer, 1984). Biotin is a water
soluble vitamin present in egg white. Avidin is a biotin
binding protein with a molecular weight of 60,000. Experiments
were adapted to conjugate doxorubicin to avidin or biotin
either directly or indirectly via albumin as a bridge (Goding,
1986; Boorsma et al, 1986).
11.5.3 Ca) Materials
(I) Avidin (#A-9275, Sigma Chemical Co).
(2) Peroxidase-Biotin labelled l{/P-9272, Sigma Chemical
Co) .
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(3) Oox-human albumin-silccinyl (Dox-HSAj supplied by Dr.
V. Richardson, oncology Research)
(4) N-hydroxy succinimidobiotin (/H-1759, Sigma Chemic.,l
Co) •
(5) 0.'.. 1'4' sodium bicarbonate NallCOJ (pH 8.3,
#1-3506, Baker Chern. Co.) Mol. wt. 84.01, 8.<101 q in
1 litre distilled water.
(6) Succinic anhydride (I 57626 sigma Chemical Co).
II. 5.3 (b) Method 1: Oox-Avi4in conjuqation
(1) 10 mg Dox was dissolved in 2 IIll PBS <.lml
centrifuged (175 x 9, 5 min) after" hr at WI'
to remove the precipitated drug.
(2) 3 mg avidin dissolved in 2 ml PBS was added to
the Oox solution.
(3) This was followed by addition of the 11 mg/ml
of ECDl.
(4) The mixture was kept in the dark at R'l' for 01
hrs and separated on a sepharlex G-2S column.
II. 5.3 (el Method 2: DOX-Avidin-succinyl conjugation
since the above method was unsuccessful, avidin wa::> first
succinylated (Klapper Ii< Klotz, 1971) and subsequently it was
attempted to conjugate this with Dox using ECDI as follows:
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(1) 1 mq of Succinic anhydride was ildded to 7 rng of avidin
dissolved in 2 ml ow (Means' Feeney, 1971).
(2) The above was mixed with Dox and teDI (similar to the
Dox-KLH procedure).
II. 5.3 ld) Method 3: Oax-BSA-Avidin conjugation
Dox-BSA conjugates produced (S~ction II 4.0) were utilised
for conjugiltion with avidin using ECDI as the cross linker.
'rhe method utilised was similar to the production of Dox-i<LH
conjugates using ECDl as given in Section II 3.0.
II. 5.4 Dox-Biotin conjugation.
Alternatively. doxQrubicin-human serum albumin (HSA)
succiny 1 (kindly supplied by Dr. V. Richardson, Oncology
Research Laboratory) was linked directly to biotin as follows
(Goding 1986; Ford et aI, 1987a).
(1) Dox-HSA conjugates were dialysed at 4Q C with 0.1 molar
NaHCOJ buffer. The final concentt'ation of Dox-HSA was
adjusted to give 1 mg (fiSA) per ml aliquots.
(2) Imgjml of N-hYdroxysuccinimido biotin was prepa.re-oj in
DMSO and 200 Jll of the solution was added immediately to
each aliquot of Oox-HSA and vortexed.
(3) The mixtures were then incubated at RT for 4 hrs with
vortexing every 15 min.
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(4) The aliquots were finally dialyscd extensively at 4"C with
PBS, the last two buffer changes containing 0.01 azide
for some of the aliquots.
The procedUt'e was repeated in an attempt to biotinylatc
Dox-BSA conjugates instead of Dox-HSA.
II. 6.0 CEA-HRP CONJUGATE PRODUCTION
II. 6.1 Heterials
(1) carcinoembryonic Ilntigen (supplied by Oncology
Research Laboratory and purified from liver
metastases as published (Ford et aI, 19Irlb).
(2) 0.01 M sodium carbonate bicarbonate buffer (pH 9.5)
(a) sodium carbonate 5.:; 9 1n 500 ml distilled water
(1 M solution)
(b) sodium bicarbonate 4.2 9 1n 500 ml rHstillec.l
water (1 M solution)
25.4 ml of (a) was added to 74.4 ml of (tI) and made
up to 1 litre.
(3) oinitrofluorobenzer.e (1%) (/0-6879, sigma Chemical
Co. )
100 ~l in 10 ml absolute ethanol
(4) Sodium periodate NaI04 (0.08 M) (I 1867070, BOIl
Chemicals, England)
17.12 mq dissolved in 1 ml of dist\lled water.
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(5) Ethylene glycol monoethylether (Fisher Scientific
Co •• New Jersey)
16 J,Ll Ethylene glycol in 10 ml water.
II:. 6.2 Methot!.
The procedure was originally developed to labtll antibodies
with HRP (Boot'sma, 1983; Nakane & Kawaoi, 1984) and has
previously been used to produce a 11-285-14 HRP conjugate
(Woodhouse, 1982a). A modificatic.n of the method was used to
enzyme label CEA as follows:
(1) To 6.2 rng HRP (type VI, RZ "" 3) in 1 Illl carbonate buffer
(0.01 M). 100 J11 of 1% dinitrofluorobenzene in absolute
ethanol was added and stirred gently for 2 hrs at RT.
(2) 1 tnl of 0.08 M sodium periodate '<las added to the sOlution
followed by gentle mixing for 30 min at RT.
(3) Thi~ was followed by adding 1 ml of 0.16 Methylene
glycol.
(4) The mixt.url:! was then stirred for 1 hr at RT and dialysed
against three 1 litrl:! changes of carbonate buffer
overnight at 4°C.
(5) CEA 1 mg/ml in carbonate buffer was added to the above
solution and mixed gently for 3 hours at RT.
.,
(6) Subsequently, 4.11ll1 of sodium borohydride (2 mg/ml) was
added and the solution dialysed aga.inst PBS overnight at
4Q C.
(7) The CEA-HRP conjugate was separated from free HRP using
a sephadex G-75 gel filtration column.
II. 7.0 IMMUNIZATION OF RABBIT
II. 7.1 Materials
(1) Oox-KLH conjugates (Section II 3.0)
(2) Complete Freund's Adjuvant (CFA; #- 660-5721, cibco
Labs, Ohio)
(3) Incomplete Freund's Adjuvant (IFA; # 660-5720, Gjbco
Labs)
(4) Syringes and needles (18 G 1 1/2; Becton Dickinson,
Rutherford, N.J.)
II. 7.2 Metbod
Oil in water emulsions of Dox-KLH and CFA (for primary
immunization) and IFA (for secondary boosters) w(!re prepared.
rol of emulsion was injected intramUSCUlarly and
subcutaneously. The immunization dosage of doxorublcin and the
intervals at which serum samples were drawn is given in Table
5.
Table 5: I"uDhatioD and. bleeding schedule for rabbit
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,.v
Immunizing Quantity
IIgent of OOX }Jg
11.5
Adjuvant
CFA
Lorn" Pre-imml,1n8
8.C. blood drawn
1.11'1.&
B.C.
Post-iramune
blood uample
11 drawn
Poat-i11ll'llune
blood .,.mple
'2 drawn
PODt-immune
blood eample
13 drawn
Dox: Ooxoz:ubicin
KLH: lCay hole limpet hefl\()cyanin
CFll: Complete Freund's adjuvant
IFAI Incomplete Freund's adjuvant
1.11'1: Intrallluscular
l'I.c: Subcut"neoull
II. 8.0 ENZYHE LInED IHMOHOSORBENT AS8AY (ELI8A)
II. 8.1 Introduction
RadioilDJllunoassay (RIA) ....as first developed (Yalow ,
BE:rsort, 1959) recognising the specificity of antigen antibody
reactions. In addition, because at its high sensitivity in the
range of a few nanograms per millilitre, RIA has found
widespread applications in medical research and clinical
diagnosis. However, radioisotopes are inconvenient due to
their high cost, risk of radioactivity and technica 1
limitations (Messeyeff 1979). Enzyme labels have therefore
replaced radio labels for many applications and have the addod
advantage of stable storage for periods in excess of one year
(Hudson & Hay, 1980). Horseradish peroxidase (llRP) and
alkaline phosphatase are the cOll1llonly used enzyme labels for
most ELISAs, the others include tJ-gala~tosidase and glucose
oxidase.
An anti-CEA selliautomated ELISA (Woodhouse, Ford & Newman.
1982b) using micro cuvettes, was modified and adapted to be
used as a 96 well microtiter plate ELISA. The microtitre
plates are convenient for testing large numbers of hybrid"
simultaneously. ELISAs were also developed for the detection
()f anti-oox antibodies, anti-BSA and BsMabs directly.
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II. 8.2 Materials
The materials that are common to the different ELISAs are
given in this section. Additional materials are given under
the appropriate ELISAs in the sections below (II 8.3 to 8.9).
(1) Microtitre ELISA plates (Linbro)
(2) Titcrtek digital multichannel pipette and disposable tips
(Flow Labs).
(3) Buffers for ELISA:
a) Carbonate buffer (pH 9.2), sodium carbonate Na1CoJ
0.7959, sodium bicarbonate NaHCOJ 1.465 9 dissolved
in distilled water. If pH over or below 9.2. 6 M
Hel or 10 M NaOH was used, respectively, to adjust
the pH. The volume was made up to 500 rn!.
b) U eSA in carbonate buffer (pH 9.2). BSA (# A-78BS
sigma Chemical co) 19, Buffer 100 rol.
e) 1\ 8SA in PBS-tween. eSA 19 dissolved in 100 ml PBS
pH 7.2. 100 p,'. of tween detergent (BoH c)",emicals Cat
1 R06435-74) was added.
d) citrate phosphate buffer, pH 4.0. Sodium hydrogen
phosphate (153748-500, Fisher Scientific) Na1HP04
4.08 g, citric acid crystals 4.53 9 (/827780, BDH),
dissolved in distilled water. 6M Hel was used to
adjust pH to 4.0. It was made up to a final volume
of sao mI.
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e) 0.15 M NaCl with tween (O.ll). Sodium chloride NaCl
35.49. Dissolved in 4 litres distilled water. Tween
detergent (BOH Cat I R064J5-74) 4 mI.
f) 2,2-azino-di-[3-ethyl benzthiazol1na sulphonic acidj
(ASTS) (/A-ISBS, Sigma Chemical Co). stock: 27.8
mg/ml dissolved in distilJed water and stored as 100
#l1 aliquots at -20~C. Freshly prepared 0.22249/1 i trc
of ABTS as substrate for each ELISA containcct:
100 ~l stock
12.5 rol citrate phosphate buffer
1 ~l hydrogen peroxide (30\; #845202 13011
Chemicals) •
II 8.3 J.N'TI-CEA ELISA
II 8.3 (a) Materials
(1) eEA (supplied by oncology Research Laboratory)
purified as published (Ford et aI, 1978b) in
carbonate bicarbonate buffer (Section II 8.2).
(2) 11-285-14 anti-CEA monoclonal antibody (positive
control) •
(3) Ag-S (P3X63AgS; IgG1 as negative control; Americ<ln
Type Culture Collection, Rockville, Maryland).
(4) Rabbit anti-mouse immunoglobulins t1RP conjugate (p
161, Dako, Denmark).
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(5) ABTS (Substrate prepared as in section II 8.2).
(6) Normal rabbit serum (NRS) 1:1000 dilution in PBS-
tween.
II 8. J (b) coating
After standardisation for optimum CEA coating (see under
reSUlts) ELISA. plates were coated with 100 ~l per well of
5 1l9/ml CEA in carbonate butfer (pH 9.2) and incubated .'It 37°C
for J hours followed by incubation in a humidified box at 4°C
overnight. In later assays, the coated plates were directly
incubated at 4°C without significant reduction in sensitivity.
II. &.3 (e) Assay
(1) The coating solution was discarded by inverting and
shaking the plates well.
(2) The plates were washed six times with NaCI-tween solution
using a wash bottle, ensuring that each well was filled.
(3) 200 1J1 of 1\ BSA in carbonate buffer was added to each
well, as the blocking solution. For Dox-BSA hybrids, 10%
normal rabbit serum (NRS) was used for blocking instead
of U; 6SA in order to avoid non-specie ic "sticking" to
BSA.
(4) The plates were incubated at 37°C for 1 hour.
(5) The plates were washed as before (step #2).
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(6) The test supernatants were added, 100 /11 per welL The
controls used for anti-CEA assay were: Background-
RPMI-GLN-FCS (Medium as for supernatants); positive
control, 11-285-14 Mab 2.5 /l9/m1 in RPMI; Negative
control, 1\g-8, 2.5 /l9/ml in RPMI. All these were added
in triplicate.
(7) The plates were then incubated at 37"C for 3 hours.
(8) This was followed by x 6 washes as before.
(9) Rabbit anti-mouse immunoglobulins - HRP conjugata (Rl\M)
1:1000 dilution in 1\ BSA PBs-tween was added, 100 1J1 per
well. In the case of DOX-BSA fusion hybrid supernatants
RAM was made up in 1\ normal rabbit serum in PBs-tween to
avoid the possibility of reactivity with eSA by anti-eSA
mabs.
(10) The plate was then incubated at 37GC for 3 hours.
(11) The plate was washed x 6 as before.
(12) Freshly prepat'ed ABTS subntrate, 100 #1 was addod par
well and the plates were read after 1 hour at room
temperature (RT) at 405 nl'll single wave length, by a 5io-
Tek EL 310 EIA plate reader (Mandel scientific, Rockwood,
Ontario) .
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II. 8." l\nti·DoxorUlliein ELISAa
II. 8 ... la) Materials
(1) ELISA buffers (Section # II.B.2.)
(2) Doxorubicin 2 /.I9/ml (as Doxorubicin or Doxorubicin-KLH
Doxorubicin-eSA) in carbonate bicarbonate buffer,
confirmed by spectrophotometry at 495 om optical density.
(3) Test antibody supernatants.
(4) Goat anti-rabbit immunoglobulins HRP (GAR-Hm') (# E961,
leN-Immune biologicals Lisle, ILl.
(5) Rabbit anti-mouse immunoglobulins HRP (RAM-HRP).
(6) Substrate ABTS (Section II 8.2.)
(7) eio-Tek EIA plate reader.
(8) positive control: Rabbit post-immune serum containing
anti-Dolo: antibodies.
(9) Negative control: P.abbit pre-immune serum (no anti-DoK
antibodies) •
(10) Background control: RPMI-GLN-Fcsand 11-285-14 (2.5Wl/ml)
and/or BSA-PBS-tween.
II. 8.4 (b) Coatinq
The coating depended on the biO different types of assays
performed (i) anti-Dox and (ii) anti~Dox BSA. After
standardisation Cor Cox coating, the optimum coating
concentration for Cox was found to be 2 ~g/ml (see under
Results). Therefore, 2 P9/m1 of Dox 1105 Oox alone or as Dox-BSA
100
in carbonate buffer ....as coated at 100 ~l per well and incubated
overnight at 4°C.
II. S.4 (el Asse.ys
The procedure was similar to that for the anti-CEll assay.
Pertinent differences are mentioned below for individuLlI
assays.
(i) Tost:ing rabbit sorWll;
(1) 2 ~g/ml of doxorubicin coating.
(2) Post-immune sera (with anti-OaK antibodies) tasted
along with pre-immune (no anti-Oax antibodies) In
dilutions 1/100 to 1/1,000,000.
(3) It BSA in PBs-tween used as controL
(4) Goat anti-rabbit immunoglobulin-HRP (ICN - Immune.
Biologicals) (1:4000 dilution) used as second
antibOdY·
(ii) DOX-ltLH iuunized mice sera:
(1) Cox-BSA (2/-lg/ml Oox) used as coating for testing mice
sera of fusions II, 13, 14 and 16. Doxorubicin alone
at 2/Jg/ml used for the rest of fusions.
(2) n BSA, in PBs-tween as background control.
(3) Non"'immunized mice sera used as pre-immune control.
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(iii) Oox-DS;" illUllunized mice ura:
il) Fusions 2, 5, 7 and a were tested with Dox-KLH
coating at DOK 2p.g/ml.
(2) Fusions 1, J and 4 tested with Dox-BSA coating at Do>:
2p.g/ml.
(3) lOt normal (non immunized) rabbit serum (NRS) in PBS-
tween employed as blocking agent instead of Hi BSA
in order to avoid reactivity with antibodies against
eSA.
(iv) Testinq bybrid supernatants:
(1) Dox alone used as cOlllting for all Dox-KLH fusions
except fusion J 16. DoK BSA at 2 J.l9/mi Dox used as
coating for testing hybrids from DoX-KLH fusion 16.
(2) Oox-BSA coating used for Oox-aSA fusion hybrids with
simultaneou3 5SA coated ELISAs (see below, section
II.8.S) .
(3) 11-285-14 at 2.5 p.9/ml and RPMI-GLN-FCS medium were
each employed in triplicate wells as background
controls.
(4) Sera from mice immunized with Dox-KLH or DOX-BSA used
as positive control.
(5) Non-immunized mice sera used as negative control.
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(6) For Cox-BSA fusions, the test mouse serum was di luted
in normal (non-immunized) rabbit serum (1\, NRS) in
PBS-tween, instead of 1% BSA in PBs-tween.
II. 8.5 lIonti.-BSA ELISA
II. 8.5 (a) Cuatinq
For te£:ting hybrids obtained from Oox-BSA fusions, anti-
BSA ELISAs were performed simultaneously with anti-OoX-BSfI
assays. The coating of Cox-BSA was first prepared at 2 ~q/ml
of Oax and the concentration of BSA was determined by
spectrophotometry (1\ BSA at 280 nm = 6.6). 'I'his BSfI
concentration was then utilized as coating for the para) leI
anti-BSA ELISA.
II. 8.5 (b) Assay
The procedure was identical to the anti-Oo)( BSA ELISA wi th
the same controls.
II. 8.6 ELISA tor Dox-HRP conjuqates
II. 8.6 (a) coating
The post immune rabbit serum I 3 (Table 5) containing
anti-Oo>c antibodies was used as coating to detect Dox-HRP
conjugatcl:i. 100 ~l per well of serum in dilutions of 1/100,
1/1000 and 1/10,000 in carbonate buffer were coated in
triplicate in the wells of micrntitre ELISA plates, incubatod
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at 37n e for 3 hours and then kept overnight at <loCo Rabbit pre-
immune serum (without anti-Dox antibodies) was coated
siroul taneously as a control.
II. 8.6 (b) Assay
(1) Coating solution discarded, followed by washing as in
anti-CEA ELISA.
(2) Hi eSA in carbonate buffer was used at 200 J.ll/well for
blocking, and incubated for 1 hour at 37·C.
(3) After washing, the test conjugate ....as added 100 #1/""el1
in triplicate as 1:1, 1:10 and 1:100 dilutions.
(4) The plate was incubated at J7°C for 3 hours.
(5) After washing, freshly prepared substrate ABTS was added
100 .u.l/well and the reaction read at 405 nm single
wavelength after 1 hour at RT.
II. 8.7 ELISA for Dox-p-qalactosidase conjugates
Similar to the ELISA testing of Dox-HRP conjugates
described in the previous section, except that the substrate
ONPG was used (see Dox-,6-gal conjugation Section II 5.2).
Furthermore, the en?yme substrate reaction was read after
incubation at room temperature (RT) after 3 minutes and after
1 hour.
'0'
II. 8.8 ELZSA for Dox-biotin or Dox-avidin conjuqates.
II. 8.8 la) Materials
(1) Rabbit pre-immune serum
(2) Rabbit post-immune serum
(3) streptavidin peroxidase (# 43-4323, Zymed Labs, San
Francis.-::o, Ca).
(4) Peroxidase-biotin labeled (P-9272 sigma Chemical Co) .
(5) ELISA buff·era (II 8.2).
(6) Goat anti-rabbit immunoglobulins HRP.
II. 8.8 (b) Msay
(1) Two separate ELISAs ....ere performed. Rabbit pre-immune (no
anti-Om,) and post-immune (with anti-Dox) sera in serial
dilutions of 1: 10, 1: 100. 1: 1000 and 1: 10, 000 in carbona tc
buffer were coated. at 1001-11/wel1 in triplicate.
Alternatively, Dox-avidin or Dox-biotin conjugates were
used to coat plates. The plates were incubated
overnight at 4°C after J hours at 37°C.
(2) After blocking with 200 pI of 1% BSA for I hour, the test
conjugate Coox-avidin or Dox-biotin) was added in 1110,
1/25 and 1/50 dilutions in PBS. For Oox-Avidin/Biotin
coated wells, rabbit pre-and post-immune sera were added
at 1/10, 1/100 and 1/1000 dilutions.
(3) After a 3 hour incubation at 37°C, 100J.l1 of the
corresponding indicator, either streptavidin-peroxidase
'05
(1:5000 dilution) or Biotin-peroxidase (10 1J9/m1)
added per ....ell and incubated for a further 3 hours at
37°C. For Dox-Avidin or Biotin coated plates, goat anti-
rabbit immunoglobulin HRP (1:4000 dilution) was used.
(<I) Freshly prepared ABTS substrate was added and the colour
n~a<:tion read at 40S nm, after one hour at RT.
II. 8.9 ELISA for CEA-HRP conjugates
:n. 8.9 (a) Coating
ELISA microtitre plates were coated with 11-285-14 anti-
CEA antibody or A9-S control antibody at S/J9/ml in lOOj.ll per
well in triplicate. The plates were incubated for 2 hours at
37"C and overnight at 4~C.
II. 8.9 (b) A9IJay
(1) Blocking was with either 1% BSA or 1% NRS 200/JL/well
followed by 1. hour incubation at 37°C.
(2) CEA-HRP in dilutions of 1/25, 1/50, 1/75 and 1/100 in VI;
BSA-PBS (see ELISA bUffers) was added and incubated for
3 hours at 37°C.
(3) Freshly prepared ABTS lOO~l/well was added and the
reaction read at 405 nm an the ErA Biotech plate reader.
106
II. \1.0 PRODUCTION OF BISPECIFIC MONOCLONAL ANTIBODIES
II. 9.1 IlIIlIlunization of spleen cell donors
II. \1.1 la) Haterials
(1) Complete Freunds adjuvant (CFA.; Gibea)
(2) Incomplete Freunds adjuvant (IFAj Gibeo)
(3) Dox-KLH or Cox-BSA conjugates (Section II 3.0 & 4 0)
(4) Glass syringes and needles (Becton Dickinson)
(5) PBS (Oxoid) ;autoclaved sterile.
II. \1.1 lb) Method
The concentration of doxorubicin in conjugates was
calculated by spectrophotometry. An oil in water emulsion was
prepared with Dox-KLH and CFA or IFA (table 6). 1 ml of the
emulsion was injected intraperitoneally or subcutaneously as
indical:ed in tables 6a to 6d. The immunization protocol [or
mice with Dox-BSA conjugates is given in tables 73 & b.
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t: :rabb 6a Dox-1lLB ~uDiz.tioD 8cb.dul."of Do.. 1'9
1. 2& One mouse used
3 for all three
21 fURlene. Totalcello obtained
.. 10.S7 " 10'
Fusion
Total spleen
cell.obt",ined
21 .. 4.0 x 10'
42 B.O
"
Fusion
Total spleen
cellsl obtatnctd
21 .. 16.7 X 10'
32
42 B.O
57 2.0
Fusion
2.0 Two lIliee used.
Total spleen
cells obtained
from both miclII
.. 23" 10'
32 4.0 Fusion
performed on
97th day.
"
cont nued•.••••
r.ble 6b Do..-lCLH i"l.Inhatioll .cbeclule.
Fusion' Days oQf\l~:t,.i~Q Adjuvant
. lice Table 611,
cont'd
8.0 Total epleen
"
1.1
celIe obtained
14.3 x 10'
O.S
130
Fl.lllion
Total oploon
cells Obtained
"
_a.34 .. 10'
"'
1.'
20'
Fl.lllion
Total upleen
"
cells obtained
_4.56 .. 10'
'"
'.s
11'
'"
'"
Fusion
continued ...
Tabl.6c: I Dox-KL! I_uui'latiol1 Sc:hedule.
FUllion Day" oo;~no~i~Y9 Adjuvant,
Total epleen
CFA
c:clls obtained
.. 6.72 x 10'
p",
11' m
230
m
1.0 p",
'" CFA Total apleen
cella obtained
·9.06 x 10
'
m
11' m
230 IrA
,OJ IrA
,OJ ,., P", IV.
SC
12 a& CFA Total _ 8 x
b
'"
evA
10' epleen
cells used for
in PBS
, fusions with
11-285-14 and
0.75 IrA .S,
", IFA
IFA
lnP8S
Fusion
Total ep1een
cells obtained
• 10.6 x 10'
2Jl IrA
,., IV.
SC
cont1nued · ......
Tablfl6d, I Oox-lCLH I_uohatioo Sch.dul••
Fueion Daya Quantity Adjuvant
I of Dox ,..g
'"
Fuaion
"
Total spleen
cells obtained
.. 7.94 x 101
'"
3.65 !FA
240 0.73 IV'
SC
243 Fuelon
15a& .., Total spleen
b cella obtained
.. 7.14 x 10'.
Used for 2
fuslonsl\1.110-2
IV< " NS,
sc
24. Pusion
16a& Total spleen
b cells obtained
"
Mice sera teated per mouse ..
H.1 x 10'.
inPDS IV' Two mouse
IP aphene pooled
and. u08d for
two fusions
Total spleen
cella _ 7.64 x
10'
83 Fualon
CFA; Complete Freund' s adjuvant
IFA: Incomplete Freunl;1's adjuvant
PBS: Phosphate buffered saline
IP, Intra-peritoneal
IV: Intra-venous
sc, Subcutaneous

Fusion Oily' Quantity Adjuvllnt
I o( Dox /19
in PBS
inP8S
"
"
"
Mouse (rOin
\--l------J.---l---...j ~anmeFule\~tners.ae
0.5 ml pre-
invnune blood
drawn on Day
O.
Total viable
\--l-------'.---'--...j eP11~~;6C:l;;, •
"
(udon
"
16
JO
3 fI\Onth old
mouse.
0.5 m1 blood
draw';6~n day
Total viable
\--+-----1---+---1 sp~~~~ ~e~1~
CFA used
throughout in
Fusion I 7a
and b lIim1.lar
to Balsari et
al,1988
Legem! IlS (or T.1b1e 6
II. 9.2 preparation ot" apleen cell .u.penaion
This procedure and the fusion protocol was adapted from
Woodhouse (198215), Galtre , Milstein (1981) and suresh et al.
(1986b) •
II. 9.2 Ca) Mat.dab
0) COJ flowing from incubator
(2) Absolute ethanol
(3) PBS tablets (Oxoid); autochved sterile
(4) Nylon mesh 85 sieve
(5) Sterile pasteur pipettes
(6) Laminar now cabinet
(7) Petri dishes (100 x 15 WIll
(8) Scissors 2 pairs, sterile
(9) Forceps 2 pairs, sterile
(10) Disposable plastic syringes 10 III capacity
(11) 50 'Ill sterile conical tubes
(12) Bench top centrifuge
II. 9.2 (b) lIethod
(1) The immunized mouse was killed by placing it in a jar
containing COp
(2) The mouse was dabbed with alcohol and using a sterile
pair of scissors and forceps the abdomen was opened with
a midline incision and the spleen was exposed.
'"
(3) The spleen \las removed and, after a quick. spray with
alcohol, vas placed in a petri dish containing sterile
PBS.
(4) The petri dish with the spleen was transferred to a
laminar flow cabinet.
(5) The rubber end of the disposable syringe plunget" was used
to prepare a cell suspension by pressing the splcen
through the nylon sieve into the PBS.
(6) The spleen cell suspension was left to stand in a conical
tube for a few seconds and the cells in the clear
suspension were removed with a pasteur pipette, the largo
clumps at the bottom being discarded.
(7) The cell suspension was washed in fresh PBS by
centrifuging at 1000 rpm (1759) for 5 min and the pellet
was resuspended in 10 IlII PBS.
II. 9.3 Buttars and .e4i. for Pus ions
(1) HT x 100 and x 50 stock:
Thymidine (T-9250 Sigma) 0.03819; h~'poxanthine (II 9377,
Sigma Chemical Co). 0.1361 g; distilled water 100 ml. The wator
was warmed to 60 - 70·C and the components dissolved in it to
give x 100 HT. An equal volume of distilled water was added
to x 100 HT to givo x SORT. Both were sterilised by passing
through a 0.22 ~1ft filter (Milllpore products division, Bedford,
Ma. 01130) and then stored at -20·C in aliquota.
(2) HAT x 50 Stock:
Aminopterin (A-1784, Sigma) 0.0116 g; distilled water 100
Ill; sodiulll hydroxide 0.1 H; If'!' x 100 stock 100 ml. The
aminopterin was dissolved in about 80 1CI1 ot distilled water.
NaOH Was added to aid in dissolution. The minimum amount
necessary to dissolve the reagents WBS used. The volume was
made up to 100 ml with distilled water. 10 ml of aminopterin
solution was added to 100 ml HT x 100 stock and 90 ml distilled
water to give HAT x 50 stock. This was sterilised by
filtration through a 0.22 /Jm filter (Hi11ipore products
division), and stored at -20Ge.
(3) RPHI-GLN (culture Iledium):
RPMI 1640 (320-1875 AJ Gibeo) 100 1ll1.
L-glutamine, 200nM (16-801-49 Plow lllbs) 1 ml.
Penicillin (10000 units/m1) (Flow Labs)
Streptomycin (10000 1J9/ml) solution (# 16-700-49 Flow
Labs) I _1.
Obtained sterile and mixed aseptically.
(4) RPMI-GLN-FCS (culture medium):
RPHI-GLN (see above) 500 ml.
Fetal calf (bovine) serum (FCS) 50 ml (10%) or lOamI
(20%) .
(rcs cellect" Gold (# 29-167-54) or FCS cellectM Silver
(# 29-161-54, Flo.... Labs Inc. Mclean, Va 2(102).
(5) PEG-DMSO~RPMI:
polyethylene glycol (PEG) (BOH Chemicals) 1500 avo MW.
8.0g
Dimethyl su1phoxide (OMSO) (I B10323 BOH Chemicals)
1.5m1
RPMI-GLN (see above # 3) 8.5 ml
Polyethylene glycol was steam autoclaved in a glass bottle and
allowed to cool. Dimethyl sulphoxide was sterile-filtered into
the RPMI-GLN through a 0.22 ~m filter and added to the
polyethylene glycol before it solidified.
(6) RPMI-HAT (fusion medium for hybridomas):
RPMI-GLN 100 ml
HAT x 50 stock 2 ml
Mixed aseptically.
(7) RPMI-HT-FCS:
RPMI-GLN-FCS 100 ml
HT >c 50 stock 2 ml
Mixed aseptically.
II. 9.... Biap.cHic fuaiona: spleen cella with 11-285-14
II. 9." (a) Material'
(1) Az:aguanine resistant hybridoma 11-285-14 secreting
monoclonal anti-CEil. antibody.
(2) Spleen cell suspension (previous section).
(3) Phosphate buffered saline (PBS), (Oxoid), sterile.
(4) sterile 50 ml , 15 ml conical tubes (Falcon, Becton
Dickinson, N.J.).
(5) Glass beakers, 250 ml and 1 ml.
(6) J7°C waterbath.
(7) PEG-lOt DMSO (no FCS,see Buffers and Media, above
section) .
(8) RPMI-HAT (without FCS) (see Buffers & Media, above
section) •
(9) pipettes, 1 ml, 5 ml and 10 ml, sterile.
(10) 2 stop clocks (cat # 40005, The West Bend Company,
West Bend, WI, 53095).
(11) Bench top centrifuge.
(12) Incubator at 37"C with 5t CO2 and humidification.
(13) Linbro 96 well (1 x 0.7 em, 0.J5 ml well capacity)
flat bottomed tissue culture plates (# 76-00J-05 Flow
Labs) .
II. 9.4 (b) Method
(1) The parental cells, 8-azaguarline resistant 11-285-14, in
exponential growth and spleen cells (section above) were
washed separately in sterile PBS by centrifugation (5 min
at 175 x g) and resuspended at 107 cells/ml.
(2) Spleen cells and 11-285-14 were mixed in a ratio of 5:1
in a 50 ml sterile conical tube and centrifuged at
800 x 9 for 5 minutQs.
(3) After removing the supernatant, the cell pellet
warmed by standing the tube in a beaker containing water
at 3PC.
(4) One ml of PEG-DMSO-RPMI (without FeS) at 37°C was added
to the cell pellet drop by drop over a period of 1 minute
and the cells were gently stirred very cautiously with
the tip of the pipette.
(5) The gentle stirring was continued for an additional
minute.
(6) Two ml of RPMI-HAT (without PCS) at 37"C was added over
2 minutes with gentle stirring.
(7) Eight ml of RPMI-HAT (without FCS) at 37G C was added over
3 minutes with gentle stirring.
(8) The cells were centrifuged at 400 x 9 at RT for 5 minutes
il.nd the supernatant discarded.
'"
(9) The cells were resuspended in 25 ml of RPMI~HAT-FCS as
gently as possible to avoid mechanical damage to the
cells.
(10) Fifty #1 of the cell suspension was added into each well
of a tissue culture plate already containing 100 #1 of
RPMI-HAT-FCS (see step 11 below). Approximately 480
wells (5 plates) \Jere used for each fusion.
(11) For most of the fusions, 100 1J1 of RPMI-HAT-FCS was added
into each well for the five plates, preferably the day
before or early on the day of the fusion and incubated at
J7"C in 5\ COl"
(12) On addition of the fused cell suspension, the plates were
incubated at J7°C in 5' CO2,
II. 9.5 Growth ot. bispeoi~io hybridoma. cultures
II. 9.5 (a) Materials
(1) RPMI-HAT-FCS (10% Fes SilverR )
(2) RPMI-HT-FCS (10% Fes SilverR)
(3) RPMI-CLN-FCS (10% Fes SilverR)
(4) Hypodermic needles, 18\ gauge sterile (Becton
Dickinson)
(5) Pipettes, 10 ml, sterile
(6) Suction bottle (vacuum)
(7) Javex
(8) Llnbro 96 well plates (Flow)
(9) Llnbro 24 well plates (J. 5 ml well capacity, Area 2.0
cml , I 76-033-05, Flow Labs)
(11) Titertek multichannel pipetter (Flow Labs)
(12) Sterile tips 200/Jl capacity (Flow Labs).
II, 9.5 (b) Method
(1) The plates containing the fused cells were. left
undisturbed for rive days at 37'C in 5% COl'
(2) On the fifth day, a sterile 18!l.i G needle attached to il
vacuum suction line was used to remove half the medium
without disturbing the cells at the bottom. This was
replaced with 100 iJl of fresh RPMI-HAT-FCS using il
multichannel pipetter.
(3) The above procedure was repeated every three days for two
weeks.
(4) After two weeks, half the medium was replaced with RPMI-
HT-FCS.
(5) Medium changes with RPMI-HT-FCS were repeated every three
days for at least three changes.
(6) For the initial (Dox-KLH) tusions, all further changes of
medium were done with RPHI-GLN-FCS. since the hybrids
were unstable during this transition period, for the Dox-
KLH (fusion I 16) and all Dox-BSA fusions, the hybrids
were continued to be grown in RPMI-HT-FCS. This has been
shown to improve their stability in culture as
demonstrated in some studies (Goding, 1986).
(7) When the hybrid colonies covered about 25\ of each well,
the supernatants were tested for anti-cEA, anti-ooK
and/or dual activity.
(8) positive hybrids werE! either cloned immediately and/or
transferred to 24 well culture plates containing 500 ].£1
of medium in each well.
(9) supernatants of confluent colonies were rescreened by
ELISl\s after a few days depending on growth.
(10) positive clones and sUbclones W'ere either transferred to
50 ml sterile flasks or frozen in liquid Np
II. 9.6 Preparatior. or feeder layers ror cloning.
Feeder cells consisting of splenocytes and/or thymocytes
were prepared on the day prior to fusion and maintained at 37·C
in 5% COl.
II. 9.6 la) Materials
(1) BALC/c mice
(2) Linbro flat bottomed 96 well tissue culture plates
(Flow Labs)
(3) RPHI-Hl\T-FCS (see buffers and media) with 20% FCS
cellectll Gold
(4) RPMI-HT-FCS (see buffers and media) with 201 Fes
cellectR Gold
(5) Disposable 5 ml and 10 ml syringes, sterile
(6) IBis: G hypodermic needles, sterile
(7) Nylon sieve, sterile
(') Petri dishes, sterile (Polar Plastic Ltd. ,
5t.Ltlurent, Quebec H4R 289).
(9) Absolute alcohol
(10) 50 ml conical tUbes, sterile
II. 9.6 (b) Method
(1) Mice were terminated as described in removal of spleens
for fusion (Section II 9.2).
(2) The spleens were removed in an identical manner.
(3) The skin over the upper part c.f the chest was incised in
the middle and the subcutaneous thymus was removed
aseptically.
(4) The thymuses were transferred to a petri dish with
sterile PBS and then into the laminar cabinet.
(5) 1\ sterile syringe plunger was used t.: express the thymus
cells through the nylon sieve into a petri dish ....ith
sterile PBS.
(6) After allowing the large clumps to settle to the bottom,
the supernatant was transferred to a 50 ml conicill tube
and ....ashed twice with PBS.
(7) The cells were resuspended in medium, either RPMI-HAT-FCS
or RPMI-HT-FCS depending on the number of days after
fusion (Section II 9.5).
(8) The spleen cells were prepared as described under the
fusion and were adjusted to a final concentration of 1 x
106 cells/ml to yield a cell density of 1 x lOs cells
contained in 100 ~l per well.
(9) The thymocytes were adjusted to a concentration ranging
from 5 x 106 cells/ml (Woodhouse, 1982a) to 1 X 107
cells/1Ol (Goding, 1986; Eshhar, 1985). The final density
of thymocytes was in most cases 1 x 106 cells in 100 J.Ll
per ....ell (Goding 1986, Eshhar, 1985).
(10) In some cases, a combination of spleen cells and
thyrnocytes used feeders at the above
concentrations resulting in ill cell density of 5 x lOc
splenocytes with 5 x lOS thymus cells in each well.
II. 9.7 Cloning of positive by})rids by limiting dilutions
While cloning is an essential step in the preparation of
Mabs, its ovtstanding importance in the selection of hybrid-
hybrids has been demonstrated by previous studies (Suresh et
aI, 1986 B & b). This is due to the increased polyploidy of
the hybrids and their higher propensity to lose chromosomes
than conventional hybridomas. The method of limiting dilution
was used for cloning (Hudson & Hay, 1980i Galfre & Milstein,
1981; Woodhousll. 1982).
II. 9.7 (a) Materials
(1) Positive hybrid cells to be cloned.
(2) Sterile 96 well tissue culture plates, 0.35 ml well
capacity (Linbro I 76-003-05, Flow Labs).
(3) Incubator 37·C, humidified and gassed with 5-\ COl
(4) Feeder layers (Section II 9.6).
(5) RPMI-HT-FCS or RPMI-HAT-FCS (20% Gold Fes used for
selection and cloning of Dox-BSA fusion hybrids).
(6) Titertek multichannel pipetter (Flow Labs).
(7) sterile 200 pI tips (autoclaved).
(8) Sterile petrL dishes (100 x 15 mm).
II. 9.7 (b) Method
For each positive hybrid well:
(1) The cells were pipetted into suspension and counted as in
Section II .1.
(2) The suspension was adjusted to 10 cells/ml and 5 cells/ml
in r.'Iedlum.
(3) 100 /-11 of the 10 cells/ml suspension was aliquoted into
each of the 48 wells of half a microtitre plate.
Similarly. 100 pI of the 5 cells/ml suspension
aliquoted into the remaining half of the plate.
'"
(4) The cells were incubated in a humid 37·e incubator gassed
with 5t ~.
(5) Colonies were usually visible after 1-2 weeks and then
the supernatants were tested for antibody activity.
Note: The distribution of cells per well follows Poisson
statistics, with about 60t of the welle receiving only one
cell, resulting in true clones. Many of the remainder wells
will receive 2 or more cells following aUquots of 10 cells/ml
suspension (Hudson " Hay, 1980).
Cloning was repeated at least 2 or 3 times to ensure
clonality of positive subclones.
n. 10.0 FUSION OF SPLEEN CELLS .1'1'11 8B-l MYELOMA.
Materials and methods identical to fusions of spleen cells
with 11-285-14 (Section II 9.4). The NS-l myeloma growing in
6-thioquanine (Section II 2.3) was used. with spleen cells from
mice illUllunhed with Dox-KL}f or Dox-BSA. The selection and
cloning procedure was similar to the section on bispecific
fusions (Sections 119.4 to II 9.7).
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CHAPTER XXI
RESULTS
III. 1.0 GENERATION OF 11-285-14 PUSION PARTNERS
The 11-285-14 hybridoma was first back selected in
increasing concentrations of s-azaguanine. 11 batches,
growing well at the 30 #J91 ml concentration were produced.
These 11 batches wore cloned by limiting dilution and of the
72 clones of 11-285-14 isolated, 27 were positive Cor anti-ell.A
production by ELISA. Rapidly growing clones were evaluated for
(1) growth Characteristics, (2) maintained anti-et::A production,
(3) HAT sensitivity, (4) fusion efficiency.
III. 1.1 Growth Characteristics
Three of eight rapidly growing, antl-CEA producing clones
termed Aza 1, 2 and 3, were compared with the parentill non-
azaguanine resistant 11-285-14 hybridoma in conventional (RPMI-
GLN-FCSl mediulIl. The cells were inoculated at an inithl
concentration of 0.05 x 104 cells in 10 ttll lIedium. The number
of cells was counted daily and this has been plotted in Figure
4. The mutant clones appeared to be slow growing compared to
their parental 11-285-14 cell lines during the five days thoy
were counted (Figure 4).
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Figure 4. Growth of 11·285·14 clones
6 -
---Au·1
-11·285-14(11
-~ A.II·2
-0-11·285-14(2)
-D- A 1I.~
-«l-11·Ufj·14PI
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Days
ris.J.u:£..L. Three aZllquanine resistant 11-285-14 clones (Aza-l,
2 , Jj closed Syabols) were compared with their parental 11-
285-14 (open symbols) growing in RP1U-GLN-FCS. The nu:tber of
cells started ....as 5 X lol/ml and was counted dail~"
0.6
Figure 5. Comparison of anti-CEA12 '
production
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Days
~ The supernatants of cell lines shown in Figure 4
were tested for anti-CEA production daily by ELISA. The open
symbols represent the parental 11-285-14 (1) (2) and (J)
compared with the aZ8guaninc resistant Aza-l, 2 and J. Each
point represents the mean value of absorbance readings in
triplicate. The standard deviation has bean omitted for
clarity.
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III. 1.2 l\nti-CBA production
The three Illutant clones were also compared with the
parental lines for their anti-CEA production (Figure 5). There
\oIas continuous anti-CEA production in the Illedium up to 5 days
ot testing. In addition. the anti-CEA activity of all the
eight hybridoma fusion partners was tested prior to fusions to
confirm anti-CEA production.
III. 1.3 HAT sensitivity
Prior to each fusion, aliquots of the 11-285-14 fusion
partner were transferred to KAT selection medium as controls
and were found to cease growth and to die confirllling their HAT
sensitivity.
III. 1. 4 Fusion efficiency
Fusion efficiency indicates the success in producinq
hybrids (Calfre Milstein, and Wright, 1979) anrl is defined
here as the number of hybrids resultinq frOID each fusion.
Fusions were performed to assess the eight 11-285-14 azaguanine
resistant clones as fusion partners and these are summarised
in Table 8a, b , c.
11-285-14 Fu.loll
Partner/comment,
Poor to .-odttl:~te
growth.
Good qrowth end
viability.
Total •
.
TotaL. 43
.
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Antibody actl.v1.ty
of ltybrid,
Anti-Do.
14
All _ro ~u.lonll with apl••n cella frQm DOJI-XLH t-Jnlzed .. ice
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Table 8b= PulioD .ffici...cy at: 11-285-14 cloDel
11-2B5-14 rueion
Partners I Comments
£l.2ml...rl=
Good growth and
viabi11ty.
Fillion I Total AnUbody activity
Hybrida of hybrids
anti-CEA anti-OaK
Total .. 2
£12=..11.
Poor growth and
viability. Although
initially anti-etA
positive, bocame anti-
CEA negative
8ubeequently and was
therefore discarded.
£l2.n.L..'lI:
Good growth snd
Viability.
rotal .. J 11
41 11
147 34
Total .. 4 238 '4
Au wore Ulu.ons W.l.tn ap een Cel.1S trom Oox-kLH .l.!Mlun r.ea rnl.ce
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'1'.b1e BCI ,.uaion efficiency of 11-285-14 elan••
Antibody activity or
hybrids
anti-CElt
M.A=.J.:
Good growth
and viab!.lity.
l!.U.=.2:
Good growth
and vlab.ility.
~,
Good gl'"OIlth
and viab:Ulty.
14
Total. 1
Total. 3
1-8 (Dol(-
B5AI*
Total. 9
1'6
'"
• Fl.lllions 1 - B with A:tll-J were perfol:med with eplccRIl from Dox-USA
ilMlunhed m!.clI, Rust of thy funial'll! were performed with spleonll from 00:><-
KLH illWllun1.zed lIliee.
Although clone VI gave the highest fusion frequency.
yielding 59.5 hybrids per fusion, many of the hybrids were
negative for antl-CEA and for anti-Dox activity. However, one
of the clones, Aza-), reSUlted in hybrids that were
consistentlY positive for anti-CEA activity (Table eel. Aza-)
also had suitable gro....th and anti-CEA production (Figures 4 &
5) and was therefore selected as the fusion f)artnC!r for
subsequent fusions.
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Hr. 2.0 PRODUCTION OF DOZORUBICIN-PROT£IN CONJUGATES
Doxorubicin was Dade i1lll:l.unogenic by conjugation to the
carrier proteins keyhole limpet hemocyanin (KLHl or bovine
sal'um albumin (P.SA).
III 2.1 Do)Corubicin-JtLH conjugates
The in1tial concentration of doxorubicin (Tables 9a, b &
oj is given after the deduction of weight of lactose in
doxorubicin hydrochloride (4/5th of the dry weight is lactose) .
Phosphate buffered saline (PBS) prepared as described in the
Materials and Methods was used as solvent in conjugates I 1 and
J to 15. Distilled water was used for conjugate I 2. However,
the results were inconsistent, with the drug protein c .1Dplex
precipitating out of solution prior to gel filtration on the
sephadex column. In addition, there was a poor yield of
conjugate. Modification of pH to dissolve the precipitate,
although initially successful, could not. be reproduced
(conjugates 11 , 12, TlIble 9b).
n,
Initi.l
cono::entratlon
Conjugat••
00,
.,
XUI £CD!
., ..
PD'
pH 7.2
Distilled
Watec
pR1.a
KLH
d.hlyood
in PBS
pH 7.0
20 11.4 JU.H
dialysRd
in PBS
pH 7.5
Dox:KLH Concentratlclno
lIlOh.r Dolt J(UI
raUo 1,19/",1 lIl9/1nl
No conjugate obtalnod
NO eonjugata obtainod
0.'
15
15
10
10
PD'
pH 7."
..,
pH 7.2
PD'
pH 7.2
PD'
pH 7.2
P05
pH 7.35
PD,
pH 7.2
66 I 1
132 :
No conjugllte
continued ...
lJ5
'1'ablll 9 b I Doxorubiclu-KLH conjugates
Initial Conditione Conjugatee
concentration
'0. XLH ECDI Dox:KLH Concentrations
mg mg mg molar '0. XL"
ratio uq/ml rng/ml
'"
n'pH 8.0
pr~~~~i-
dissolved
'"
No conjugate
pH 8.4
,,, No conjugllte
pH'1.3
PBS
pH'1.3
'.1 10
'"pH 1.7 NO conjugate
precipi-
tated
PBS from
"
1
tablete
pH 7.4
2.26 10 PBS from 143 1
tablets
pH 1.4
15 10 PBSfrOll\ 160 1 0.'
tablets
pH 7.2
19 2.6 pas from 27' 15 1.'
tablet8
pH 1.2
(precipitated even before addition
of ECDIJ
continued
IJ6
Table 9 c: DoxorubiciD-KLB conjugate.
Initial
conct:lntration
Conditione Conjuglltes
00.
mO
KLH ECOr
mg mo
DOJC:KLH Concontrationo
molar Oox KLH
ratio u9/ml mg/ml
21 2.6 13 PBS from
tablets
pH 7.2
330: 1 38.2 1.8
3.4 e...
(6.6) (16)
10 No con:\ugate, precipitated il1lll'lcdlatcly
1., 11 10
'"(5) (15) pH 7.2
3., ,
'"
305
(5) (IS) pH 7.2
25 0.1 15 11 PBS S6B:
(5) (17) pH 7.2
.., 16 10
'"
238 1
pH 7.2
21 12 ..
'"
163 1
pH 7.2
Legend: 1. Conjugations 1 - IS, 26 & 27: Initial concentration of Dox
given aB dry weight.
2. Conjuglltionil 16 - 25; Oox concentration bllBOd on abnorbancQ
at 495 nm.
For conjugatee I 22 to 25' Parentheeill indicatCD tho <.Icy
weight for Dox Bnd KLH.
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From conjugate 116 onwards, PBS made from tablets (O>wid,
England) proved to be a more reliable solvent and the results
wC!re more consistent (Tables 9b & ge). In addition, from
conjugate , 16, the precipitated drug was removed by
centrifugation, and the dissolved drug concentration was
calculated by spectrophotometry. This, more accurate
concentration of the drug, is given from conjugate I 16 onwards
in Tables 9b and 90. As illustrated for conjugates 22 to 25,
when compared with the dry weight of approximately 5 mg, there
was a loss from 50 to 80\ of the drug due to precipitation even
pr lor to the conjugation step. The number in parentheses for
conjugates 22 to 25 indicates the dry weight of doxorubicin and
hemocyanin prior to dissolving in PBS. For conjugates 1 to 15
and for 26, 27, only the initial dry weight of doxorubicin is
given.
The DoX-KLH-ECDI mixture was eluted from a sephadex G-25
column. The timer for eluent flow was set at 5 to 10 minutes
per fraction, The volume obtained was approximately 4 ml per
fraction and 50 to 60 fractions were collected from each
conjugation experiment. Approximately five of these fractions
contained the conjugate. This was ascertained by reading each
of the fractions at 495 nm and 280 nm. The protein fractions
were identified by the readings at 280 nm and the amount of
drug calculated from the readings at 495 nm.
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Figure 6. Dox·KLH conjugate separation
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~ Dox-KLH-ECOI mixture was eluted down a sephadax C-25
gel filtration column. The fractions collected were determined
by spectrophotometry tor Doxorubicin and KLH. KLH with its
higher molecular weight separates first as confirmed by a high
280 nm protein peak. The reading of 495nm in the protein peak
indicates the amount of drug conjugated to KLH. The free drug
is the last to elute as indicated by a later 495nm peak.
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This separation of the conjugate from the free drug for
conjugate I 25 is shown in Figure 6.
The results of the various conjugation experiments have
been summarised in Tables ga, 9b & 9c delineating the
conjugation conditions and protein drug concentrations. The
highest molar ratios for individual fractions before pooling
the individual conjugate fractions is indicated in the tables.
III. 2.2 Doxorubicin-BSA conjugates
A list of Dox-BSA conjugates produced with ECDI, the
initial drug and protein concentrations and the experimental
conditions are shown in Table 10. Since a major portion of the
drug precipitates out of solution, the accurate amount of drug
used for conjugation prior to loading the column was determined
by spectrophotometry and is given in parentheses for some
conjugates. This was not checked for all the conjugates, since
it did not have a direct bearing on the amount of conjugate
produced. PBS made from tablets (Oxoid, U.K.) was used for all
conjugations and Sephadex G-25 was used for separation of free
and conjugated drug similar to Dox-KLH separations. The
individual fractions were of 2 to 4 ml volume and of the
greater than 50 fractions collected, about 10 ml of conjugate
resul ted from each experiment. The molar ratio and
concentrations are shown for the individual fractions showing
the highest reading after each conjugation. Conjugate #10
separation is illustrated in figure 7 as an example.
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Figure 7. Dox-8SA conjugate separation
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~ OoX-BSA-ECOI mixture was eluted down a sephade>c G-25
gel filtration column. The fractions collected were determined
by spectrophotometry for Doxorubicin and BSA. eSA with its
higher molecular weight separates first as confirmed by a high
280 nm protein peak. The reading of 495nm in the protein peak
indicates the amount of drug conjugated to KLH. The free drug
is the last to elute as indicated by a later 49Snm peak.
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III. 3.0 PRODUCTIOIf OF DOXORUBICIN-ENZYME CONJUGATES
Attempts ",ere .ade to link doxorubicin to enzymes either
directly with heterobifunctional linkers or indirectly through
an avidin/biotin bond.
III. 3.1 Doxorubioin-borseradieb peroxidase conjugat.a
Since the anti-CEA and anti-Oox ELISA were standardised
using horseradish peroxidase (HRP) labelled detector sccontl
antibody, HRP was the enzyme of choice to be conjugated wi th
doxorubicin. A summary of the methods attempted in chemical
coupling ot the drug to HRP is given in Table 11. The
principles behind each approach have been dealt with in tho
Materials and Methods section II 4.1.
The conjugates were separated trom the free drug by
Sephadex G-25 gel filtration. The presence of IIRP was
confirmed by addition of 100 ul of ABTS substrate to 50 pi o[
each fraction aliquoted into a 96 welll11icrotitre ELISA plate.
The plate was read by the EIA Biotech reader at 405 nlll.
3"
'lable 111 Doll:or\ll:licin-HkP eonjugste.
Method, HRP type
and conditions
Highest optical
daneity reading's for
conjugate fractlenD
obtained
Results
.n.
Comments
280
~
'03
~
495
~
HRP Type VI
(RZ _3.0)
Buffer pH 7.4
2. HPR Type VI
(RZ .. 3.0)
Buffer pH 7.3
J. HRP Type VI
(RZ .. 0.6)
Buffer pH 9.5
HRP Type VI
(RZ .. 3.0)
B1.lffer pH 7.3
S. HRP Type I
(RZ .. 1.1)
J. Padod.t_ Metbod
0.171 0.258 0.098
3.165
Carbodit.ide Method
0.640
1.779 0.366
Fractionll I 15 to 2&
were positive for
enzyme activity and
we/;a extensively
dialye&d. Negative
for presence of 001(
by ELISA
Similar to above
reaulte
SimLlsr to above
rBBulte
Similar to above
resultll
DO;;;Qrublcin not
detected by ELISA
6. ECDI, HRP Type I LOBI 1.312 0.435 Fractions I 9 to 14
(RZ .. 1.1) showing highest HRP
NaF 0.001 M activity were
dialysed to remove
excess NaF and tested
for 0011 by ELISA,
continued ..... ,.,
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1'abl. 111 Doxol'ubiclll-BRP cDlljugat;•• (continued)
Method, HRP type
and conditions
Highest optical
denaity I:eadinga for
conjugate fractions
obtained
ReBuitD
004
CQIMlenta
260
=
403
1. HRP Type I
(RZ-I.Il
NaF, D.HI and
EDTA 0.001 H
8. 0.1\ glutaralde-
hyde HRP type I
(RZ-l.1)
9. HRP Type VI
(RZ· 3) Pag6
1967
1.750 0.506 DilIly80d fl:actionll 9
to 19 showing otrong
ent;ymo activity.
Negative by ELISA fOl'
doxorubicln
Preciptated.
No conjugate.
0.310 0.647 0.150 Negative by ELISA for
doxorubicin
10. HRP Type I
IRZ • 1.2) Paq(i
1981
1.026 0.561 Same reaulto Oil abovo
DOIC-,6-galactoaid•• 1Il conjugat••
11-13. HBS all the Procedure repeated throe tlmos.
hatoeo blfunc- Negative readings by Spectrophotometry and by
tional linker ELISA
No conjugate detected
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The main problems that were associated with coupling Dox to HRP
are discussed below.
Firstly, both Cox and HRP are visible at optical density
(00) 280, 403, 495 and 510 nm leading to difficulty in
determining the precise molecular concentrations of the drug
and enzyme separately. Although the molar extinction
coefficient (HEel of 1% HRP at OO~IO nm is 6.58 (molecular
weight of HRP"'40,OOO; Sigtll8 Chemicals). the difference in
readings between 00110 nm and 0049' nm was negligible and
therefore, 0049J nm was determined instead of 00510 nm. Single
fractions with the highest readings obtained for each
conjugation are given in Table 11-
conjugate #7 is illustrated in the following example to
show evidence for Dox-HRP conjugation. This conjugate was
produced incorporating the modifications suggested by Dr B.
Hasinoff, Chemistry Department, Memorial University (Personal
communiciition, also see Materials & Methods). The elution
profile of the fraction from this conjugation is given in
Figure 8. If we assume OD~1ll nm reading (1.750) to be entirely
due to HRP, OOm nm should read 0.218 based on the control
readings for HRP as calculated below. For a given control
solution of HRP (type I, RZ 1.1)
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~~:::=~:~;;=a; and ~~:::=~:i;;=7. Extrapolating these
values to the conjugate, instead of the expected 0.218 at OOm
(l.~SO) a reading of 0.506 was obtained at 0049, ( conjugate
#7; Table 11). The difference (0.506 - 0.218) of 0.288 would
be accounted for by the drug conjugated to HRP and was
calculated to be approximately 13 /J9/ml. This figure is a
slight underestimation of the drug concentration, since the
00403 reading of 1.75 includes 'contamination' by thp. drug
absorbance as well (usually about a third of the OD~~s nm of the
drug absorbs at 00400 om also).
Having confirmed the presence of doxorubicin as explained
above and the presence of HRP by addition of ABTS to the
conjugate fractions (Figure 8 and Table 11), the definitive
evidence for Oox-HRP conjugate would be recognition by <l.nti-Dox
antibodies. The presence of doxorubicin was tested by ELISA.
Rabbit serum containing anti-Oox antibodies was used to coat
plates and the Dox-HRP employed as the detector. Ilowever, tho
ELISA failed to detect the presence of Doxorubicin in conjugato
17, indicating either absence of Dox or the presence of Ooy. in
such a modified form that it was not recognised by the
--280 nm
_t_ 403 nm
-40-4;6 nm
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Figure 8. Dox·HRP conjugate separation
1---,--'1--,-'1-'-1----.-1
10 20 30 40
Fraction"
50
~ Dox-HRP conjugate fractions are separated from the
free drug in a simihlr fashion to Dox-KLH and Cox-5S1\. as
explained under Figurt!s 6 and 7. However, HRP is determined
by both 280nm and 40Jnm and is shown to be eluted in the
initial peak fractions. A simUltaneous reading at 495nm of
this initial peak indicates the amount of Dox conjugated to
HRP. The free drug is the last to elute and the later
fractions show predomlnently Doxorubicin at 495nm.
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anti-Dox antibodies. similar negative results were obtained
with Dox (conjugate I 7) used as ELISA coating (data not
shown) .
The probable reasons for the failure of Dox-IIRI'
conjugation are discussed in detail in the final chapter iJnd
include the formation of free superoxide radicals by Cox in
solution resulting in self-coupling of the enzymc (Dr. Brian
Hasino!f, Chemistry department, Memorial univarsity; pcrson<ll
communication). In addition, the presence of metallic ions in
solution could hinde:r the chemical procedure (llasinorf, Davey
& O'Brien, 1989).
Although ten conjugations were performed to 1 ink
doxorubicin to HRP, conjugation I 7 has been illustrated above
to indicate the final outcome of these experiments. 'l'ilble II
summarises results of these direct linkage attempts us! ng
periodate, carbodiimide or glutaraldehyde.
III. 3.2 Doxcrubicin-,lJ-qalactosidue conjugates
The only reported enzyme labelling of Dox in the
Ii terature was that of Dox-,l3-qalactosidase by Fuj i lola ra et <.II,
(1981) using the heterobifunctional reagent M-malcimidobcn"l..Oyl-
N-hydroxysuccinimide estE!r (MBS). This procedur(! ....as attempted
three times without success (Table 11). A.n attempt was also
made to link Dox and ,l3-galactosidase with feDI but was
unsuccessful (Table 11).
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III 3.3 Doxorubicin-avidin and doxorubicin-:tliotin conjuqates
Due to the failure of the above methods, indirect methods
were attempted to link doxorubicin through an avidin/biotin
bridge. The conjugates obtained were tested with biotin
peroxidase or streptavidin-peroxidase as the indicator in
ELISAs. A summary of the various conjugation experiments is
shown in Table 12.
Table 121 Doxorubicill-Avidill/Biotill colljugates
Initial Material Cross-linker Resulte
(1) DOl( + Avidin Separated by gol filtriltion.
No con u ate.
(2) Dox-riSA-succinyl «-hydroxy The mixture was extensively
succinimide dialysed and up to 1/10
biotin ester dilution containing 21'g ml·'
of Dox wall tested by ELISA.
N ..tiv... result ....
(3) Dox-BSA U-hydroxy Similar negative re!lultB as
succinimide above. ELISA 1453 Dox-8SI\-
biotin luter Biotin recognised by Rabbit
(lDOX abe.
(4) DOl( + Avidin
Buccinic
anhydride
(5) Dox-USA"- Avidin
(6) Dox-BSA-Biotin
(7) Dox-BSA with
Blotin and OHSO
Biotin-
hydroxy
Quccinimide
<I!lter
Blotin-
hydroxy
.ucclnimlde
ester
D...finite conjugate on ;leI
filtration up to 24 1'9/m1 of
Dox at 495nm. Dox was not
recognised by rabbit anH-
Dox antibodies, both as
coatin and indicator.
Extenaivo dialyd.1I and
negative by ELISA.
Extensive dlaly.ie and
tested by ELISA. No
significant difference
between pre end po.t-immune
rabbit anti-Dox sera.
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Oax-avidin conjugate (# 4, Table 12) appeared to be tho
most promising, the separation from the free drug is shown in
Figure 9. The conjugate yield contained up to 24 ~g of
doxorubicin per ml, when assessed by spectrophotometry. ELISl\s
were then performed with Dox-avictin as the coating antigon.
The presence of doxorubicin was not detected by rabbit post
immune serum containing anti-Dox antibodies (Figure 10). '1'0
confirm the activity of the rabbit anti-Dox antibodies, tilt'
same solutions of pre-immune and post immune SC['Cl were tested
in the ELISA using comparable quantity of Dox-BSA as the
coating. As shown in Figure 10, there was a greatar than six
fold positive difference with the post-lrnuune serum, supporting
the presence of anti-Dox antibodies and appropriat~ coating.
Alternatively, the rabbit serum was used to coat the t:l.lS11
plates and Oox-Avidin conjugate (/4, Table 12) was next added.
Biotinylated HRP as the indicator did not indicate th~ presence
of conjugate by ELISA (reSUlts not shown). These ["esu 1ts
suggest that although doxorubicin appears to be link~d to
avidin by spectrophotometry. it is probably pl:"cscnt j n i.I
modified form not recognised by the anti-Oox antibodies.
Attempts were also made to link doxorubicin to avidin or
biotin using Dox-BSA or Oox-HSA (human serum 21 bum in)
conjugates in order to pl:"omote protein-protein conjugation.
Thp.:se experiments were unsuccessful, and are summlllciscd in
Table 12.
Figure 9. Dox-avidin conjugate separati~~'
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~ Oox-avidin mixture is eluted down a sephadex G-25
qel filtration column. The initial 280nm peak in the fractions
indicates the presence of the protein (avidin). The reading
of 495nm in this initial peak indicates the conjugation of Dox
to avidin. The smaller molecular weight Cox elutes at the
later peak, calculated from the reading at 495nm.
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Figure 10. Dox·avidin conjugate
ELISA
2 -,--------------
E=::==o--_····· --.--
1--~-I--·--I--,- ..··1 •.•.,-)
4
Dox or Uox·Avldin coallny In uy
-u-Ple·lmI1lUlle: Uox-nldln ctJ~"ng
---Post-Immune: Uox-avldln coaling
-o-Pre·lrnmune: Uox coa.tlng
-t-Posl-lmmUIIIl: UO,l( coaling
lli~J:'L-l_O--t. llo)f-avidill fractions F!lllt.Qej nr: t"!lr'! JIIJ\:Jnl POllio:
in iFlqure 9, were eynluated by EI,lSfI (or till:' prCfH!IlCC DC
Doxj:>rubicin. 'I'he concentration of !}o)( ill !l())!.-llvhllll fractioll~
wag calculated by spectrophotometry and used 11" EJ~l!JA coatill"J
as shown.
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IIZ "'.0 PRODUCTION OF CEA-HRP CONJUGATE
The unsatisfactory results of enzyme labelling Dox led to
the exploration of an alternative approach in developing a
bispecific antibodY assay. The periodate method was used to
label etA with HrtP (type VI, RZ 3) and the CEA-HRP was
separated by Sephadex G-75 (Mol. wt. of CEA = 180,000 and HRP
= 40,000). All the HRP and CEA in solution appeared to be
conjugated since there loIas no free enzyme or CEA peaks
visualised after the appearance of the CEA/HRP peak (Figure
11). 50 j.tl of each fraction was aliquoted into each well of
an ELISA plate. On addition of the substrate ABTS, thu CEA-HRP
fractions (Figure 11) correlated with strong HRP activity. To
conf irm that (a) CEA was conjugated to HRP and (b) CEA-HRP
could be recognized by anti-CEA Hab (11-285-14) I ELISAs were
performed as outlined under Materials and Methods. Figure 12
illustrates these results. CEA-HRP thus produced was used to
develop an ELISA to detect BsMabs directly.
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Figure 11. CEA·HRP conjugate separation
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~ CEA-HRP mixture was eluted down a sephadex G-75 go I
filtration column. The fractions collected were determined by
spectrophotometry for CEA (260nm) and HRP (403nm).
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Figure 12. CEA·HRP ELISA
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Roclprocal of CEA ·HRP dllullon
~ The CEA-HRP conjugate peak fractions separated as
shown in Figure 11 were pooled and tested by ELISA. ELISA
plate was coated with 5ug/1lI1 of 11-285-14 (anti-CEA). Ag-8.
(non specific antibody that does not recognise CEA) was used
as a coating control. Reciprocal of CEA-HRP dilutions added
is shown here. Each point represents the mean value of
absorbance readings in triplicate +/- twice the standard
deviation.
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III. 5.0 DEVEI,OPMENT OF ENZYME LINKED IMMUNOSORBENT ASSlIYS
III. 5.1 Development ot anti-CEA EL:I8A
The appropriate CEJ\ coating was determined by evaluating
eEA coating concentrations ranging from O.625~9 to 20/-l9 per mI.
The coating was tested with anti-CEA 11-285-14 at 0.1 to 1000n9
per ml concentrations. CEA coating at 5J,l9 per ml was found to
be twice as sensitive as 2.SJjg/ml (Figure 13). The results
were identical for 5 and lOJl9/ml CEA coating and therefore CEA
was employed at a coating concentration of 51l9/ml in anti-CE/\
ELISAs.
The optimal dilution of the second antibody indicator,
rabbit anti-mouse immunoglobulin horseradish peroxidase (HAM-
HRP) was determined using CEA coating at Sj.J9/mL 11-285-14 ilt
a concentration rang". of 0.1 to 1000 ng/mi was used as the
first antibOdy. 1/1000 dilution of RAM-HRP was selected for
future ELISAs, after comparison with dilutions ranging from
1/250 to 1/4000 (Figure 14).
>57
-II)- ceA 0.825 1,111
_D_ ceA 1.25 uv
-'CEA 2.5 ug
-t_ CEA 5.0 UII
-6-CEA 10 UtjI
-to CEA 20 11\'1
Figure 13. CEA coating standardisation
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~ ELISA performed with CEA coating range from 0.625u9
to 20 ugjml. 11-285-14 (anti-CEA) antibody ....as added in
varying concentrations as shown. 5ug/ml eEA coating was
selected for future ELISAs. Each point represents the mean
value of absorbance readings in triplicate +/- twice the
standard deviation.
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Figure 14. RAM·HRP standardisation
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~ ELISA performed with CEA coating at 5ug!ml.
Varying concentration of 11-285-14 Hab added as shown. VClrylnq
ran9'e of rabbit anti-mouse immunoglobulins labelled with IlRP
(RAM~HRP) dilutions, were evaluated as the indicator. Each
point represents the mean value of absorbance readings in
triplicate +/- twice the standard deviation.
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III. 5.2 Development .;.f anti-doxorubicin ELISAs
Following immunization of a rabbit with the Dox-KLH
conjugates (see below: section III. 6.0), the rabbit serum was
used to develop an anti-doxorubicin ELISA. The optimal
doxorubicin coating was selected by comparing doubling
concentrations of uoxorubicin trom IJ,l9/ml to 8pg{ml (Figure
15). The rabbit post immune serum (containing anti-oox
antibodies) W<lS the first antibody. The second antibody
detector was goat anti-rabbit immunoglobulins linked to HRP
used at il dilution of 1 in 500.
The results (Figure 15) are illustrated using varying
range of doxorubicin as the coating. since there was no
significant difference between the readings obtained with
various coating concentrations, 2/.1q/lI'Il Dox was selected as the
coating concentration for future assays. The results are shown
in Figure 15. Due to the questionable stability of Dox
(Section IV 2.2) and the reproducibility of the assay, Dox-BSA
coating at a concentration of 2ug Doxjml was employed for
testing hybrids obtained from Dox-BSA fusions. The results
with Do)C-BSA coating were similar to assays using cox alone
(data not shown).
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Figure 15. Dox coating standardisation
-m-Doll[ 8ug/ml
-D-Dol( holm!
-0-001( 2ug/ml
-.-0011: IUll/ml
.woe-Plelmmune control
.....L.11-_-_...-_-'~~..--.---.-C-.-----,-,~---.-...- __, ,
1/100,000 1/ 10,000. 1/1000 1/100 1/10
Serum dilution
~ ELISA performed with doubling concentrations of Oax
coating ranging trom lug/ml to 8ug/1l1. Rabbit post-immune
serum (containing anti-DaK antibodies) was added in varying
dilutions as shown. Pre-immune serum (no anti-Oox) was added
in similar dilutions as control. Each point represents the
mean value of absorbance readings in triplicate +/- twice the
standard deviation.
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III. 5.3 Development ct anti-BBA ELISAs.
subtraction assays were performed to select hybrids from
flax-eSA fusions. Hybrids were tested for both anti-oox eSA
activity (as above). and anti-eSA activity by ELISAs. Hybrids
that were positive in anti-Dox-BSA and negative in anti-BSA
ELISAs, were selected for further expansion. The coating for
anti-eSA assays was selected for individual assays, based on
the parallol anti-Cox-eSA ELISAs. While the doxorubicin
coating in the Dox-BSA assays were constant (2J,lg/ml), the eSA
quantity varied, depending on the batch of Dox-BSA conjugate
produced (Geeticn III 2.2., t<tble 10). The accurate quantity
of eSA was determined by spectrophotometry (see Materials 3i,d
Methods) prior to each Dox-BSA assay and a similar
concentration used in the corresponding anti-BSA ELISA. This
eliminated any possible discrepancy between the anti-Oox BSA
and anti-BSA ELISA resUlts due to a difference in the BSA
coating. The remaining steps in the anti-BSA ELISA were
identical to the anti-Oox BSA assay.
III 5.4 Development ot bispecific antibody Assay
Since HRP was the enzyme utilised in anti-CEA and anti-oax
ELIShs, several attempts we~e made to enzyme label Oox with
HRP. Oox-HRP would then be useet to develop an ELISA to detect
dual activity directly. However, enzyme labelling experiments
of oox with HRP and n-galactosidase were unsuccessful (Sections
'62
III 3.1, 3.2 and 3.3). A CEA-HRP conjugate was then prOduced
(Section III 4.0) and was found to be recognised by anti-C~;A
antibodies (Figure 12). A direct ELISA for dctcction of
bispecific antibodies vas developed using the CEJI.-IIRP
conjugate. Hybrids that were positive in both anti-Oox and
anti-eEA ELISAs, were then selected for dual activity EI,IS/\
testing directly. ELISA plates were coated with doxorubicin
(for Dox-KLH fusions) or Dox-BSA (for Oox-BSA fusions). 'l'c:;t
hybrid supernatarts were added next for assessing anti-
cOl>xorubicin binding. CEA-HRP was then added, \<Ill i eh, i r
recognised by the other arm of the bispecific antibody y.lcldcd
a positive result on addition of the substrate (1\81'5). 'I'he
various ELISAs developed are illustrated diagrammatically in
Figure 16.
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III. 6.0 EVALUATION OF IHKUNOGElfICITY OF DOX-PROTEIN CONJUGlloTES
III. 6.1 I_uDoqenicity in a rabbit
The immunogenici ty of Dox-KLH conjugates was eva luated by
immunizing a rabbit according to the schedule in Table 5
(Materials and Methods). The rabbit serum drawn on different
days (Table 5) was tested tor anti-COx antibodies by ELiSA.
The serum drawn prior to immunization was used as control (pra-
immune serum). Doxorubicin by itself was used for ELl::;i\
coating. Results show the presence of high titre antl-Oox
antibodies up to a 1/100,000 dilution of the sera (Figure 11),
indicating successful immunogenicity of Oox-KLII.
III 6.2 l_un098n101ty in mice
On confirlling the Illmunogenicity of Dox-KLH in the rabbit,
mice were immunized and the spleens of these mice were used for
fusions. The i1llIllunization schedules, along with the amount of
Dox in DoX-KLH, adjuvant and the route of administration havc
been sWllIlIarised in Tables 6a, 6b and 6c (Hatcritlls and
Methods). The length of the immunization varied for cach
fusion and the reasons for this are discussed in Chapter IV.
On the day of the fusion, the mice were terminated and the
spleens used for fusion. The sera from these mice were tested
for anti-Dox antibodies by ELISA. As in the rabbit, the sera
of the mice indicated successful immunization with an anti-DoX'
titre of up to 1/100 to 1/1000. These results are presented
under the appropriate fusions (Figures 18, 19 , 20).
165
Figure17. Rabbit anti-Dox antibodies
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~ ELISA performed ....ith Dox coated plates. The post-
immune rabbit serum drawn at different intervals 1,2 and 3
(Table S, section II. 7.0) was evaluated in varying range of
dilutions. The reciprocal of dilutions is shown. Rabbit serum
drawn prior to immunization was employed as control. Each
point represents the mean value of absorbance readings in
triplicate +j- twice the standard dc·.. iation.
Titl'e in this thesis is defined as the highest dilution giving an absorbance
highet" than the control value + 2 standard deviations.
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Ill:. 7.0 DOX-P;LH «11-285-14) BISPECIFIC FUSIONS
III. 7.1 Introauction
Fusions were performed using the methodology dCEicr j bed in
Materials and Methods. The immunization schedules for eilch
fusion has been tabulated in Tables 6a, 6b & 6c (Materials and
Methods). The number of spleen cells used [01:" e<Jch fusion imd
the total number of 11-285-14 hybridoma cells used, includinq
their viability, spleen ce11:11-285-14 ratio and the cell
density per well are summarised in Table 13. Individui.ll
fusions are described below according to the total number of
hybrid colonies obtained and subsequent clone!:>, and their
reactivity in 3nti-CEA and anti-Dox ELISAs. BsMab ELISAs using
CEA-HRP conjugate 'Jere performed only for those hybrids iln!J
clones positive in both anti-CEA and anti-Oox ELISAs. 'I'hc
hybrids obtained from Oox-KLH immunised mice fusions <Jrc
summarised at the end of the DoX-KLH individual fusions
(Section III 7.12) (Table 21).
III 7.2 Dox-kLH Fusions 1, 2 and 3
These were trial fusions performed to become familiar with
the procedure and to evaluate three different batches of
azaguanine resistant 11-285-14 cells as fusion partners. A
spleen from a single mouse ....as divided and used for the three
fusions (Tables 6a & 13). No hybrids resulted from those
fusions.
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III 7.3 Oox-KLH Fusion ..
The immunization schedule is given in Table 6a. The mouse
serum yielded 1/1000 anti-oox antibody titre (Figure 18). The
ratio of spleen cells and 11-285-14 (batch I VI) cells used in
this fusion along '.dth their viability and density per well are
summarised in Table 13a. The hybrids obtained were tested by
ELISA. The code number of the ELISAs performed, the number of
hybrids tested and the number that were positive in anti-eEA
and anti-Dox assays is sho....n in Table l4a. A total of 48
hybrids were obtained from this fusion. 45 of these hybrids
were positive for anti-CEA activity and 11 for anti-Dox
activity as well. Bispecific assays using CEA-HRP were
performed, but the results were negative and they arc not shown
in this table.
Hybrids were selected based on ELISA readings when
compared to background cont.rol readings. RPMI-GLN-FCS medium
was used as negative control. Nine individual hybrids which
had the highest absolute ELISA readings (OD~ll'M1) in both anti-
CEA and anti-Dox assays are depicted in table l4b. These
hybrids were further expanded into larger wells or 50 ml
flasks.
Two of the positive hybrids (# 4 A6 and J C7, Table 14b)
were cloned. The 4 clones obtained were tested for anti-DoX'
activity, but were found to be negative (ELISA 345; data not
shown). The hybrids that were initially positive for anti-CEA
no
Figure 18. Dox-KLH Fusions 1 to 5 sera
0.50
-(i)-P,,·lmmlln. conl.o!
-o-Fulon·I,2&3
-o--FII.lon_4
0.40 -·-fllllon·5
~ 0.30
"u
"j 0.20 \« i •
~.10 1i2:::.~~('\~i
0.00
- ---'-"'Iml-'-'"' ""1-r,JII I1II-rTllllUl-'"'III1l1-I- n "111
.01 .1 10 100 1000 10000
RecIprocal 01 aelum dllullon IX 1000)
~ ELISA performed with Dox (2uq/ml) coatod platos.
ThEl sera of mice drawn on the day of fusion was tested for
anti-Dox acitivity, in dilutions as shown. Pre-immune control
was from a non im1llunised mouse (no anti-Dox). Each point
represents mean of the absorbancO! values read in triplicate.
Standard deviations have been omitted for clarity.
ELISA I Number of welle tested Anti-eEl\.
activity
Anti-COX
activity
171
310
JJ1
JS9
Total
hybrids
"
4l
44
13
2l
10
28
10
8 (4clonslI
".
"
45 11
NT, Not. tB.Ilted aimliltaneouJJly in both anti-CEA and anti-Dox le8,.ya dUEt to
limited quantity of Bupernatants
Legend for '1'ab19 1481 As the hybrid colonies appeared in wells, the
supernatants were tssted by repetiti'/8 ELIsAa. Total hybrids (.) represent
the hybrid coloniee olltained in the fueloo and. not the sum total tested.
Clones .IIrD not counted BS original hybrId coionieB and therfore not
included in the total CO'Int. For example, aB the first 39 welle containing
hybrid colonies appell.l"ed, the supernatants were tested in aerial ELISAB
starting from ELISA #294. In ELISA 1310, the Blltlle 39 wells were retasted
In addition to 5 new colonies. However most of these colonIes ceaeed to
proliferate or were neqativ8 for anti-cox activity.
rabl. Ubi Dox-n.a t ..d,OIl 4 ELISA r ••ult..
ELISA
Antl-CU. readinq Atltl-DOlt readIng
, Hybrid 00. Hean + 00.
.... >s'
In B,
IV 1IJ ~V,,
0.265
312 4.. 0.442 ~
3c' 1.180 0.108
~ Not tUBted (NT) ~
~-SF' 0.582
3Sl ]ell 0.711 ~ 0.086& 352
0.732 ~
0.082
Not t •• t.ed due to lialted quantIty of lupernatant
av.U.ble.
M + 250 • H••n .. Itandard devIatIon (x21 of backqround l:'ontrol
valuel.
aDa Ablorbanell at. 405 nBl
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and anti-Oox. activities, includlng hybrid 14A6, subsequently
turned negative for both activities (Table 14b).
III. 7.4 Dox-ItLB Fusion 5
Immunization details are given in Table 6a (Materials and
Methods). The spleen cells "'e~e divided into four and fusions
were performed with tour diffe::ent azaguanine resistant 11-285-
14 batches (Table 13). Due to an error in calculation 1 )C lO~
colls of clone VI were used instead of 6 x 106 (table 13).
Therefora, the ratio between spleen cells and 11-285-14 was
69: L The mouse serum revealed 1/1000 titre anti-Dox antibodies
by ELISA (figure 18).
Fusion I 5 resulted in 33 hybrids. 14 were from clone A
as fusion partner. 7 hybrids resulted frolll clone III, 10
hybrids from clone V, and 2 from clone VI as 11-285-14 fusion
partners. This individual breakdown for these clones has been
compared in Tables 8a , 8b as part of their fusion efficiency.
The· number of ELISAs performed and their serial numbers are
given in Table 15. However, these hybrids could not be
propagated in cUlture.
ELISA I Wella tested Antt-CEA
(tncludtnq subclonss) acttvtty
174
311
Total
hy!'rtds
18 18
NT ., Not tested
Leqend as for Table 14"
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Ill: 7.5 Dox-JtLH Fusion «I
Two t:1ice w~re utilised for this fusion. Six injections
of Dox-KLH were given, the total dose of doxorubicin being 41
pg per mouse (Table 6a). spleen cells rroll both mice were
pooled yielding 2.3 x 10' cells. In order to compare the
fusion efficiency of the different 11-285-14 fusion partners,
the spleen cells were divided and five separate fusions were
performed (Table 13). Two 96 well culture plCites were used for
each batch of 11-285-14. Although a smaller number of cIano
III was available, with poorer viability (72\, Table lJ), tho
viable cell density in each well was comparable around ".6 x
10
'
. The mouse sera olJtained prior to fusion were tasted by
anti-Dox ELISA and showed up to 1/1000 titre anti-Oox
antibodies (Figure 19). Since the spleen cells were divided,
and five different 11-285-14 fusion partners were used, the
fusion efficiency of these five 11-285-14 clones could be
compared. The individual breakdown has been given previously
in Tables 803 , 8b and is as follows. Clone VI yielded the
greatest number of hybrid!:>, 41. Clones III, IV, V and fI,
resulted ~n 25, 6, 11 and 2 hybrids respectively. The EI,lSAs
performed and the serial nUinbers are given in Table 16. Tn
order to simplify the selection process, it was decided to
perform anti-oox and/or bispecific ELISAs as the initiol
assays. Hybrids sho....n to be positive in these ELISAs were then
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Figure 19. Dox-KLH Fusions 6 to 10 sera
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~ Legend as for Figure 18. The serum was collected
from the mice on the day of fusions and tested for anti-CEA
activity.
17'/
considered tor anti-CEA ELISA. However, although 44 hybridz
(out of the 95 total) were anti-Oox positive initiallY, on
subsequent testing they were found to be negative in both antj-
Dox as well as biapecific assays. 13 out of 2J hybrids tested
showed anti-CEA activity.
326 19
330 86
337 38
344 & 20
'"346 12
354
Total
hybl:'ids
NT· Not tasted
Legend as fol:' rablll 14.
DuMllb
activitv
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XXI. 7.' OOx-ItLH PuSiOb 7
Fusion 7 was performed 132 days following the primary
immunization (Table 6b). 19.8 JIg of doxorubicin was the total
illJlunization dose. The number of spleen colIs obtained was 14.3
)( 101 • Since clone VI gave the highest fusion frequency in the
previous fusion (43\ of the total hybrids). compared to four
other 11-285-14 fusion partners (Fusion 6 , Table 8b), clone
VI was selected for this fusion. The mouse serum obtained
prior to the fusion contained up to 1/100 anti-Do>.: antibody
titre (Figure 19). Five plates were used in the fusion with
a cell density of 3.6 x 10' per well (Table 13).
At this stage, some technical problems involved in the
selection process of hybrids will be mentioned. A total of 146
hybrids were obtained in the fusion, the highest number up to
that time. Some or these hybrids were seen as early as two
weeks after the fusion while others appeared as late as one
month after the fusion. Sequential assays were necessary to
test new hybrids as well as to retest hybrids that were
positive in earlier ELISAs. Approximately lOOlLl of hybrid
supernatant was available for ELISA testing. Taking any more
supernatant would disturb the hybrid colony at the bottom of
the welL Given this limited amount of supernatant, only one
ELISA could be performed at a given time. Although the
supernatant could be diluted and used for all three ELISAs,
this was avoided. The dilution would diminish the antibody
concentrati:m increasing the chance of false negative ELISf\s.
It was therefore elected to perform the bispccific
antibody ELISA directly, as an initial screening assay.
However, 104 out of the total 146 hybrids obtained from Fusion
7, when tested in the bispecific assay were found to be
negative (ELISA 354 & 355; Table 17a). Surprisingly, When many
of these hybrids were tested for anti-oox activity in ELISf\s
359 and 360, they were found to be positive (Tanle 17b).
Hence, suspecting the early negative bispecif ic ELISA cesu 1ts
were due to loss of anti-CEA activity, an anti-CEll ELISf\ WI'1~
performed (ELISA 363 a & b; Table 17a). Only 1'i out of the l"n
hYbrids tested (9\) were anti-CEA positive, confirming that the
negative bispecific ELISA results were likely due to loss or
anti-CEA antibody production, rather than loss of anti-Oox
activity. The weak ELISA readings of bispecific assays of some
hybrids is given in table 17b. Three of the hybrids that were
positive in anti-doKorubicln ELISAs 359 and 360 were cloned.
All of the 51 clones obtained were found to be negative in
anti-CEA assay (I 367, Table 17a), thus eliminating the
possibility of bispecific antibodies.
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T.ble 17.: Dox-1lLB PUdOD 7 rellults
E"!SA I Welb hllt-ed Anti-CEil.
(including /letivlty
clones)
354&
J5~
359&
360
92
362
36Ja,b
51 (Btl
Bubclonell)
rotal 146
Hybrlde
Leqend or Table
Anti-OOX
Ilctiv1.ty
BliIMllb
activity
Hybrid ~~;~l~~~ Mtl-Dolt BBMabread!n 8 teadinos
ELISA I M+2SD 00405 00 00 M+2
'05 '05 SO
359/360 0.078~ 0.100~ 0.11, 361
0.104 0.138
363/364 0.118 ~ 0.09
0.151 0.099
BeMab .. Biepecific Monoclonal Antibody
00 .. Optic.l dandty at 405 nm
H + 250 .. Mean + 2 x Standard deviation of control 1n triplicate
NT" Not tusted
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III. 7.7 Dox-~LH Fusions 8, 9 and 10
Due to the loss of anti-CEA activity of hybrids resulting
from B VI as 11-285-14 fusion partner (fusion 7), fusions H,
9 and 10 were performed using clones A, III nnd VI ilS fusion
partners (Table 13). However, no hybrids resulted from these
fusions, despite ill 1/1000 anti-Om, antibody titre detected in
the serum of the mouse used for Fusion 10 by ELISA. (Figure 19) •
Ill. 7.8 Dox-ltLH Fusion 11
The immunization protocol used is shown in '1'ilble uC.
Sevell injections of Dox-KLH were given and thll fusion per-fonned
294 days after the primary immunization. A total or 24.SlJC] of
doxorubicin was used. The serum of the mouse obtained prior
to the fusion yielded a 1/1000 antibody titre (Figure 20).
Clone aza-2 was utilised as fusion partner in this rusion
(Table 13).
59 hybrids resulted from this fusion. In keeping with tho
preceeding paragraphs, hybrids were first tested in anti-CEA
and anti-doxorubicin ELISAs. Those positive in both ELISM;
were then evaluated for dual activity using CEA-HRP conjugate.
The ELISAs and the number of hybrids tested, including ]r,
subclones are given in Table l8a. The highest ELISA reactinrJ$
with the corresponding hybrid codes is given in table 18b.
The problems in selecting hybrids in this fusion wero
similar to fusion 7. As illustrated in Table lab (EI~ISAs t1])
,.2
Figure 20. Dox-KLH Fusions 11 10 15 sera
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~ Legend as for Figure 18. The sera of mice were
drawn on the day of Dox-l(LH fusions 11 to 15 and te~ted for
anti-oox activity.
'8)
, 414), some hybrids like )-11 were positive for anti-CEA and
negative for anti-Cox and vice versa for hybrid I)-c>.
Furthermore, hybrids like 1-1 were initially positive in all
three ELISAs (I 401-403). I)ut on cloning (ego 1-1-3) l.>c::nIlO
negative for anti-eEA and only weakly pO!Jitive for anti-Dol.;
activity (Table IS b) .
ELISA' Woll. t.'ted Anti-CE1r.
activity
26 26
Anti-DOll
aetivity
lJo/'lab
activity
404alib
"
19
406. 407 28
10408
JO
41' 11
415&
b
417a 16
b
Total
Hybrids
20
NT • Not l.ated d.... to limited quantity or supernatant..
Legend a. for Table 1411.
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Tabl. ISbl Dox-IU.B fl.lsiQIl 11 ELISA x.sults
Hybci .... Anti-CEA readinQ Anti-Pox ~eading BsMabs
r.",dln
El.ISA Code OO~ Mf2SD OO~ o,~ M+250
I
401, 0.010~ 0.100 r-£:l-L
'"<OJ l-J r~ r-£:l-L
~ ~
0.092 0.09
,CO ~ ~<OJ
'"
~~ ~
0.013 D.oe
'"
0.095 0.148~ 0.093, 414
~
~
J·-6 0.078 0.J16
411& 0.068 0.072 r~ 0.011 Not tested
'" 3-1101 ~
0.066
.. 250 .. Mean + standard deviation (X 2) of backqround control values
00 .. Optical deneity at 40Snm
III. 7.9 Dox-ltLH Fusion 12a
Two fusions were performed using the spleen from <'I mouse
immunized with the protocol shown in Table 6c. AZLl-2 was the
11-285-14 fusion partner (fusion l2a). The second fusion WiW
performed with 6-thioguanine resistant NS··1 myeloma c~!l~;
(fusion 12b). flo hybrids were obtained with the Il-285-!·1
fusion (12a). H'.:Iwever, 31 hybridS were obtained with the NS-l
fusion (12b). Results of the NS-l fusion arc given lilter
(section III.8.0).
III. 7.10 Dox-Jl:LH Fusion 13
rusion 13 was performed 24) days after primary
immunization. 15.35~g of doxorubicin was given as Dox-KLII in
divided doses (Table 6c). 10.6 X 101 spleen cells wcr<:
obtained and clone Aza-3 (11-285-14) was used as tho fusion
partner at a ratio of 4.6:1 (Table 13). The mouse serum showed
an anti-Dox titre of 1/1000 by ELISA (Figure 20).
Of the 45 hybrids reSUlting from this fusion all tested
positive for an~i-CEA and 30 for anti-Dox. The ELISAs and the
number of hl'hrids tested are summarised in Table 19.:). Two of
the strongly positive anti-Dox hybrids, I 17 and I 2) ('I'able
19b) were cloned. 61 clones were obtained from these t~/O
hybrids, with 7 demonstrating weak bispecific activity. The
highest ELISA readings are given in Table 19b.
420...
b
Wella llnti-CEA anti-OOX BaHaba
t.eated activity act.ivity activity
,. 16
"' "'
"
NT 21 NT
32 19
18.
424 &.
m
4JO&.
4J1a
133&
'"
..
"(c10ne8}
3S
"•
"T
NT
4J8 " 16 16
'"
5 5
441, 442
'" 443
447, 448
" 449
12
Total 106 (45+ 23 +9
hybrids 61 clones) .:-lone5
NT. Not tested
-ELISA 431b was peE"forrnad with Dox-KLH coated plates
:.egend as for Table 14.'1
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Given the weak reactivity in anti-Oox ELISl\s compared to
anti-eEA. the hybrids were tested for ar.tivity against Dox-KLlI
coated plates (ELISA 43lb). Since the mice were immuniscd with
Dox-KLH, it was anticipated that many of the hybrids would be
strongly reactive against Dox-KLH. However, only 7 (20\) out
of 35 tested showed anti-Dox-KLH activity (Table 19a). 'l'he
ELISA readings for two of these hybrids (25 and 30) ilrc gj VOIl
in Table 19b (ELISA 431b). Hybrids"# 17 and 23, which were
pl"e"iollsly positive for anti-Oox in ELISA 421 turned out to be
negative for anti-Dox-KLH, in ELISA 431b. This illustriltes the
instabili ty of antibody production by the hybrids.
III. 7. 11 DoX-'kLH Fusions H. and 15
These two fusions were performed with Aza-l and IIz<I-1.
clones of 11-285-14, respectively. lIall of the. spIae:"! calls
from fusion 15 were also utilised for fusion with NS-l myclomn
cell line. The immunization protocol and fusion details arc
summarised in Tables 6c and 13. Sera from the immunized mica
yielded a 1/1000 anti-Dox antibody titre (Figur.e 20). No
hybrids resulted from these fusiolls.
He
Table. Ubi Da..-KL11 fUlloD 13 ELISA relult;s
Hybri<: ,,"tl-CEA reading Anti-Oox B,Motb reading
ell.din
ELISII
"". 00.• "".
M+2S0,
1.663 ~ 0.07
1.563 0.117
-l.!_ ~
2J 0.158
424' 1.861 ~ 0.06(1 ~
'" ~ ~-
1.224 ~ ~
2J 1.0B7 ~ ~
1.690 ~ ~
1.571 0.067 0.137
430& 0.319 0.065~ 0.076 Not; tVBted4318
0.314 ~
0.109
43tb~ Not tested ~ 0.172 Not tested
~2~ ~
~- ~
30 0.265
441, 0.233 0.012 0.105 0.105 0.107 0.062
442'
0.319
'" 23-1 0.123 0.150 0.08
0.241 0.20e
447, 0.669 0.100 0.091 0.071 .ot teated
448&
0.070
'"
17-K 0.716 0.069 0.065
0.795 0.079
Note: ELISA 4Jlb performed with Oox-KLH coated phta$.
'.9
'III. 7. 12 Dox-KLB Fusion 16a
Of the several clones of 11-285-14 used in the fusions
described above, Aza··) (fusion 13) yielded hybrids that were
consistently anti-CEA secretors. Aza-) was therefore selectod
as the fusion partner for fusion 16. A shorter immunization
protocol of 22 days was used. The selection of mice uscd in
this fusion was as follows. 5 mice from a Ii ttar were
immunized with a total of 28. SjJg of doxorubicin in the form of
Dox-KLH (Table 60). Prior to fusion, the sera of the 5 mice
(drawn from the tail vein) were tested by ELISA. Although
immunized in an identical fashion, two mice (I 2 and J)
demonstrated a higher anti-cox titre up to 1/100 and 1/100(l,
respectively (Figure 21). The spleen cells from these two mice
were pooled and 't'ere dividp.d for two fusions. Fusion 16a was
performed with Aza-J and Fusion 16b with 6-thiaquaninl2
resistant NS-l myeloma cell line. It was anticipated that thi.s
approach, if successful, would result in BsMabs in fusion loa
and/or hybrids secreting anti-oox monoclonal antibodies in
fusion 16b.
Fusion l6a resulted in 195 hybrids, the maximum number up
to that time. The initial 60 hybrids obtained were tested in
both anti-CEA and anti~doxorubicin ELISA (Table 20a). All of
the 60 hybrids tested were positive for anti-CEA activity
confirming the anti-CEA stability of hybrids resulting from
Aza-J. However, only 3 (5\) were positive for anti-Dox
1.500
1.000 -
0.000
190
Figure 21. Selection of mice
for Dox-KLH fusion number 16
--(!}-P'e·lmlnUIlII aonlrol
-Mou••·,
-o-MoUI,,_2
-t-Moule-3
-o-MOUle-4
-.- Mouse-5
.01
.1 10 100
Roclprocal 01 .arum dllulion (X 1000)
~ ELISA performed with Oax-BSA coating (2ug/lUl Dox).
Five mice were immunized in an identical fashion (Table 6d,
section II. 9.1). The sera was drawn prior to the fusion date
and evaluated by ELISA for anti-DaK activity. The control was
serum from a non immunized mouse (pre-immune). Each point
represents the mean value of abcorbance readings in triplicate.
The standard deviation has been omitted for clarity.
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activity. It was therefore decided to concentrato:! on anti-Dox
ELISAs. Hybrids positive for anti-Dox activity were selected
for cloning and further e},-pansion. The numbers of ELISAs
performad and the results are given in Table 20a.
ELISA # walla tested }lnti-CEA Anti-DOX
activity activity
484" 60
485
82
487 &- 164
.88
56
49J 36
495,
272496,
497&
.,.
Total 195 hybrids + 60·
hybrids 249 clonlls
NT " Not tested
'" J'.il hybrids obtained were not tested for anti-CEil llctivlty.
However,tha 60 hybrids that were tested wera 4nti-CEII reactIve.
Legend a8 for Table 14a.
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Table 20bl nox-n.U FuaioD. 16 ELISA rOl;ults
Hyl'rid Anti-eEl'.
ELISA I OO~ Mean OO~ Hean
+250 +250
484 " 0.225 0.138
--2..:..!!!...
'8' 0.461 ~
0.256 0.139
'" ~ Not taBled ~ 0.092
~ ~
~
~ ~
~
~ ~
f--!=!- ~
6-32 0.068
'" ~ Not tetlted ~
1 3- 14- 2 ~
,5-12-2 ~
6-32-2 0.770
489, ~ Not telted ~ 0.124490&
491 ~- ~~ ~6-32-2 0.111
6-32-2 Not tOllted 0.104
ELIsAa 486,487,488 an" 491 performed with mll>tiBorp ELISA
plateu (Gibco , 4-42404) due to lack of conventional ELISA plates
mentioned in Hateriale and Methods.
H + 2so = Mean + Gtandard devlation (x2) of background control
values.
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A total of 195 hybrids resulted from Fusion 16a. 51
anti-Oox positive. Only those hybrids showing the highost
anti-Oox: absolute ELISA readings were considered for cloning.
For example, although several hybrids were above the o.on
(mean + 2 x standard deviation) control b;lckground, only 1'/
were over 0.1 ELISA reading at 405 nm (ELISA 486; Table 2Gb)
and were cloned by limiting dilution. 249 clones resulted from
this procedure. E[,ISA readings for 4 of the posit:.a.vc cloncl;
are shown in Table 20b (ELISA 488). However, these cll)nc~;
became non reactive in subsequent ELISAs (Table 20b). Direct
BsMab ELISA$ ....ere not performed, since the Itybr ids beCilmc
negative for anti-oox activity.
The outcome of fusion 16 is best illustrated by hybr.id I
6-32. Hybrid 6-32 was positive for both anti-CEA and <1nti-[)ox
ELISAs 484 and 485 (Table 20b) and was immediately cloned.
Although the original hybrid lost its anti-oox activity (EI..1S/\
486), the subclone 6-32-2 was highly positive (ELISA 48B), with
an absolute EL.ISA reading of 0.770 (Table 20b), the highest up
to that date. However, on subsequent growth and testing,
6-32-2 lost its anti-oox activity (ELISA 491). simililrly, ill!
the initially positive hybrids including their clones bccallle
negative for anti-Oox activity (ELISAs 495-498, Table 20a),
within 3 to 4 weeks of the fusion.
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'I'he results of all the Oox-KLH fusions are summllorised in
'fable 21.
Table 211 SWIUllry of DoX-ELB fusions hybrid.
Hybrido Total_ Ant.i-CElI
(wells) Hybrids'"
ClonQIJ
1,2,3
18
",97 14 21
8,9,10
"
2J
12
13 106
"14,15
". 195 ... GO"
Total .. 1001 282·
"
.. Not all hybrids obtained were tested for anti-CEA activity.
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III.S.D NS-1 FUSIONS
As mentioned in the introductory chapter, an altern.:'ltivc
method of generating bispecific antibodies is by fusing t ....o
different hybridomas (section 1.10.0). The resulting hybrid-
hybrid would then secrete antibodies with dual parental
specificities.
In an attempt to produce a hybridoma secreting monoclon,)l
antibodies against doxorubicin, fusions ....ere performed between
NS-l myeloma cells (6-thioguanine resistant) and spleen ccll~
from doxorubicin immunized mice. A hybridoma thus produced,
could be used as a fusion partner with the 8-uzaguaninc
resistant anti-CEA 11-285-14 hybridoma..
III. 8.1 Dox-JtLH (NS-I) Fusions 12b, iSb, 16b lind 17
Four fusions were performed with the first tllrcc
corresponding to fusions 12a, 15a and 16a of Dox-KJ,I[
bispecific fusions discussed in section III 7.0. (sections 7.9,
7.10, 7-11 and 7.1:'). A fourth fusion (# 17) was performed
separately. The immunization protocol with Dox-KLII and the
number of spleen cells used for the fusions is sho....n in tubl c
6c along with the other Dox-KLH fusions, in the Materials and
Methods section. The number of N5-1 cells used and other
fusion details are summarised in Table 22.
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Table 221 Dox-KLH (NS-1) fu,ioQ details
Spleen ,
cella vlabUity
total
vIable
x 10'
NS-l
total
viable
cello
x 10·
.. Spleen Cell
viability : NS-l denoity
catio per
well
95\ 8.04 2.5
·10'
94\ 7.47 4.8 2.2
·1 10'
--
95\ 14.05 2.17
·10'
2.59
·10'
920 .., 1.73
·10'
Despite identical fusion conditions, fusion 12b (NS-l
fusion purtner) yielded 31 hybrids compared to fusion 12a (11-
285-14 fusion partner) which did not result in any hybrids.
However, only a sIngle anti-Oox hybrid resulted from 12b, which
Cailed to grow in cUlture.
Fusions 15a and b did not yield any hybrids. Fusion 16
was performed under identical conditions using half of the
pooled spleen cell:; each for fusions 16a (with 11-285-14) and
1Gb (with NS-l). While 16a resulted in a large number (195)
of hybrids, 1Gb resulted in a single, anti-Dox negative hybrid.
Fusion # 17 resulted in 11 hybrids that died in culture
following contamination by yeast.
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III. 8.:Z DOll-B8A (58-1) YuSiObS
Three NS-l myelolla fusions were performed with spleen
cells from Oox-BSA (bovine serull albumin) imlllunized mice. 'rhc
reason for selecting BSA as the carrier protein is discussed
in the following section (III 8.3). The imt:lunization protocol
is given in Table 23.
Fuslon Oayll Quantity Adjuvant
I of DOll: /lq
60"'9 40 day old mOUDe
at timo of
1< 60119 immunioatlon.
Total vi..ble
60.119 _pleen cello
obtained •
7.12 x 10'.
SO". I 2 month old
16 SO,.
maulle. Total
ulabl" ..plllen
52 SO~ cel18 obtained ..9.54)1 10'.
SO Fusion
SO". I I 2 IDOnth old
,.,. moule. Totalviable spleen
,. cells obtained ..12.2 Ie 10'.
Pualon
eFA & IFA: Complete and incomplete Preund '0 .d1uvant
SCI aubcutaneOllli1i
IP: intraperitoneal
PBS: phosphate buffered saline
>0,
The spleen cells and NS-l cells used and other fusion details
are given in Table 24.
Table 241 Dax_IiSA (NS-l) t"UdOD det.aih
runion Spleen Cell" Spleen Cell
I celltNS dOlnaity
Total . Totd .
1 ratio PO'
viable viability viable viability
well
cells cella
71.211: 1.424 x
"
l.lx
", ", 10'
9.5411 1.908 x
"
J.9x
", ", 10'
12.2)1 2.22x 5.0x
10' ", 10'
Most significant of the NS-l (00X-85A) fusions are the
results of fusion I 1 resulting in 227 hybrids. The ELISA
results are summarised in table 25a. 26 of these were strongly
positive for anti-Oox- BSA over 5 to 6 times the anti-BSA ELISA
readings and 10 times the control background. The highest
ELISA readings are shown in Table 25b. However, these strongly
positive hybrids either became negative in later ELISAs and/or
ceased to prolif~rate in culture.
ELISA I Tot.l hybrldo AntL-Dox-BSA Antl-BSA
activity acUvit
510 a.b
511 a.b
514 , SIS
"
Sl7c , S18c
5]9 & 520
Total m
hybrid ..
Le'illilnd a .. DxplainBd for Table 144
Tabl. 25bl Dox-BSA NS-l IUDio!! 1 ELISA reDultD
ELISA # coda 1--""'-""T"="-If-=-T''''--11
00.,. H+2SD 00... 101+250
2-'
2-16
2-20
0.111
M + 2S0 " Mean + Btandard deviation Ix 2) of background conLrol
valueR.
Tho NS-l fUlIlon to."lts ato liIumma.dllDd 1n or.bIG 26.
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F.. Blon I Imlunogen ffybz:oids
Total
AntL-Doltl
DOK-BSA
I\rItL-BSA
tIT. Not testQd
• Theile hybrids were nellatLva in the anti-BSA ELISAs
III. 9.0 DOX-BSA (11-285-14) BISPEC:IFIC FUSIONS
III. 9.1 :Introduction
Analysing the poor results of Dox-KLII fusions, hybrids
from the initial fusions showed loss of anti-CEA activity, thus
diminishing the chance of obtaining BsHabs. To overcome th i s
problem, Aza-3 was used as the 11-2B5-l4 fusion partner which
yielded consistent anti-CRA secretors. The maln problem j n
subsequent flox-KLH fusions appeared to be the insti:lbil i ty of
hybrids for anti-Oox -;ecretion in culture. Since even tile
anti-Oox-KLH activity appeared weak, as demonstrated in fUDion
13, it was decided to switch the carrier protein to bovine
serum albumin (BSA). Dox-BSA was used as the immunogen in un
attempt to improve the success rate. Evidence for DoX-I3SA as
a suitable immunogen came from the discussion with Or. S.
Menard (personal communication, European Irnnuno1ogy Meeting,
1988, Rome, Italy). This was further supported by a report
from Dr. Henard's group of the production of anti-doxorubicin
monoclonal antibodies using Dox-BSA immunized mice (Balsari,
Alzani, Parrell0, Morelli, Taqliabue, Gianni, Isetta, Menard,
colnaghi & Ghione M, 1988).
An approximate four week immunization duration was
followed as shown in the MateriAls and Methods ('fables 'fa ,.
7b). It was possible to link a much greater quantity of
doxorubicin to BSA than it was to KLH (Tables 6 ,. 7). ISO/ig o[
doxorubicin in the form of Oox-BSA could be given as l1ntiqcn
per mouse prior to fusion (Tables 7a & 7b). The sera of llIice
drawn prior to the fusions revealed high titre antibodies
(1/1000 up to 1/1,000,000) in ELISAs performed with Dox-J<LH
coating indicating successful immunization (Figures 22 & 2J).
These results are presented under the individual fusions.
since hybrids produced from Aza-J as the fusion partner
appeared to be consistent anti-CEA secretors, Aza-J ....as used
for all Dox-eSA fusions. Eight fusions "Were performed.
III. 9.2 Dox-BGA Fusion 1
Fusion 1 was performed Jl days following the primary
immunization. The serum contained anti-Dox antibodies up to
1/1000 titre (Pigure 22). The number ot spleen cells and Aza-J
cells used in this fusion are given in Table 27. Only a single
hybrid resulted from this fusion which was an anti-eSA
secretor.
Figure 22. Dox-BSA Fusions 1 to 4 sera
-ill-Pre-immunt conlJol
--Fullon·1
-O-Fullon-2
-'-FuIlon_3
-o-Fullon-4
.001 .01 .1 10 100
Aeclprocel 01 se'um dilution IX 1000)
.Ei.9J.u:L.ll.. ELISA performed to evaluate sera drawn from mice
on the day of Dox-BSA fusions I 1 to 4. 2ug/ml of Cox in the
form of Dox-KLH was employed as coating. The prc"'-immunc
control was sera from a non immunised mouse. Each point
represents mean values of absorbance readinl)s in triplicate.
The standard deviation has been elhdnated for clarity.
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III.!L3 Dox-BSA Fusion 2
A lillIe mouse from the same litter as in fusion 1 (Table
7a) was used for this fuston with an ide.ntical immunization
protocol. The serum revealed up to 1/1000 titre. anti-Do);
antibodies (Figure 22). 12.6 x 10/ spleen cells were obtained
and the fusion details are given in Table 27.
77 hybrids resulted from this fusion. The ELISAs, number
of hybrids tested and results are given in Table 28a. Some of
the ELISA readings are given in Table 28b. Hybrids that wero
initially positive in Dox-BSA and negative in BS/I coated ELISA:;;
(I 508) were considered anti-Oox secretors. However, these
subsequently became negative, inclUding the clona 2-2 that W.lZ
obtained from hybrid I 2 (Table 28b; ELISA I 513).
ELI5A, 'rotal hybridll loti-Dol< anti-eSA anti-CEll
act1.vity activity actlvlty
508&
SO.
510
"511&
512
513 to
516
51711.& 35 16
517b
528
'rotal W
hybrids
°Anti·Oox positive hybrids were negative 10 anti-aS'" £LI5110.
NT" Not tened
LegendallexpliinedforTable14a
"6
Tabl. ::llbl D(ox-BSA fusion 2 ELISA re.ults
Anti-Dox-BSA
ELISA I Code OD~ M+2SD OD~ H+2SD OD~
508& 0.383 0.071~ 0.071 Not testedW,
0.183 ~
0.091
5100\ 0.084~ 0.089~511&
512 ~ t-~
0.199 p~!!.... p"..:.E.!..
~ ~
15 ~ 0.248
27 0.187 0.057 Not tested
513 & 2-2 0.196 0.055~ 0.090 Not tsel;ed516
0.051 ~
~
15 0.065 ~
0.055 ~
0.055 0.102
III. 9.... CoX-BSA Fusion 3
Fusion was performed 6 weeks after primary immunization
(Table 7a). A lesser number of Aza-3 cells were used due to
availability. Therefore, the spleen cell to 11-285-14 ratio
was 13:1, higher than for the other fusions (Table 27). The
mouse serum showed up to a 1/1000 anti-Dox titre by ELISA
(Figure 22). Twelve hybrids resulted from this fusion. The
ELISAs performed and the ELISA readings are given in Tables 29a
and 29b.
Tabla 29a; Dox-BSA fusion 3 results
ELISA I total nybridG
529 10
Total
hybrids
Anti-Oox-aSA Anti-BSA
ELISA I OD~ OOm
1-2 0.162 0.056 0.09 0.051
1-' 0.103 0.102
'29 o.oao 0.059
0.051
Legends as exp1ainod. for Table 14a and 14b
III. 9.S Dox-BSA Pusion 4
The results were similar to fusion J. The immunization
protocol is shown in Table 7a. The post-immune mouse serum
demonstrated up to a 1/1000 anti-Dox titre by ELISA (Figure
22). The fusion details are summarised in Table 27. Of the
10 hybrids obtained, there "'as only one hybrid recognising
doxorubicin. ELISA results and absolute readings are given jn
Tables JOa and Jab.
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ELISA I total hybl:id' ant.i-Do:K-BSA
Tabl_ JObl Dox-eSA fusion" ELISA results
Anti-BS'"
ELISA I OO~ 00.0» K+2SD
0.164 0.116 0.080 0.095
0.091 I 0.290 I
Legend lUI for TllbleB 14a and 14b
III. 9.6 Dox-BSA Fusions 6, 7 and 8
Al though fusion 5 was performed prior to fusions 6,7 & 8,
due to the repeated cloning and sUbcloning involved, the
results af fusion 5 were obtained later and therefore given in
the next section. Fusions 6, 7 and 8 were performed following
a four week immunization protocol with 155/l9 of doxorubicin
total. dosage for each mouse (Table 7b). The primary booster
for fusion 8 mouse was given in complete Freund's adjuvant
instead of the incomplete Freund's adjuvant utilised far other
Oax-B51\. fusions (Balsari et al, 1988). 'the sera of these mice
tested in anti-oox ELISAs revealed high titre (1/1,000,000)
antibodies (Figure 23). Accidentally, the serum from the mouse
used for fusion 6 was discarded, and therefore not tested for
anti-oox antibodies.
Figure 23. Dox-BSA Fusions 5 to 0 sera
-{!}-P,e·lmmuno conllol
__ Fullon_S
-<>-Fullon-l
,\""'",
. ~---',
.001 .01 10 100 1000 10000
RecIprocal 01 Serum dilution (X 1000)
~ Legend as for Figure 22. The serum was drawn on
the days of Fusions I 5.7 and a.
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The number of spleen cells obtained and fusion qetails are
summarised in Table 27. Nineteen hybrids resulted from these
three fusions. only 3 were anti-Dox positive, all resulti;lg
from fusion 7. The ELISAs performed and the ELISA readings for
a few of the hybrids from fusion 7 are given in Tables 31a &
]lb. No ::ltable bispecific hybridoma lines were obtained from
fusions G, 7 and B.
ELISA" Total hybrids
tested
Total
hybrida
Anti-Ooll
anti-Doll-BSA
ELISA .,
anti-BSA
0.15"/ 0.100 0.079
3-1 0.104 0.0"/9
549 3-3 0.114 0.068
Legend as for Table 14a and b.
III. 9. 7 Dox-IlS~ Fusion 5.
A 4 week immunization protocd was used (Table 7b). 155P9
of doxorubicin in the form of Dox-BSA was the tat .. l
immunization dosage. The mouse serum contained alII, 000, 000
anti-cox antibody titre when tested against Oox-KLH coated
plates (Figure 23), the highest antibody titre at that time.
The spleen of the mouse yielded the maximum number of spleen
cells obtained up to that time (14.76 x 107). The fusion
details are summarised in Table 27. The cell dens! ty per we 11
was the highest amongst the Dox-BSA fusions.
A large number of hybrids (178) resulted from this fusion.
A list of the ELISAs performed and the number of hybrids testoeJ
serially is given in Table 32. Given the stability of anti-Cr.A
secretion by hybrids produced from Aza-3, the focus was on
assessing the anti-doxorubicin secretion. Hybrids post t i vo
in anti Dox-BSA ELISAs and negative in anti-BSA were Selected
for cloning. The ELISA readings for some of the hybrltlz
selected are given in Tables 32 and 33. Although, initjill
ELISAs from # 537 to 546 revealed hybridS {:Iositive for 85A,
several readings for anti-Oox-BSA were at least twice that of
anti-eSA. Such hybrids were still considered for furthor
evaluation, since the original hybrid colony could have. been
a mixture of cells secreting antibodies against OOK" or 1l5A
individually andlor BsMabs.
The hybrid colonies 1-14a and l-14b were selected for
cloning based on ELISA readings 5 to 6 times over the
background for anti-Dox BSA compared to equivocal anti-aSA
readings. They were also positive for anti-CEA activity
(ELISAs 551 & 552, Table 32). Hybrids were initially cloned
at 10 cells per ml by limiting dilution (1 cell per \<Iell) and
subsequently at 5 cells per ml (0.5 cells per well). Clones
of 1-14a/b and their second and third generation subclones were
tested for anti-Oox activity.
Of the 178 hybrids obtained from this fusion, 107 were
anti-oox positive.. 20 of these hybrids sho\<ling the highest
ELISA readings were cloned. 245 clones thus obtained were
further subcloned resulting in 1325 second and third generation
clones. 286 of the InS potential bispecific hybrids with the
highest absolute ELISA readings have been cryopreserved in
liquid nitrogen for future evaluation. Seven third generation
clones of l-14a and 1-14b (listed under ELISAs 584 & 587; Table
33) were expanded in culture and retested for anti-Oox-aSA,
anti-BSA, anti-CEA as well as in the bispecific assay directly.
ELISA readings for these hybrids are given in Table 33 (ELISAs
561 to 567).
rTabl.32 DQx-SSA :ruaioD 5 re.ult.s
ELISA # Hybrid wells tested anti-Dol( anti-BSA .... nti-CE/\
"
"
49
'"
'"
'"
s. 13
!:l50 7.
m
162
"fo!lnti-
Dox-kLH)
'62 l8? 14. 13
56' .. 2J
'"
68
567 17
568
8. 56
57.
571 82
'72 81
'"
24
57' 36
S15 83
continued
Tabh 32 I Dolf-BSA f\lllian 5 ruulh (continued)
Hybrid wella teated anti-Dox ant1.-BSA anti-CEI\.
'"
80
8J "
36 10
J9
"
Total 178 + 1570 clone a 107 +
hybrids 179
elones
• 1\.11 the wella tested were positive for ll.nti-CEI\.
NT • Not tested
Legend as for Tab1w 14a
"<
~.b18 33 Dox-BSA fudoD 5 EL1SA re.ult.
ELISA # Code of hybdd Anti-Oox-aSA Antl-C"'''
OD~ OO~ M...2S0 OO~" I Mt2SlJ
2-1 0.486 0.114~
2-27 0.556 ~
2-28 0.532 0.300
~
....£.:..Q2.!..
~
0.161 ~
0.069
~ 0.201
0.068
~
3-56 0.193 0.061
1-14 0.198 0.019
.J!..:..!!!.. 0.128
4-30 0.156 0.081
m ~ 0.066 ~O.lOlS52
1-14b 0.582 0.084 l.891
1-14a-26-10 0.214 0.062
1-14a-14-33 1.109 0.113~
1-148-14-35 l.012
....Qd£
1-14b-51-11 0.833 ~
1-14b-57-12 0.306
~ 0.134
1-14a-26-6 ~
1-148-26-48 0.179
570 1-14a-9-1 ~
1-148-57-21 0.576 0.107
1-14a-57-11-25 0.091 NT I
1-14.-57-11-10 0.329 NT
contlnucd ..
Tlb1. 33 I Dox-BSA hlLon 5 ELISA rllll1t. (conti nued)
Code of hybrid Anti-Oox-aSA
ODa H+2SD OD~ 00.", ..,,,
0.106 0.079
1-14b-57-9-6 0.385 0.164 0.149
1-1401-57-1.1- 0.418 0.151 0.123
25-17
581&583 1-1401-26-61-1 0.543 0.103~ ~
1-143-26-61-2 ~ ~
~ ~
1-1401-26-61-10 ~ ~~5_2
1-14b-57-9-6-4 0.088 1.799
OOm
58. 0 1-141.-26-61-1 0.088~ ~587
~ ~
1-1401"26-61-4 0.318 ~ ~
1 141.-26-7-2 0.448 ~ ~
1 1401-26-7-35 0.069 0.091
1-14b-57-9-64 0.247 0.062~ ....2.:.!.!.!..
37-40-6 ~.n6 0.098 0.158
00 • Optieal density {abso~banesl at 405 nm
M + 250 • Maan + standard deviation (x2) of background control v.l\1es
A recent report has suggested the possibil i ty of
immunogenicity induced by the linkers ,a-alanine mcthyltinc
malonate ethyl ester (BAMME) and O-alanine pyrrole (BliP)
(Johnson OA, Barton RL, Fix OV, Scott WL & Gutowski MC, 1991).
The clone 1-14a-26-61-1 was tested by ELISA for reactivity with
the ECOI linker used in Oox-BSA conjugates (although such i\
reaction against ECDr has not been documented in tho
literature), and was found to be nonreactive. The reSUlts in
ELISA I 597 for the clone l-14a-26-61-1 against ECOI was 0.11;1
(Mean + 250) compared to a control background of 0.138 (M -j
2S0). This clone has been expanded and the positive results
for anti-CEA, anti-oox, dual assay and negative resUlts in
anti-BSA assay are shown in Table 33 (ELISAs' 581, 583, 504,
587) •
Oox-BSA fusion results are summarised in Table 34. Fusion
5 resulted in the maximum number of positive hybrids showing
dual reactivity for both CEA and doxorubicin in ELISlI.
Table J41 Su..sry ot Dox-BSA tllsiOD hybrids
Fusion Hybr1.ds Ant1.-
I OOX
Hybrids Clones Total
Anti Antl- 8sHab
-8SA eEA activity
14 34
" "
'"
1570 1748·
'"
OS 7···
(245+132 hybrids (50)
') + 179
clones
11
"
17
Total_
'"
,
• Tho total number includes 1st g8nerat1.on clones (245) and their 2nd lind
Jrd gen<:\rllt1.on sIIbc1onili1/l teated (1325)
Anti-Dox hybrids Were 12xc1usively positive in Dox-nS1< ELISAa "nd negativa
in anti-SSA ELISAs •
•• Antl-eEA activ1.ty wall positive for all hybrids that were tested •
••• Parentheses indicate II that: at least SO were positive for dual activity
after lIubclcnln9 twice. Hcwever these were eryopreBsrved without
expansion, while 7 clones were expanded prior to preservation.
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CHAPTER :IV
DISCUSSION
IV 1. 0 :INTRODUCTION
For the production of BsMabs we chose what initially
seemed to be the mast straight forward approach ie. hybridoma
x spleen cell fusions particularly as an anti-doxorubicin
sensitive hybridoma was not available at that time (Surcsh at
aI, 1986b; Corvalan & smith, 1987). Twenty-four fusions WGrc
performed using HAT sensitive 11-285-14 and spleen cells
obtained from mice immunized with DoX-KLH or Dox-BS1\.. 'l'hc
hybrids resulting from Dox-KLH fusions were unstable in
culture, in addition to having a low titre antibody activity
(by ELISAs). The possible reasons for the failure of these
experiments and the successful results of the Dox-IlSA
blspecific fusions will be discul"sed in the following
sections. In addition, the implications of these results tinct
the iuture prospects of BsMabs recognising both CEA and
doxorubicin will be discussed.
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:IV 2.0 DOX-UB FUSIONS
sixteen fusions were perforJlled using the hybridoma
technology with HAT sensitive 11-285-14 and spleen cells from
mice immunized with Oox-KLH. A total or 621 hybrids resulted
with 47 hybrids demonstrating dual activity (Table 21).
IV 2.1 Sel8otion or .11-285-14 fusion partners
The initia} step was to produce. HAT sensitive (8-
azaguanine resistant) 11-285-14 mutants with suitable growth
characteristics, anti eEA production and fusion properties.
11-285-14 itself is a hybridoma produced by the fusion of III
HAT sensitive parental NS-l myeloma, with spleen cells from
mice immunized with CD. (Woodhouse, 1982a). This makes 11-
285-14 HAT resistant, and adds to the dlttlculty in selecting
HAT sensitive mutants. Although resistance with respect to
growth in 8-azaguanine was easily obtained at the recommended
concentration of 30 ugl ml (Suresh et aI, 1986b), the 11-285-
14 mutants were 1I10w growing in comparison with their parental
11-285-14 growing in RPMI medium (Figure 4). Furthermore, of
the 72 HAT sensitive 11-285-14 clones produced, only 27
(37.5\) were pC":litive tor anti-CEA )lab secretion by ELISA.
The initial clones used for fusions gave disappointing
results due to their poor growth and/or loss of anti-CEil.
activity either prior to fusions as for clone V or in the
resulting hybridS. Clone VI gave the highest fusion
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efficiency at 59.5 hybrids per fusion. However, only 21 (35t)
of the hybrids were positive for anti-CEA activity, thus
diminishing the chance of obtaining hybrids producing SaMaba.
Clone Aza-), despite haVing a lower fusion efficiency at 38.1
hybrids per fusion, resulted in all hybrids that were tested
being positive for anti-CEA activity, thus enhancing the
chance of obtaining dual positive hybrids.
In addition to the factors relating to the hybridoma
fusion partner, several other variables Illay play a role in the
production of BsMabs, including the drug (antigen) i tsal r,
carrier protein, immunization protocol, and fusion procedures
which are discussed in the following sections.
IV 2.2 Doxorubicin - protein conjuqates
Doxorubicin, being a h?~ten (molecular weight 580) had to
be first conjugated to a carrier protein to induce an immune
response. KLH ....as an attractive choice since it is one of tha
most immunogenic substances known (Korver, Zeijlemakcr,
Schellekens & Vossen, 1984). In addition, its molecular
structure and antigenicity has been well elucidated (Linzen,
Soeter, Riggs, Schneider, Schartau, Moore, Yokota, Behrens,
NakaShima, Takagi, Hemeto, Vereijken, Bak, Beintema, VolbediJ,
Gaykema & HoI, 1985). The mechanism of 1<LH induced
immunogenicity is considered to be a combination of chemical
modification and l"ecruitment of carrier specific helper T
cell;; (French, Fischberg, Buhl & Scharff, 1986). Although
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several heterobifunctional crosslinking agents are available
for the production of hapten-protein or protein-protein
conjugates. including giu tara Idehyde, N- (")'-
tlIaleilllidobutyxyloxy) succi.imide (GHBS) end N-succlnimidyl 3-
(2-pyridyldithio) propionate (SPDP) (Keans' Feeney, 1971;
Fujiwara et 2111, 1981; Pierce Chemical Company: Crosslinking
Reagents p3J3-J38; Wold, 1965), carbodiimlde (EeDI) ....as chosen
as the cross linker. The reason for this was that the EeDr
reaction had been well documented with the conjugation of
doxorubic1n via its amino group to form an amide bond with the
protein (Vunakis et aI, 1974; Goodfriend et aI, 1964).
A major problem that was encountered in producing
conjugates was the loss of the drug by precipitation out of
solution even prior to the conjugation reaction. As
de.onstrated in the conjugation experillents in Tables 9a, b,
e and Table 10, 50 to 80t of the drug pecipitated out of
solution. Such losses have also been docutlented in previous
stUdies (Pietersz at al,1988 ). The loss of hemocyanill was
more variable ranging from Sot (conj #22) to no loss (conj )
125) (Table 9C). Molar ratios ranged from 57 to 568 moles
Cox per nole KLH when calculated with a molecular weight of
10,000,000 for KLH (sigma range 9 to 15 X 106). This compares
with conjugations by other groups that have incorporated 8 to
10 1IIoles of Cox per 100,000g of KLH (Vunakls et aI, 1974),
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Le. 800 to 1000 molar ratio assuming a molecular weight of
KLH of 10 x 106•
Experiments involving conjugation of OaK to enzymes
were much more complicated and yielded disappointing results.
HRP was the initial enzyme of choice since the anti-CEA and
anti-Dox assays were standardised with HRP as the indicator.
In addition, the amino acid structure and biochemical
properties of HRP have been well delineated (Welinder, Smillie
'" Schonbaum, 1972; Welinder '" smillie, 1972; Dolman, Newell,
Thurlow and Dunford, 1975). Ten attempts were made to link.
Oox to HRP using periodate, carbodiimide or glutaraldehyde ilS
the crosslinkers (Table 11). Although the conjugation results
indicated Oox was linked to HRP, the rabbit anti-oO)(
antibodies did not recognise Dox-HRP when tested by ELISA
(results similar to Cox-avidin non recognition as shown in
Figure 10). The reasons are unclear, but the interpretation
includes the possibility of doxorubicin epitopes being altered
by the chemical modification. The possible reasons for the
failure of Dox-enzyme conjugations are discussed below.
(i) There have been no reports in the literature to date,
indicating successful conjugation of Dox to HRP.
(it) The stability and solubility of Dox has always beon poot"
in comparison to other anthracycline derivatives and
extremely variable under identical conditions when used
224
by different groups (Hoffman, Grosaana, Dam!n S. Woodcock,
1979; Benvenuto, Anderson, Kerkor, s.ith & Loo, 1981;
Bosanquet 1986). In general, doxorubicin has been found
to be sensitive to light, adsorbs to me~rane filters and
containers (except siliconised glass and propylene), can
degrade rapidlY in medium, as well as chelate metal ions
(Bosanquet, 1986).
(iii)The use of the periodate method, which is the most
frequently used method in the conjugation of HRP to
proteins, involves borohydride for the stabilization of
the Schitt' bases. However, when doxorubicin was used,
this step has been shown to cause loss of activity, for
unknown reasons (Ghose, Ramakrishnan, Kulkarni, Blair,
Vaughn, Nolldo, Norrell & Belitsky, 1981; Pietersz et aI,
1988). This loss of activity also applies to Dox-avidin
conjuqat'!s and may explain the non~recognitionof Dox-HRP
and Dox-avidin conjugates produced, by the rabbit anti-
Dox antibodies in ELISAs (Sections III. 3.1; III. 3.3;
and Figure 10). In addition, there are practical
difficulties involved in the chemical conjugation and in
estimating the quantity of conjugate formed (Section
III,3.1) .
(iv) Many of the problems in producing antibody-drug
immunoconjugates, presented in Chapter I (section I. 8.1)
also apply to the conjugation of Oox to enzymes. The
"s
problem is one of linking the hydrophobic drug to
hydrophilic protein moieties. In addition,
heterobifunctional agents such as carbodiimide and
glutaraldehyde, ....hen used for linking anthracyclines to
proteins, cause polynlerisation, thus hindering the
coupling (pietersz et aI, 1988 !io 1989). '1'his problem has
been circumvented by Page's group from Quebec (1987, and
Personal Communication ISOBM XV Annual Meeting, Quebec
City, Aug. JO-sept. 3 1987) by activating daunor.-ubicin
derivatives with aldehydes and using glutaraldehydo as
the linking agent to anti-eEA monoclonal antibodies. 'l'he
derivatives were found to be pharmacologically active and
stable against acid hydrolysis without signif icant
polymerisation of the conjugates. Coupling ratios of up
to 12 moles drug per antibody molecule were obta ined.
However, this procedure was not reprOducible when
doxorubicin was substituted for daunorubicin, as shown in
Section III 3.1.
(v) Finally, this problem was discussed with Dr. Brian
Hasinoff, Assistant Professor, Chemistry Department,
Memorial university of Newfoundland who has work.ed
extensively with the structure and chemistry of IIRP and
doxorubicin (Hasinoff, 1970 & Personal Communication>.
Additional problems appeared to be the formation of free
superoxide radicals in solution by HRP and doxorubicin
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resulting in self coupling of the enzyme. Further, the
presence of metallic ions in the buffer solution
interferes .... i th the coupling reaction by binding strongly
with Dox forming a complex, (Hasinoff' Davey, 1988;
Hasinoff. Davey & o'Brien, 1989). Sodium flour ide and
EDTA were added to the reactions in an attempt to
overcome the above two problems, but did not result in
conjugate formation.
At this stage, alternative enzymes were considered, based
on a report of p-D-galactosidase conjugation to doxorubicin
using the m-malelmidobenzoyl-N-hydroxysuccinimide ester (MBS)
as a coupling agent (Hirano, NagaI, Adachi, Ito & suglura,
1983). However, similar problems as with Dox-HRP conjugations
discussed above were met, including failure of recognition of
Dox-,B-galactosidase by rabbit anti-Oox antibodies. Indirect
methods were attempted to enzyme label OOX via the avidin-
biotin bridge, by first conjugating OOX to either avidin or
biotin and then using commercially available biotinylated or
streptavidin peroxidase. Procedures were extrapolated from
the avidin-biotin system used for labelling antibodies with
enzymes or FITe ( Goding, 1986; Boorsma, Van Bommel & Vander
Raaij-Helmer, 1986; Ford et al,19878 ).
Given these problems in producing Oox-enzyme conjugates,
a CEA-HRP conjugate was produced by the periodate method and
utilised to develop the BsHab dual assay (Section III. 5.4).
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IV 2.3 11llIllunizatioft
Immunogenicity of Dox-KLH was confirmed in a rabbit and
shown to induce high titre anti-Dox antibodies up to 1/100,000
dilution of the serum (Figure 17). DoX-KLH was also used
to immunize mice in preparation for the fusions. The technique
of production of Mabs by Kohler & Milstein (1975), has
undergone several modifications and there has been no
standardised immunization protocol. Further, immunization
varies with the antigen used. In general, particulate and
cell surface i:l;ntigens are given Lp. or Lv. and soluble
antigens are given by the s.c., Lm., Lp. or Lv. routes
(French et aI, 1986; Brown & Ling, 198B). For the initial
Dox-KLH fusions, the intraperitoneal approach was used, since
this route has been recommended in enhancing Nab production
(French et aI, 1986). However, the Freund's adjuvant caused
increased adhesions and granulomas, making the dissection of
spleens difficult. In addition, the length of the
immunization may be variable, ranging from weeks to months
(Galfre & Milstein, 1981; Brown & Ling, 1988). This justifies
the variation in time of the Dox-KLH immunization protocol
(Tables 6a, 6b & 6c) which depended upon the availability of
Dox-KLH conj ugates and ongoing fusions delaying the
performance of the next fusion. For better analysis of the
fusions, the parameters have been delineated according to the
length of the immunization schedule, quantity of Cox given,
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adjuvant and route (Table 6a, 6b , 6c). Several of the
l ....unizations resulted in up to 1/1000 titre anti-Dol'
antibodies (Figure 18 to 21) including fusions 11 and 13 using
a prolonged ilDlllunization protocol (>200 days; Table 6a, 6b a),
indicating successful iDJllunization. However, more hybrids
resulted froll fusion 116 with a shorter immunization schedule.
IV. 2.4 En7iyme l.inke4 i1lUllunoaorbent assays (EJ,.1BAs)
An anti-CEll. assay had been standardised in the laboratory
using cuvettes as a solid phase support (WoodhOUSl:l, Ford &
NeWlllan, 1981; Woodhouse et aI, 1982bj Ford et.al. 1987a). For
BsMab detection, 96 well microtitre p1llotes were chosen instead
of the CU'/ottes, due to their convenience in testing a large
nUm>er of supernatants sillultaneously (Brown" Ling, 1988).
In addition. the absorbancQ readings cou~d be measured using
an autollated .icrotitre plate absorbance reader (EIA Bio-Tekl
and computer progralls were available for rapid analysis of the
data (Caulfield" Schaffer, 1984).
The dual assay was standardised using a similar Dox
coating as the anti-Dox assay. A 1/50 to 1/75 dilution of
CEA-HRP showed significant recognition by 11-285-14 compared
to the control (Figure 12). Aliquots of CEA-HRP were frozen
il1 -20"C for future use. For the initial fusions, it WIU
convenient to perform the dual assay alone to evaluate the
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hybr ids. However, as illustrated by fusion 17 (Table 21),
lUost hybrids (over 90%) were negative for anti-CEA activity
(only 14 positive out of 146). This resulted in low titre dual
specific antibodies many of which, when later tested for anti-
CEll. activity, were found to have lost their reactivity with
CEll.. In addition, since our supply of CEA was limited, it was
decided to conserve CEA-HRP by performing the dual assay only
on theBe hybrid supernatants that were found to be positive in
both anti-CEp. and anti-Dox assays, which would enhilncc the
selection of BsMab positives. Indeed, Milstein's group have
recommended simultaneous testing for the individual
specificities due to the non reliability of dual spccil'ic
assays for initial testing (Suresh at al 1986a & b) .
IV 2. S Fusions
The total spleen cells obtained and used with 11-285-14
for each fusion have been summarised with the number of cells
aliquoted per well of the fusion plate (Table 13).
Analysing the results, with the number of hybrids as the
end point of these fusions, seven of the sixteen fusions
yielded hybrids, Le. 14,5,6,7,11,13 and 16a. Ilowevcr, us
seen from Tables 6, 13 and 21 it is difficult to identify LI
common dEnominator amongst these. The immunization period
varied from as short as 3 weeks for fusion 116a to 42 weeks
for #11. The amount of Dox employed ranged from 19 to 41 ug
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in total. However, successful fusions resulted from mice
which yielded greater than 9.06 x 101 spleen cells each. This
is above the average of 7.53 X 107 spleen cells yield per
mouse, utilised for those fusions not resulting in hybrids.
Therefore, it may be interpreted that a spleen cell number
over 9.06 x 101 usually resulted in hybrids, with fusion #4
being the exception, yielding hybrids when only 4.0 x 10'
spleen cells were obtained from the mouse. This is reflected
by a lower cell density per well in this fusion. Excluding
[us.\on 14, it is possible to conclUde that a higher number of
spleen cells indicate better immunization, and therefore, more
positive hybrids. However, when the sera of these mice were
analysed for anti-oox antibodies by ELISA, as an indicator of
immunization, sera of all fusions showed an antibody titre of
1/100 to 1/1000 indicating successful immunization.
It has been documented that the viability of the fusion
partners is important for successful fusions (Brown & Ling,
1988). The Viability prior to DO>1-KLH fusions was eKcellent,
being at least over 88% for the spleen cells and mostly over
80t for 11-28!i-14. The importance of suitable 11-285-14 as the
fusion partner is reinforced from fusion 16a using Aza-J,
where all the 195 hybrids produced were positive for anti-CEA
activity, while only 14 out of 146 were positive in fusion 17
using clone VI. Finally, although fusion 116a resulted in 195
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hybrids, fusion 116b performed with NS-l cells under identical
immunization and fusion conditions, resulted in only 1 hybrid
which was negative in the anti-Dox ELISA. This highlights tho
difficulty in identifying a common denominator and the
appropriate conditions for fusions that would result in
hybrids secreting BsMabs.
IV 2.6 Selection and cloning
The results of Dox-KLH fusions were disappointing,
although 621 hybrids resulted from the 16 fusions. 36.5\
hybrids were anti-oox positive and at least 57.8\, anti-CEA
positive (Table 21), exclUding the hybrids not tested for
anti-CEA. 46 hybrids (8%) showed dual activity, but were
weakly so and became negative on subsequent cloning and
expansion.
At this stage, the data was presented at the Ninth
European Immunology meeting in Rome, september 1988 and
elicited interest from Dr. sylvia Menard, Milan, who was part
of a group that was working on the production of monoclonal
antibodies to Oox. Although their data had not been pUblished
at that time, there were similar problems with the production
of Mabs, with a long imml:nization schedule resulting in low
titre, poor quality hybrids. This was circumvented by Or.
Menard's grou~ by using a shorter immunization protocol of 2-)
weeks which resulted in high titre stable hybrids. In
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addition, eSA was used as the carrier protein which made
immunization with up to 50 uq Cox possible at a given time.
Based on this information, fusion 116 was performed using
a short immunization cycle of only 3 weeks using Dox-KLH as
the immunogen (Table 60). Surprisingly, although sera from
the mice had lower titre anti-Cox antibodies the maximum
number of hybrids (195) resulted from this fusion, with <I few
having highest anti-Oox readings by ELISA (Table 20b) to that
date. However, these hybrids were unstable, either dying in
culture turning negative for anti-Oox activity.
Furthermore, fusion #16b, performed under identical fusion
conditions produced only a single hybrid which was negative in
anti-Oox ELISA.
The Oox-KLH fusion results are consistent with the
resul~~ obtained by Dr. Menard's group (Balsari et al 1988),
in the production of anti-Oox Mabs using Dox-BSA conjugates as
the immunogen. Fusions performed with low doses of Dox (10
ug), with a prolonged immunization schedUle, resulted in a
scanty number of unstable non prOducing hybrids. However, in
their stUdy a high serum antibody titre was obtained in
response to only larger doses of Dox (50 ug) unlike the good
response (up to 1:1,000 titre) in our mice with as little as
4 to 8 ug of Cox given in the form of Dox-KIJl conjugate. The
results in this thesis confirm the potent immunogenicity of
Dox-KLH conjugates, but raises the question as to why this did
2JJ
not translate into hybrids with a stable production of anti-
Dox, despite a high serum antibody titre. The causes could be
multifactorial, based on our current knowledge of the
molecular and cellular mechanisms of the immune system.
Firstly, these hybrid-hyrids have to retain an aneuploid
number of normal chromosomes follo..... ing the fusion, which iJdds
to their instability (songsivilai & Lachmann, 1990).
secondly, as discussed earlier, this polyploidity
predisposes to a random 105s of chromosomes, with a higher
propensity to involve one or more of the immunoglobulin loci
which are spread amongst three different chromosome!>
(Yancopoulos & Alt, 1986, Suresh et aI, 1986a).
Thirdly, in addition, the explanation may lie in the
immunomodulating properties of doxorubicin. It has b(!en
suggested that long term immunization with oox selects low
affinity B lymphocytes resulting in low affinity, unstable
hybrids (Balsari et aI, 1988). conversely, it has recently
been demonstrated that low doses of Dox can enhance the
secretion of immunoglobulin by hybridoma B cells, perhaps
associated with differentiation to plasma cells (Teillaud,
Fourcade, Huppert, Fridman & Tapiero, 1989). However, our
experience has been similar to the Balsari et.al report that
long term irnmur,ization with low quantities Dox may select poor
quality, unstable hybrids (Balsari et aI, 1988). Indeed,
these results suggest the following hypothesis regarding the
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role of doxorubicin as an immunogen. Doxorubicin, itself
being ill cytotoxic chemotherapeutic agent, when coupled to a
carrier protein, acts as a toxic antigen when taken up by
antigen presenting cells (APes). In particular, high affinity
8 cells, are pror.e to be destroyed. LoW affinity B cells lDay
escape detruction as they contact smaller quantities of the
drug, or perhaps, are stimulated indirectly as bystander
cells. These surviving low affinity B cells are then
available for fusions, reSUlting in hybrids with low titre
anti-Cox activity. The carrier specific immunosupprlJss!ve
properties have been demonstrated by preliminary experiments
recently, where ill Dox-BSA conjugate had significantly
diminished the primary immune response to BSA in mice
(Balsari. Cerofolini "Ghione, 1991). similarly, the antibody
response to Dox-KLH appeared to be diminished in the hybrids
produced in our Dox-KIJI fusions (Fusion 13, Tables 19a , b).
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IV 3.0 DOX-BBA FUSIONS
With the evidence supporting Dox-BSA as a suitable
immunogen (section IV.2.6.) eight fusions were performed with
cox-BSA immunized mice. Hybrids were obtained demonstrating
dual activity.
IV 3.1 DaX-BBA conjugates
The experiments were similar to Dox-KLH conjugata
production, with ECOI as the crosslinker. The details of the
conjuqates have been summarised in Table 10, and as in Dox-KLll
conjugation, there was considerable loss or the drug even
prior to the conjugation reaction. For example, for conjugate
17 in Table 10, of the 17 mg of doxorubicin at the start of
the experiment, 2.8 mg (16.4\;) was available as dissolved
doxorubicin, the rest having precipitated out of solution.
For the 10 ml of conjugate obtained, the conjugate yield waE:
1. 35 mg DoX as Dox-BSA (Table 10). Thus, 1es~ than 8t of tho
drug resulted in the SUbsequent conjugate. These results arc
compatible with the Dox-KLH conjugations and with drug-protein
conjugations performed by other groups Which have reported 80-
90% loss of the drug during conjugation (Pletesz et aI, 1988).
The highest molar ratio was up to 5.5 moles of the drug
linked per mole of eSA (Table 10) which is within thO
acceptable range of Dox-protein conjugation reported by others
(Hurwitz at al 1975). It is interesting that Dox-KLll
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conjugations yielded up to 569 moles DOl( per mole KLH.
How-ever, KLH is a larger molecule with weight range of 9 to 15
j( 106 (Sigma Chemical Co.), nearly 200 times that of BSA
(66,000 mol. weight). A practical advantage of Oax-BSA over
Oox-KLH was the high concentration of the drug (up to 135ug)
present per ml of Dox-BSA conjugate, compared to 39 ug of
doxorubicin per ml Dox-KLH. This higher concentration
facilitated the use of smaller volumes for immunization in the
mice, reducing the amount of Freund's adjuvant required.
IV 3.2 IllIIlunization
The immunization protocol (Table 7) was standardised to
approximately 4 weeks duration and mice received a higher dose
of DOl( at 50 uq per injection. compared with the Dox-KLH
immunizations. The Oox-BSA conjugates produced an anti-Oox
antibody response. in mice up to 1/1,000,000 titre as tested
against Oox-KLH coated plates in ELISA (Figure 23). It is
interesting however, that the spleen cells obtained were
variable despite identical immunization conditions. For
example, mice used for fusions #1 and 2 yielded 8.16 x 10
'
and
12.16 x 10' spleen cells respectively. This may have
contributed to the single hybrid resulting from fusion 11
compared to 77 hybrids from fusion #2 (Table 27 & 34).
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IV 3.3 Fusions
Unlike the initial Dox-KLH fusiOl'S, Dox-BSA fusions and
subsequent selection of hybrids was performed with spleen
cells and thymus cells as feeder layers. In addition, 20\
fetal calf serum was supplemented for the Dox-BSA fusions and
for cloning as recommended by Galfre and Milstein (1961).
Of the eight Cox-BSA fusions performed, fusion 15 yielded
the maximum number of hybrids (Table :\0). Interestingly, the
number of spleen cells were the highest for fusions 12 and 5
(table 27), and these two fusions yielded 85.8% of the total
hybrids obtained (table 34). This appears to be a common
factor amongst the Dox-KLH and Cox-BSA fusions where the
highest number of spleen cells resulted in the greatest number
of hybrids. However, the anti-Oox titre of the mouse sera did
not appear to correlate with the reSUlting hybrid nUlIlbcr. For
example, Fusion 8 sera resulted in the highest anti-oox ti trc
(1/1,000,000), but a poor yield of spleen cells and hybrids
was obtained (Figure 23 &- Tables 27 &- 34).
IV 3." Selection and cloning
This has been technically the most demanding part of this
project, due to the rapidity of growth of the hybrids and
therefore, the urgency of screening positive hybrids for
cloning. To enhance the stability of hybrids while cloning,
both 20% res as well as feeder layers were used. With the
"8
assurance of stable anti-CEA activity of hybrids by using the
Aza-J clone as the 11-285-14 fusion partner, initial selection
of hybrids was based on anti-Oox activity. However, anti-CEA
assays were intermittently performed to reconfirm anti-CEA
activity. Fusion 15 yielded the maximum number of hybrids,
178 in total, 107 of which were positive for anti-Oox activity
(Tables 28a , band 30). positive clones were recloned down
to 1 cell and 0.5 cells per well based on the Poisson
distribution (Hudson & Hay 1980). 245 anti-oox clones
obtained were further subcloned to yield 1325 second and third
generation subclones. Several of these clones (286 in total)
have been cryopreserved in liquid nitrogen directlY or after
initial expansion. Seven of these subclones have been
expanded to maintain adequate stocks for future use. Hybrids
I 1-14a-26-61-1, 1-14a-26-61-2, 1-14a-26-61-4, 1-14a-57-9-6-4
have all shown anti-Oox and anti-CEA activity, and have been
negative for anti-eSA activity (Table 33). In addition,
hybrid 1-14a-26-61-1 has been tested against the Dox-BSA
linker ECDI coated plates, by ELISA, in order to eliminate the
remote possibility of fJ.Ise positives due to recognition of
the linker instead of doxorubicin. All the ELISAs performed
used the appropriate positive and negative controls to confirm
the validity of the results. The dual assay ELISA readings
have been lower when compared to anti-CEA ELISA values.
However, these readings depend on the concentration of
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antibodies In supernatants tested. In addition, the CEA-HRP
conjugate itself may b~ of too great a molecular weight (CEA
+ HRP ,.. 224,0001 to be beld by the univalent antibodies
(B5Habs) due to their decreased avidity. This situation would
be reversed 1n vivo where the antibodies would bind to a more
stable cell membrane CEll. molecule, the labile antigen binding
site recognising a much smaller doxorubicin (molecular weight
580). In confirmation of this concept, bispecific antibodies
recognising eEA have been shown to effectively target vinca
alkaloids both in vitro and in vivo (Conalan & Smith, 1987).
Such poor activity in assays that test for the presence DC
BsHabs directly has been documented in other studies (Surcsb
et.al. 1986b). Therefore, though technically demanding,
individual assays for the different specificities arc
recommended (suresh et aI, 1986b).
As presented in the introductory chapter (section I
10.2), and documented by Milstein's group, there is a
preferential association of homologous heavy and light cha ins
in hybrids secreting SsMabs (Milstein' Cuello, 1984; Surcsh
et aI, 1986b). This results in three main species of
antibodies secreted by the hybrids. These are the BsMab, in
addition to the parental antibodies. Furthermore these
studie,:; have indicated that the yield of SaMabs may be as high
as 30 to sot of the total secreted immunoqlobul1ns.
In the final results of this thesis, seven stable hybrid
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cell lines have been produced, secreting antibodies that
demonstrate both anti-oox and anti-CEA activity by ELISAs
(Table 33). While it may be argued that these two
specificities may be related to the secretion of parental
unispecific antibodies, the seven cell line supernatants also
show dual specifity by ELISA, which would not be seen with
unlspecific antibodies. The weaker reactivity of BsMab
supernatants in dual assays are likely due to competetive
inhibition by unispecific antibodies (Suresh et al,1986a & b).
In addition, these cell lines have been obtained followIng
cloning, at least two or three times by limiting dilution,
ensuring clonality and stability of growth and antibody
secretion. Whether these BsMabs are efficaceous in targeting
would be the SUbject of an additional research project;
however, the objectives set at the begining of this thesis
have been achieved with the productio·· of these BsMabs
demonstrating dual reactivity against CEA and doxorubicin.
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IV ... 0 PROSPECTS FUR BISPECIPIC ANTIBODIES
The potential applications of BsMaba, both
investigational and therapeutic reagents, may be realised from
the following examples of bispecif1e antibodies that have boon
produced by other groups.
IV .f.1 Immunocytochemistry and IlllIlluno&9says
Bifunctional antibodies have been produced against
enzymes like HRP or to various hormones/antigens, with
simultaneous anti-somatostatin, anti-substance P or anti-
flouresee!n isothiocyanate (rITe). activities with potential
widespread applications in immunocytochemistry and enzyme
i.mmunoassays (Milstein & Cuello, 1983; Suresh et aI, 198Gb;
ltarawaje.... , Behrsing, Kauaer & Micheel, 1988). These
procedures were made simpler because of the one step shortened
incubation time in comparison with the conventional two step
assays and may have a potential in routine screening where
rapidity rather than maximum sensitivity is required.
However, sensitivity is not necessarily sacrificed, as
demonstrated by anti-FITC and anti-HRP BsMabs, in the
detection of FITC-Mab labelled AFP or HCG bound to solid
phase, where the assay was equally sensitive as conventional
ELISA systems (Karawajew et aI, 1988). Furthermore, BsMabs
recognising both HCG and urease have been used in high
sensitivity immunoassays for HCG, detecting levels as low as
24'
25 mIU/ml (Takahashi , Fuller, 1988; Takahashi, Fuller &
Winston,1991).
IV. 4.2 or cell tarq_ting
SsMabs are currently being evaluated in the targeting of
the body's own immune system in the therapy of cancer and
v i raJ diseases (Fanger, Segal & Remet-Lemmone, 1991; Waldmann,
1991). Jleteroconjugated Mabs of two specificities have been
shown to targot cytotoxic T-effector cells via the T cell
receptor (TOR) against a H-2 antigen on EL-4 murine thymoma
(Barr, Macdonald, Buchegger , Fliedner, 1987). Bispecific
antibodies recognising the CD3 surface antigen induced lysis
of virally infected cells carrying the herpes simplex virus
(HSV-l) glycoprotein C (Paya, Mckean, Segal, Schoon, Showalter
, Leibson, 19~9).
As a further refinement, it has bQen demonstrated that as
little as 2ng/ml of BsMab can target T cells via the TcR
inducing lysis in vitro of over one third of the Durine tumor
cells expressing the thy 1.1 antigen (staerz & Bevan, 1986).
Interestingly, the mechanism of lysis of cells by retargeted
T-effector cells circumvented the Jlajor histocompatibility
complex restriction (Clark, Gilliland & Waldmann, 1988 a & bi
aian, Titus, Andrew, Mezzanzanica, Garrido, Wunderlich &
Segal, 1991). It has been well established for conventional
cell mediated immunity I that the target antigen, in
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association with the major histocompatibility complex is a
prerequisite for triggering T cells (Lanzavecchia, 1990).
Recently a universal BsMab has been produced recognising the
T cell CDJ antigen and rat kappa light chain simUltaneously,
thus indirectly retargeting effector cells to any targC!t
coated with rat kappa bearing antibOdy (Clark at aI, 1988;
Waldmann, 1989). Bsmabs may also have potential in treatment
of certain viral infections, as recfJntly demonstrated by an
anti-CD3 bifunctional antibody rodirecting cytotoxic 'I'
lymphocytes of any specificity to cells that express gp120 of
the human immunodeficiency virus (AIV), inducing lysis in
vitro (Berg, Lotsher, steimer, Capon, Baenziger, Jack & Wabl,
1991) .
Efficacy of BsMabs in vivo has been demonstrated in mice
bearing BCL-l lymphoma. 5 ug of BsMabs directed agilinst
C03/TCR complex and surface Id antigen of BCL-1 tumours, when
given intravenously induced a cure compared to contr"ols
(Brissinck, Oemanet, Moser, Leo & Thielemans, 1991).
Furthermore, the feasibility of heteroconjugated bispecific
antibodies in patients has been demonstrated in a small number
of patients with malignant glioma, reSUlting in effective
retargeting of lymphokine activated killer (LAK) cells <tnel
regression or early erlldication of tumor (Nitta, Sato,
Yagita, Okumara & Ishii, 1990). currently, Phase I-II trials
are underway, with BsMab retargeted lymphocytes, for the
intraperitoneal treat_nt of ov..rian e ..rcinomB patients
(Bolhuis. sturlll.Gratama , Braaklllan .1991) •
IV. 4.3 I_UDocb_otb.rapy
While .any studies hav,! focussed on targeting effector T
cells. tnere have been tew reports involving BsMabs against
chelllother..peutic aq8nts an(/ tumour associated antigens. The
reasons may be similllr to the poor results obtained in the
Dox-KLH fusions. >;s discussed in section IV 2.6.
p.. rticular, as discussed, the concept ot the drug acting as a
lethlll antigen may playa major role in diminishing tho immune
response by destroying the antigen presenting cells (Belsad
et al, 1991). To date there are only three such BsMabs
documented in the literature produced by the hybridona
technology. These are BsHabs against vinca alkaloids and eEA
(corvalan et al, 19881. anthracyclines and rat hepatoma
antigen (Tsukada, Ohkawa. nibi, Tsui;uki. Oguma , Satoh. 1989)
and llethotrexate and qp72 antigen expressing human
osteosarcollla (Pin, Robins, Embleton. Jacobs, Markham.
Charleston, Bald....in. 1990). The well studied BsMabs against
CEA aurt vinca alkaloids have been demonstrated to show
superior suppression ot human colorectal tUlllour growth in vivo
in nude mice as compared to the free drug (Corvalan et aI,
19S5).
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Few reports have included chemically heteroconjugate.d
bispecific antibodies, an exaaple being F(ab2} anti-eEl. and
anti-bleomycin (as a benzoyl derivative). These antibodies
were injected into patients with colon cancer. 24 to 120 hours
prior to injection of indium labeled drug. There was tumour
targeting \lith low uptake by liver and the bone marrow
(stickney, Slater' Frincke, 1989).
IV. 5. 0 CONCLUSION AND FUTURE
Reviewing the several modifications of the e>:perimenta I
protocol that eventually led to the production of IJsMabs
against both CEA and DoxorUbicin, the following steps arc
recommended for those interested in sillilar product i on.
Selection of suitable carrier protein, shorter illllllunizat ion
protocol, feeder layerd with upto 20\ FeS supple.mentation for
growth of hybrids .. standardization ot three ELISAs and urgent
cloning of positive hybrids.
EVidence that carcinoembryonic antigen is a suitable
antigen for targeting with BsMabs has been provided by recent
studies involving lysis of CEll. expressing cancer cells in
vitro with ricin toxin A chain (Embleton, Charleston, Robins,
Pirnm, and Baldwin, 1991) and in vivo with vinca alkaloids
(Smith, Gore, Brandon, L1'nch, Cranstone " Corvalan, 1990).
The in vivo stUdies with anti-vinblastine/anti-CEA BsMnbs
revealed increased local t'Jmor drug concentration and could
24.
effectively suppress the growth of human tumor xenografts in
nude mice, compared with the free drug (Corvalan et aI, 1988).
The effectiveness of anthracyclines suitabh~
chemotherapeutic drugs for targeting has been supported by a
recent preliminary report of a BsMab recognising a metastatic
hepatoma cell line and daunomycin, also cross reacting with
doxorubicin. These BsMabs were more effective in vivo than
antibody-drug conjugates, perhaps due to increased local
concentration of unmodified drug (Tsukuda, Ohkawa, Hibi,
TsuzUkL oguma & Satah, 1989).
with these promising reports of the suitability of CEA as
the target and doxorubicin as the therapeutic agent, it is
reasonable for an optimistic expectation of the further
evaluation of a3sMabs produced as the end result of this
project. Future progress would involve:
(1) Production of larger quantities of antibody in vitro and
in vivo as ascites in Balb/C mice.
(2) purification involving Protein S sepharose as the first
stage followed by passage down a CEA affinity column and
passage of the eluted material down a doxorubicin affinity
column. The eluted material should only contain antibodies
with dual specificity.
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(3) Evaluation of the affinity of the purified SsMabs could
be performed by looking at binding assays with radiolabelled
or enzyme labelled CEA and then, sUbsequently. with
radiolabelled aoxorubicin.
(4) competitivlI inhibition studies with other anthracyclines
should be performed to determine the degree of cross
reactivity, if any.
(5) The targeting potential of SsMahs would initially be
evaluated in vitro utilizing CEA expressing human tumour cell
lines growing in culture. The cytotoxic tty of a mixture of
the SsMahs and varying concentrations of doxorubicin would be
compared with appropriate quantities of BSMahs, free drug, 11-
28S-14-Dox immunoconjugates and PBS (control). Subsequently,
the efficacy of SsMaba in vivo, in the suppression of human
tumor xenograits growing in nUde mice, would be evaluated.
Comparisons ....ould be made with groups of mice treated with
appropriate controls as tested in vitro. In addition, the
half life pharmacokinetics, tissue distribution and toxicity
would be studied.
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Cii) Targetinq Doxorubicin-Carrier protein:
AS recalled frolll the Results (Table 34) while evaluating
hybrids for anti-CEA/anti-Dox activity, several hybrids were
found to have anti-CEA/anti-BSA activity, since eSA was used
as the carrier molecule. So.a of these hybrids showing both
anti-eEA and anti-eSA activities by ELISAs have been preserved
under liquid nitrogen. Such BsMabs could have a role in
targeting several molecules of doxorubicin conjugated to a
single molecule of eSA as a carrier. This is supported by the
recent report by Pimm et al (1990) that a bispecific antibody
reactive with methotrexate and a human osteosarcoma associated
antigen (gp72) demonstrated auqmented cytotoxicity of
methotrexate-human serum albumin conjugate. Given the inter-
species homology between serum albumins (Heloun, Morave); &
Kostka, 1975) anti-CEA/anti-BSA BsMabs may be effective in
delivering several .olecules of doxorubicin linked to human
serulll albumin, which would be less immunogenic than BSA in
patients.
In conClusion, thirty bispecitic fusions have been
performed. Twenty four fusions were bispecific, sixteen using
Dox-KLII and eight using Cox-BSA immunized mice (Tables 22 &-
34). In addition, six fusions were performed as an indirect
approach in producing a hybridoma secreting anti-cox Mabs,
which did not result in suitable hybrids. 1,192 hybrids and
1,962 clones thereof, have been evaLuated for anti-Cox
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activity, and positives further selected based on anti-CEA
activity. 286 ot these hybrids deJ:lonst.rllting both activities
have been stored at -70·C and seven of the ClOnCl$
demonstrating the highest absolute ELISA readings and positive
reactivity in bispecific, anti-CEA, anti-Oox assays, haVe! bC!C!n
further expanded to provide adequate stocks for future
studies.
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